CA3020193C - Method for producing n-acetyl-d-glucosamine and/or d-glucosamine hydrochloride by microbial fermentation - Google Patents

Method for producing n-acetyl-d-glucosamine and/or d-glucosamine hydrochloride by microbial fermentation Download PDF

Info

Publication number
CA3020193C
CA3020193C CA3020193A CA3020193A CA3020193C CA 3020193 C CA3020193 C CA 3020193C CA 3020193 A CA3020193 A CA 3020193A CA 3020193 A CA3020193 A CA 3020193A CA 3020193 C CA3020193 C CA 3020193C
Authority
CA
Canada
Prior art keywords
glucosamine
acetyl
microorganism
genetic modification
effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3020193A
Other languages
French (fr)
Other versions
CA3020193A1 (en
Inventor
Lan SUN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/CN2017/080649 external-priority patent/WO2017174036A1/en
Publication of CA3020193A1 publication Critical patent/CA3020193A1/en
Application granted granted Critical
Publication of CA3020193C publication Critical patent/CA3020193C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/02—Monosaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01157—Glucosamine-1-phosphate N-acetyltransferase (2.3.1.157)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01016—Glutamine-fructose-6-phosphate transaminase (isomerizing) (2.6.1.16), i.e. glucosamine-6-phosphate-synthase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/0106—N-Acylmannosamine kinase (2.7.1.60)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01025—N-Acetylglucosamine-6-phosphate deacetylase (3.5.1.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/99—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in other compounds (3.5.99)
    • C12Y305/99006—Glucosamine-6-phosphate deaminase (3.5.99.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/03—Oxo-acid-lyases (4.1.3)
    • C12Y401/03003—N-Acetylneuraminate lyase (4.1.3.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y501/00—Racemaces and epimerases (5.1)
    • C12Y501/03—Racemaces and epimerases (5.1) acting on carbohydrates and derivatives (5.1.3)
    • C12Y501/03009—N-Acylglucosamine-6-phosphate 2-epimerase (5.1.3.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y501/00—Racemaces and epimerases (5.1)
    • C12Y501/03—Racemaces and epimerases (5.1) acting on carbohydrates and derivatives (5.1.3)
    • C12Y501/03014—UDP-N-acetylglucosamine 2-epimerase (non-hydrolysing) (5.1.3.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y504/00—Intramolecular transferases (5.4)
    • C12Y504/02—Phosphotransferases (phosphomutases) (5.4.2)
    • C12Y504/02001—Phosphoglycerate mutase (5.4.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y504/00—Intramolecular transferases (5.4)
    • C12Y504/02—Phosphotransferases (phosphomutases) (5.4.2)
    • C12Y504/0201—Phosphoglucosamine mutase (5.4.2.10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method for producing N-acetyl-D-glucosamine and/or D-glucosamine hydrochloride by means of microbial fermentation. By expressing a vitreoscilla hemoglobin in a microorganism, N-acetyl-D-glucosamine and/or D-glucosamine hydrochloride are produced with higher efficiency and higher yield.

Description

METHOD FOR PRODUCING N-ACETYL-D-GLUCOSAMINE AND/OR

FERMENTATION
Field of Technology This invention belongs to the field of microbial fermentation. Specifically, this invention relates with production of N-Acetyl-D-Glucosamine by microbial fermentation, and further preparation method of D-Glucosamine Salt.
Background Technology N-Acetyl-D-Glucosamine (NAG or GlcNAc), also called N-Acetyl-Glucosamine or N-AcetylGlucosamine, is a basic constituent unit for multiple important polysaccharides in biological cells, and has an important physiological function in organisms. N-Acetyl-D-Glucosamine may be used clinically to:
Increase the function of human immune system; inhibit growth of malignancy or fibrocytes; treatment effectively various inflammations; and be as a low-heat sweetener in diabetic patients, and a food additive for infants and young children;
and so on. Hydrolysis of N-Acetyl-D-Glucosamine may be used to produce D-Glucosamine Hydrochloride, which may be used as a food additive for fighting and preventing cancer, and lowering blood lipids and blood pressure, and is presently a third-generation food additive with healthcare function in chitin health food series. Moreover, N-Acetyl-D-Glucosamine is a major raw material for synthesis of Chlorozotocin, an anticancer agent; as a biochemical reagent, it may also be used as an immune adjuvant for resisting bacterial infection, and an activating agent for counteracting influenza viruses in human body.
Now all over the world, a lot of patients suffer from arthritis pain to different extents. In the United States only, there are 33 millions of patients suffering from arthritis and arthralgia; in our country, more than more than 0.15 billions of WSLEGAL\068076\00030\21038773v1 patients suffering arthritis and arthralgia. As D-Glucosamine products have special therapeutic and healthcare effects against arthritis and arthralgia, it has been used extensively, and now has become a very important raw material in domestic and foreign markets.
It is believed that N-Acetyl-D-Glucosamine has similar effects to D-Glucosamine. It is know that intake of N-Acetyl-D-Glucosamine can induce production of new cartilage and block episodes of osteoarthritis, or is used to treat osteoarthritis in some cases. As D-Glucosamine is bitter while N-acetyl-D-Glucosamine is 50% sweet of sucrose and is easily ingested.
Therefore, N-acetyl-D-Glucosamine has aroused concern as alternative of D-Glucosamine.
Presently, Glucosamine is mainly derived from biological extract at home and abroad. Biological extraction is mainly to extract chitin or chitosan from shrimp and crab shells and then hydrolyzed by concentrated hydrochloric acid, or extract from citrate slags by acid or alkali. The annual output is approximately 20,000 tons.
However, when extracted from shrimp and crab shells, each ton of the product is accompanied with a great amount of waste residue, and more than 100 tons of waste water; when extracted from citrate residue, each ton of the product is accompanied with 30-50 tons of waste acid residue - the process is a high-pollution process and has been prohigited in many places. Moreover, Glucosamine extracted from aquatic shells is not suitable for patients sensitive to aquatic products in whom it may result in severe allergy problems or even life-threatening.
Besides, the biological extraction and purification processes are complicated, and the product smells fishy and is unstable. Moreover, due to environmental pollution, it is inevitable that Glucosamine extracted from shrimp and crab shells may be contaminated by heavy metals.
Therefore, Glucosamine produced by biological extraction method cannot meet the needs of people in quantity and quality; it has to develop a new alternative method. If it is produced by chemical synthesis method, there are the following
2 WSLEGAL\068076\00030\21038773v1 three shortcomings: High production cost; severe environmental pollution; and potential safety risks. Now the method has been cancelled at home and abroad.
In comparison, the microbial fermentation method for production of Glucosamine is a good route, in which, glucose and inorganic salts are as raw materials, and undergo liquid fermentation by excellent strains, and separation, concentration, and purification to directly product Glucosamine. No noxious gas is produced during production. Glucosamine produced by fermentation method does not smell fishy, and the production resources are not limited. As well, strain improvement is carried out by metabolic engineering, with high output, and great potential for large-scale industrial production. Therefore, the microbial fermentation method for production of Glucosamine has a significant revolution to replace conventional biological extraction, and has an advantage in the cost and makes a contribution to environmental protection in reducing pollution of three wastes.
The routine methods of microbial fermentation for production of N-Acetyl-D-Glucosamine include: Method (for example, US5998173, "Process for producing N-acetyl-D-glucosamine") to produce N-Acetyl-D-Glucosamine from chitin manufactured from shrimp shells by enzymatic degradation; the enzymes are produced microbially; Method (for example, US20030073666A1, "N-acetyl-D-glucosamine and process for production of N-acetyl-D-glucosamine") to produce N-Acetyl-D-Glucosamine from chitin manufactured and purified from fungal residue (such as fungal residue of Aspergillus niger, used by citrate fermentation) by enzymatic degradation or acid-partial hydrolysis; the enzymes are produced microbially (by Trichoderma); method (for example, US20110059489A1, "Method for fermentative production of N-acetyl-D-glucosamine by microorganism") to produce N-Acetyl-D-Glucosamine by fermentation of Trichoderma, using directly glucose as carbon source, other than chitin and chitosan oligosaccharide produced from fungal residue or shrimp shells; method (for example, JP2004283144A, "Method for producing glucosamine and
3 WSLEGAL068076\00030\21038773v1 N-acetylglucosamine") to produce N-Acetyl-D-Glucosamine from incubation of Chlorella cells infected with Chlorovirus, or of recombinant Escherichia coli introduced with the gene of Chlorovirus; method (for example, US6,372,457, "Process and materials for production of glucosamine"; W02004/003175, "Process and materials for production of glucosamine and N-acetylglucosamine") to produce D-Glucosamine or N-Acetyl-D-Glucosamine by fermentation, using genetically modified microorganism, particularly genetically modified Escherichia coli.
The method for production of N-acetyl-D-glucosamine from degradation of chitin derived from the shells of shellfish such as crab and shrimp, by microorganism or by enzymes produced microbially, is relatively conventional, and has the problems of low yield, high cost, and insufficient animal source, etc.
The method for production of N-acetyl-D-glucosamine from incubation of chlorella cells infected with Chlorovirus is of complicated operation, etc., as it is involved with the step of crushing cells to obtain N-acetyl-D-glucosamine. The method for production of N-acetyl-D-glucosamine by trichoderma, using glucose as carbon source, had the advantages of requiring no chitin or chitin oligosaccharide as carbon source, produced from the shells of shellfish or from fungi dregs. However, as the fungi such as Trichoderma are of low fermentation temperature (27 C), long term (10 days), and relatively low yield (15 mg/mL), and thus are of long production cycle, high cost, and easy contamination, seriously restricting industrial application of the method.
Clearly, aiming at the increasing market demand for Glucosamine, the method to produce N-Acetyl-D-Glucosamine by genetically modified microorganism is an important method with application potential to realize large-scale industrialization.
New, genetically modified microorganism may be obtained by multiple modes, such as gene recombination, gene transfer, gene mutation, gene deletion, gene overexpression, or change to metabolic pathway, etc.
US6,372,457, a United State patent, discloses the method and materials to
4 WSLEGAL\068076\00030\21038773v1 produce D-Glucosamine by microbial feimentation. This Invention is involved with genetically modified microorganism for the method for production Glucosamine, as well as recombinant nucleic acid molecules, and proteins produced by the said recombinant nucleic acid molecules. The said genetically modified microorganism in this Invention are mainly involved with the genetic modification increasing the activities of Glucosamine-6-Phosphate Synthase, including multiple gene mutations or amino acid deletion and substitution.
However, the patient is not involved with changes of Glucosamine-6-Phosphate Synthase gene promoter replacement or deletion, leading to decreased or increased activities of Glucosamine-6-Phosphate Synthase. Moreover, the patient is mainly intended to produce D-Glucosamine, the only one target product, by genetic modification of Glucosamine-6-Phosphate Synthase, and is not involved with production of N-Acetyl-D-Glucosamine. Furthermore, as D-Glucosamine is quite unstable in fermentation broth, degradation products may be possibly toxic to microorganism. This production mode of D-Glucosamine by genetic modification is of very low yield, and is restricted in practical application.
The biosynthetic method for production of D-Glucosamine and N-Acetyl-D-Glucosamine is disclosed in W02004/003175. The method is to produce Glucosamine and/or N-Acetyl-D-Glucosamine by fermentation of genetically modified microorganism. This Invention also discloses the genetically modified microorganism for production of Glucosamine and N-Acetyl-D-Glucosamine. Additionally, this Invention also describes the recovery method of N-Acetyl-D-Glucosamine produced by fermentation method, including method for production of high-purity N-Acetyl-D-Glucosamine. This Invention also discloses the method for production of D-Glucosamine from N-Acetyl-D-Glucosamine. The said genetically modified microorganism in this Invention are mainly involved with the genetic modification increasing the activities of Glucosamine-6-Phosphate Acetyltransferase. It has been reported and
5 WSLEGAL\068076\00030\21038773v1 demonstrated in previous literatures that the expression of yeast Glucosamine-6-Phosphate Acetyltransferase gene (GNA1) in Escherichia coli may acetylate Glucosamine-6-Phosphate into Acetylglucosamine-6-Phosphate (Mio Ti, Yamada-Okabe T, Arisawa M, Yamada-Okabe H: Saccharomyces cerevisiae GNA1, an essential gene encoding a novel acetyltransferase involved in UDP-N-acetylglucosamine synthesis, J Biol Chem., 1999 Jan 1;274(1):424-9).
In production of N-Acetyl-Glucosamine, as the microorganism for high-density fermentation requires a large amount of oxygen; it requires persistent stirring and thus increases energy consumption. Moreover, persistent stirring may produce a lot of forms, thus influencing the output.
Contents of the Invention In this Invention, the microorganism is reformed by genetic modification, so that the microorganism may produce N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt in high efficiency and high output, thus to decrease production cost for industrial scale production.
Specifically speaking in this Invention, by expression of vitreoscilla hemoglobin (Vhb) in microorganism, it may increase the microorganism's utilization ability for dissolved oxygen, accelerate synthesis of proteins and metabolic products, promote microbial growth, increase fermentation potency and level, so that the microorganism may produce N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt in higher efficiency and higher product under limited oxygen conditions.
On top of the above contents, this Invention is further involved with one or more of the following contents:
1. By increasing the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganisms, this Invention may strengthen phosphorylation of N-Acetyl-D-Mannosamine (ManNAc) into
6 WSLEGAL\068076\00030\21038773v1 N-Acetyl-D-Mannosamine-6-Phosphate (ManNAc-6-P) in microorganism, so that microorganism may produce more efficiently N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine in a higher yield.
2. By increasing the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism, strengthen transformation of N-Acetyl-D-Mannosamine-6-Phosphate (ManNAc-6-P) in microorganism into N-Acetyl-D-Glucosamine-6-Phosphate (G1cNAc-6-P), excreted into extracellular domain to become N-Acetyl-D-Glucosamine (G1cNAc), so that microorganism may produce more efficiently N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt in a higher yield.
3. By increasing the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and meanwhile decreasing preferably the effects of Glucosamine-6-Phosphate Synthase (GlmS, also called L-Glutamine-D-fructose-6-Phosphate Aminotransferase), strengthen amination of Glucose-6-Phosphate (Glc-6-P) in microorganism into D-Glucosamine-6-Phosphate (G1cN-6-P). The reaction catalyzed by D-Glucosamine-6-Phosphate Deaminase (NagB) is reversible, while that catalyzed by Glucosamine-6-Phosphate Synthase (GlmS) is irreversible, but has a severe problem for product inhibition. When the NagB-catalyzed reaction proceeds in the direction from Glc-6-P to produce G1cN-6-P, its function is the same as that of GlmS, and may replace GlmS, without any problem for product inhibition. Increase effects of NagB, accelerate the NagB-catalyzed reaction to proceed in the direction from G1c-6-P to GlcN-6-P, meanwhile decrease preferably the effects of GlmS, mitigate the product inhibition problem of GlmS, to achieve the purpose of increasing G1cN-6-P, so that such microorganism may produce more efficiently N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt in a higher yield.
4. By increasing the effects of Glucosamine-6-Phosphate Synthase (GlmS, also called L-Glutamine-D-Fructose-6-Phosphate Aminotransferase) in
7 WSLEGAL\068076\00030\21038773v1 microorganism, and meanwhile decreasing the effects of D-Glucosamine-6-Phosphate Deaminase (NagB), strengthen amination of Glucose-6-Phosphate (Glc-6-P) in microorganism into D-Glucosamine-6-Phosphate (G1cN-6-P). The reaction catalyzed by D-Glucosamine-6-Phosphate Deaminase (NagB) is reversible. When the NagB-catalyzed reaction proceeds in the direction from Glc-6-P to produce G1cN-6-P, its function is opposite to that of GlmS, and may offset the effects of GlmS.
Decreasing the effects of NagB, block the NagB-catalyzed reaction to proceed in the direction from G1cN-6-P ot G1c-6-P, and meanwhile overexpress GlmS, accelerate GlmS-catalyzed amination of Glc-6-P into GleN-6-P, to achieve the purpose of increasing G1cN-6-P, so that microorganism may produce more efficiently N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt in a higher yield.
5. By increasing the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB), strengthen transformation of UDP-N-Acetyl-D-Glucosamine (UDP-G1cNAc) in microorganism into N-Acetyl-D-Mannosamine (ManNAc), so that microorganism may produce more efficiently N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt in a higher yield.
6. Decrease the effects of reuptake of target products into cells, or of relevant enzymes or proteins to degrade beneficial intermediates, increase sugar conversion rate and N-Acetyl-D-Glucosamine yield in microorganism, so that microorganism may produce more efficiently N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt in a higher yield. Include but are not limited to one or more of the following contents:
(1) Decrease the effects of Mannose transporter EIIM, P/IIIman (ManXYZ) in microorganism, and block return of hexoses such as N-Acetyl-D-Glucosamine (G1cNAc) to cells for degradation.
(2) Decrease the effects of N-Acetylneuraminate Lyase (NanA) in
8 WSLEGAL\068076\00030\21038773v1 microorganism, and block degradation of N-Acetyl-D-Mannosamine (ManNAc) in microorganism.
(3) Decrease the effects of N-Acetyl-D-Glucosamine-6-Phosphate Deactylase (NagA) in microorganism, block transformation of N-Acetyl- D- Glucosamine- 6-Phosphate (G1cNAc-6- P) into D-Glucosamine-6-Phosphate (G1cN-6-P) in microorganism.
(4) Decrease the effects of N-Acetyl-D-Glucosamine Specific Enzyme IINag (NagE), and block transportation of N-Acetyl-D-Glucosamine (G1cNAc) into microbial cells for degradation.
(5) By increasing the effects of PhosphoGlucosamine Mutase (G1mM) in microorganism, strengthen transformation of D-Glucosamine-6-Phosphate (G1cN-6 -P) into D-Glucosamine-1 -Phosphate (G1cN-1 -P).
(6) by increasing the effects of bifunctional N-acetyl Glucosamine-1 -Phosphate Uridyltransferase (also called Glucosamine-l-Phosphate Acetyl Transferase, GlmU), strengthen transformation of D-Gluco samine- 1 -Pho sphate (G1cN- 1 -P) into N-Acetyl-D-Glucosamine- 1 -Phosphate (G1cNAc- 1-P), and further transformation into UDP-N-Acetyl-D-Glucosamine (UDP-G1cNAc).
Based on one implementation scheme of this Invention, this Invention is involved with the method for production of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb); and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
Preferably further include C) Deacetylation of N-Acetyl-D-Glucosamine (G1cNAc) to produce D-Glucosamine Salt.
9 WSLEGAL\068076\00030\21038773v1 In this Invention, the microorganism contains at least one transformation of recombinant nucleic acid molecules of the nucleotide sequence encoding vitreoscilla hemoglobin (Vhb).
In this Invention, using vitreoscilla hemoglobin (Vhb) as object, random base replacement is introduced by error-prone PCR random mutagenesis method for DNA reorganization, to screen an ideal mutant of the protein. The random mutagenesis method for introducing mutations by error-prone PCR is to screen an ideal mutant by introducing random base replacement, while DNA reorganization may increase more significantly the probability for benign mutations, thus to obtain mutants with higher application value. To increase activities of vitreoscilla hemoglobin (Vhb), the microorganism is rebuilt by the combination of error-prone PCR and DNA reorganization, and the mutant gene is controlled by promoter for oxygen regulation to carry out expression and screening, to obtain mutant protein with higher activities than wild type under limited oxygen conditions.
On the other hand, the nucleotide sequence encoding vitreoscilla hemoglobin (Vhb) contains at least one genetic modification that may increase the activities of vitreoscilla hemoglobin (Vhb). Preferably, the said genetic modification contains one or more substitutions at the following corresponding sites of the amino acid sequence SEQ ID NO:61: Methionine at Site 45 is substituted by leucine, cysteine at Site 86 is substituted by glycine, and tyrosine at Site 95 is substituted by serine.
More preferably, the nucleic acid sequence encoding the said vitreoscilla hemoglobin (Vhb) is SEQ ID NO: 64; the amino acid sequence of the said vitreoscilla hemoglobin (Vhb) is SEQ ID NO:65.
On the other hand, at least approximately 30% (more preferably at least approximately 50%, further more preferably at least approximately 70%, further more preferably at least approximately 80%, and further more at least approximately 90%, and most preferably at least approximately 95%) of the amino acid sequence of the said vitreoscilla hemoglobin (Vhb) is the same as that of SEQ
WSLEGAL\068076\00030\21038773v1 ID NO:61, where the said vitreoscilla hemoglobin (Vhb) is active.
On the other hand, the said vitreoscilla hemoglobin (Vhb) has the amino acid sequence of SEQ ID NO:61.
On the other hand, the gene copies in the recombinant nucleic acid molecules, encoding vitreoscilla hemoglobin (Vhb), are more than or equal to 1.
On the other hand, the recombinant nucleic acid molecules contain an endogenous promoter, with a higher expression level of promoters, enhancers, and fusion sequences, etc., than those of natural endogenous promoters.
Preferably, the recombinant nucleic acid molecules contains a higher expression level of promoters than that of natural endogenous promoters, such as HCE promoter, gap promoter, trc promoter, and T7 promoter, etc.; more preferably, the recombinant nucleic acid molecules contain trc promoter. trc promoter is a combined promoter of trp promoter and lac promoter, with a higher transcription efficiency than that of trp, and with strong promoter characteristics to be regulated by lad repressor protein.
In this Invention, microorganism transformed by recombinant nucleic acid molecules transform are selected from free type (that is to say, recombinant nucleic acid molecules are mounted into plasmids) and integrated type (that is to say, recombinant nucleic acid molecules are integrated into the genomes of microorganism). Preferably, recombinant nucleic acid molecules are integrated into the genomes of microorganism.
Based on the preferably optimized implementation scheme, the said microorganism contains one or more of the following genetic modifications:
(1) Contain at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism;
(2) Contain at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism;
(3) Contain at least one genetic modification that may increase the effects of WSLEGAL\068076\00030\21038773v1 D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and preferably contain at least one genetic modification that may decrease the effects of Glucosamine-6-Phosphate Synthase (GlmS);
(4) Contain at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, and preferably contain at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) (5) Contain at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism;
In respect to the above (1), the genetic modification to increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism is selected from: a) increasing effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism;
and/or b) overexpression of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism.
A technician in this field may understand that, to increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, it may be realized by screening for a gene mutant of N-Acetyl-D-Mannosamine Kinase (NanK), encoding N-Acetyl-D-Mannosamine Kinase (NanK) with increased activities. The screening for a NanK gene mutant may be achieved by error-prone PCR
technology to produce a high-frequency mutant gene. To increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, it may also be realized by increasing its gene copies or replacing it with a promoter with a higher expression level than that of the natural promoter, for overexpression of N-Acetyl-D-Mannosamine Kinase (NanK). In a specific implementation scheme, the microorganism is transformed by molecules of at least recombinant nucleic acid, containing at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism.
In a preferably optimized implementation scheme, the microorganism is WSLEGAL\068076\00030\21038773v1 transformed by molecules of at least recombinant nucleic acid, containing one nucleotide sequence encoding N-Acetyl-D-Mannosamine Kinase (NanK).
On the other hand, the nucleotide sequence encoding N-Acetyl-D-Mannosamine Kinase (NanK) contains at least one genetic modification that may increase the activities of N-Acetyl-D-Mannosamine Kinase (NanK). Preferably the said genetic modification contains one or more substitutions at the following corresponding sites of SEQ ID NO: 17:
Substitution of lysine at site 36 by arginine, substitution of isoleucine at Site 103 by methionine, and substitution of arginine at Site 223 by serine. More preferably, the nucleic acid sequence encoding the said N-Acetyl-D-Mannosamine Kinase (NanK) is SEQ ID
NO: 26; the amino acid sequence of the said N-Acetyl-D-Mannosamine Kinase (NanK) is SEQ ID NO: 27.
On the other hand, at least approximately 30% (more preferably at least approximately 50%, further more preferably at least approximately 70%, further more preferably at least approximately 80%, and further more at least approximately 90%, and most preferably at least approximately 95%) of the amino acid sequence of the said N-Acetyl-D-Marmosamine Kinase (NanK) is the same as that of SEQ ID NO: 17, where the said N-Acetyl-D-Mannosamine Kinase (NanK) is active.
On the other hand, the said N-Acetyl-D-Mannosamine Kinase (NanK) has the amino acid sequence of SEQ ID NO: 17.
On the other hand, the gene copies in the recombinant nucleic acid molecules, encoding N-Acetyl-D-Mannosamine Kinase (NanK), are increased.
On the other hand, the recombinant nucleic acid molecules contain an endogenous promoter, with a higher expression level of promoters, enhancers, and fusion sequences, etc., than those of natural endogenous promoters.
Preferably, the recombinant nucleic acid molecules contains a higher expression level of promoters than that of natural endogenous promoters, such as HCE promoter, gap WSLEGAL\068076\00030\21038773v1 promoter, trc promoter, and T7 promoter, etc.; more preferably, the recombinant nucleic acid molecules contain trc promoter. trc promoter is a combined promoter of trp promoter and lac promoter, with a higher transcription efficiency than that of trp, and with strong promoter characteristics to be regulated by lad I
repressor protein.
In this Invention, microorganism transformed by recombinant nucleic acid molecules transfonu are selected from free type (that is to say, recombinant nucleic acid molecules are mounted into plasmids) and integrated type (that is to say, recombinant nucleic acid molecules are integrated into the genomes of microorganism). Preferably, recombinant nucleic acid molecules are integrated into the genomes of microorganism.
In another preferably optimized implementation scheme, the microorganism contains at least one genetic modification of the natural endogenous promoter to the gene encoding N-Acetyl-D-Mannosamine Kinase (NanK). Preferably, the natural endogenous promoter with the gene encoding N-Acetyl-D-Mannosamine Kinase (NanK) is replaced by a promoter with a higher expression level, such as HCE promoter, gap promoter, trc promoter, or T7 promoter, etc.; more preferably, the natural endogenous promoter with the gene encoding N-Acetyl-D-Mannosamine Kinase (NanK) is replaced by trc promoter.
In respect to the above (2), the genetic modification increasing the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism is selected from a) increasing the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism; and/or b) overexpression of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism.
A technician in this field may understand that, to increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism, it may be realized by screening for a gene mutant of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE), encoding WSLEGAL\068076\00030\21038773v1 N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) with increased activities. The screening for a NanE gene mutant may be achieved by error-prone PCR technology to produce a high-frequency mutant gene. To increase the effects of N-Acetyl-D-Mannosamine-Phosphate Epimerase (NanE) in microorganism, it may also be realized by increasing its gene copies or replacing it with a promoter with a higher expression level than that of the natural promoter, for overexpression of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE). In a specific implementation scheme, the microorganism is transformed by molecules of at least recombinant nucleic acid molecules, containing at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism.
In a preferably optimized implementation scheme, the microorganism is transformed by molecules of recombinant nucleic acid, containing one nucleotide sequence encoding N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE).
On the other hand, the nucleotide sequence encoding N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) contains at least one genetic modification that may increase the activities of N-Acetyl-D- Mannosamine-6-Phophate Epimerase (NanE). Preferably the said genetic modification contains one or more substitutions at the following corresponding sites of SEQ ID NO:
29:
Substitution of cysteine at Site 133 by arginine, and substitution of tyrosine at Site 187 by histidine. More preferably, the nucleic acid sequence encoding N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) is SEQ ID NO: 56; the amino acid sequence of the said N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) is SEQ ID NO: 57.
On the other hand, at least approximately 30% (more preferably at least approximately 50%, further more preferably at least approximately 70%, further more preferably at least approximately 80%, and further more at least approximately 90%, and most preferably at least approximately 95%) of the amino WSLEGAL\068076\00030\21038773v1 acid sequence of the said N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) is the same as that of SEQ ID NO: 29, where the said N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) is active.
On the other hand, the said N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) has the amino acid sequence of SEQ ID NO: 29.
On the other hand, the gene copies in the recombinant nucleic acid molecules, encoding N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE), are increased.
On the other hand, the recombinant nucleic acid molecules contain an endogenous promoter, with a higher expression level of promoters, enhancers, and fusion sequences, etc., than those of natural endogenous promoters.
Preferably, the recombinant nucleic acid molecules contains a higher expression level of promoters than that of natural endogenous promoters, such as HCE promoter, gap promoter, trc promoter, and T7 promoter, etc.; more preferably, the recombinant nucleic acid molecules contain trc promoter.
In this Invention, microorganism transformed by recombinant nucleic acid molecules transform are selected from free type (that is to say, recombinant nucleic acid molecules are mounted into plasmids) and integrated type (that is to say, recombinant nucleic acid molecules are integrated into the genomes of microorganism). Preferably, recombinant nucleic acid molecules are integrated into the genomes of microorganism.
In another preferably optimized implementation scheme, the microorganism contains at least one genetic modification of the natural endogenous promoter to the gene encoding N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE).
Preferably, the natural endogenous promoter with the gene encoding N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) is replaced by a promoter with a higher expression level, such as HCE promoter, gap promoter, trc promoter, or T7 promoter, etc.; more preferably, the natural endogenous promoter WSLEGAL\068076\00030\21038773v1 with the gene encoding N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) is replaced by trc promoter.
In respect to the above (3), the genetic modification increasing the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism is selected from a) increasing the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism; and/or b) overexpression of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism.
A technician in this field may understand that, to increase the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, it may be realized by screening for a gene mutant of D-Glucosamine-6-Phosphate Deaminase (NagB), encoding D-Glucosamine-6-Phosphate Deaminase (NagB) with increased activities. The screening for a NanG gene mutant may be achieved by error-prone PCR technology to produce a high-frequency mutant gene. To increase the effects of D-Glucosamine-Phosphate Deaminase (NanB) in microorganism, it may also be realized by increasing its gene copies or replacing it with a promoter with a higher expression level than that of the natural promoter, for overexpression of D-Glucosamine-6-Phosphate Deaminase (NanB). In a specific implementation scheme, the microorganism is transformed by molecules of at least one recombinant nucleic acid, containing at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deaminase (NanB) in microorganism.
In a preferably optimized implementation scheme, the microorganism is transformed by molecules of at least recombinant nucleic acid, containing one nucleotide sequence encoding D-Glucosamine-6-Phosphate Deaminase (NanB).
On the other hand, the nucleotide sequence encoding D-Glucosamine-6-Phosphate Deaminase (NanB) contains at least one genetic modification that may increase the activities of D-Glucosamine-6-Phosphate Deaminase (NanB).

WSLEGAL\068076\00030\21038773v1 On the other hand, the gene copies in the recombinant nucleic acid molecules, encoding D-Glucosamine-6-Phosphate Deaminase (NanB), are increased.
On the other hand, the recombinant nucleic acid molecules contain an endogenous promoter, with a higher expression level of promoters, enhancers, and fusion sequences, etc., than those of natural endogenous promoters.
Preferably, the recombinant nucleic acid molecules contains a higher expression level of promoters than that of natural endogenous promoters, such as HCE promoter, gap promoter, trc promoter, and T7 promoter, etc.; more preferably, the recombinant nucleic acid molecules contain trc promoter.
In this Invention, microorganism transformed by recombinant nucleic acid molecules transfolin are selected from free type (that is to say, recombinant nucleic acid molecules are mounted into plasmids) and integrated type (that is to say, recombinant nucleic acid molecules are integrated into the genomes of microorganism). Preferably, recombinant nucleic acid molecules are integrated into the genomes of microorganism.
In another preferably optimized implementation scheme, the microorganism contains at least one genetic modification of the natural endogenous promoter to the gene encoding D-Glucosamine-6-Phosphate Deaminase (NanB). Preferably, the natural endogenous promoter with the gene encoding D-Glucosamine-6-Phosphate Deaminase (NanB) is replaced by a promoter with a higher expression level, such as HCE promoter, gap promoter, trc promoter, or promoter, etc.; more preferably, the natural endogenous promoter with the gene encoding D-Glucosamine-6-Phosphate Deaminase (NanB) is replaced by trc promoter.
In this Invention, the genetic modifications decreasing the effects of Glucosamine-6-Phosphate Synthase (GlmS) in microorganism is selected from a) decreasing effects of Glucosamine-6-Phosphate Synthase (GlmS) in microorganism; and/or b) reducing expression of Glucosamine-6-Phosphate WSLEGAL\068076\00030\21038773v1 Synthase (GlmS) in microorganism, including but not limited to: Partial or complete deletion, or partial or complete deactivation of the endogenous gene encoding Glucosamine-6-Phosphate Synthase (GlmS), and/or partial or complete deletion, or partial or complete deactivation of the natural endogenous promoter with the gene encoding Glucosamine-6-Phosphate Synthase (GlmS). Preferably, the genetic modification decreasing the effects of Glucosamine-6-Phosphate Synthase (GlmS) in microorganism is complete deletion (loss) of the natural endogenous promoter with the gene encoding Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
In a specific implementation scheme, the microorganism is transfoillied by molecules of at least one recombinant nucleic acid, containing at least one genetic modification that may decrease the effects of Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
In respect to the above (4), the genetic modification increasing the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism is selected from a) increasing the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism; and/or b) overexpression of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
A technician in this field may understand that, to increase the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, it may be realized by screening for a gene mutant of D-Glucosamine-6-Phosphate Deaminase (NagB), encoding D-Glucosamine-6-Phosphate Deaminase (NagB) with increased activities. The screening for a GlmS gene mutant may be achieved by error-prone PCR technology to produce a high-frequency mutant gene. To increase the effects of Glucosamine-Phosphate Synthase (GlmS) in microorganism, it may also be realized by increasing its gene copies or replacing it with a promoter with a higher expression level than that of the natural promoter, for overexpression of Glucosamine-6-Phosphate Synthase (GlmS). In a specific implementation scheme, WSLEGAL068076\00030\21038773v1 the microorganism is transformed by molecules of at least one recombinant nucleic acid, containing at least one genetic modification that may increase the effects of Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
In a preferably optimized implementation scheme, the microorganism is transformed by molecules of at least recombinant nucleic acid, containing one nucleotide sequence encoding Glucosamine-6-Phosphate Synthase (GlmS).
On the other hand, the nucleotide sequence encoding Glucosamine-6-Phosphate Synthase (GlmS) contains at least one genetic modification that may increase the activities of D-Glucosamine-6-Phosphate Synthase (GlmS).
On the other hand, the gene copies in the recombinant nucleic acid molecules, encoding D-Glucosamine-6-Phosphate Synthase (GlmS), are increased.
On the other hand, the recombinant nucleic acid molecules contain an endogenous promoter, with a higher expression level of promoters, enhancers, and fusion sequences, etc., than those of natural endogenous promoters.
Preferably, the recombinant nucleic acid molecules contains a higher expression level of promoters than that of natural endogenous promoters, such as HCE promoter, gap promoter, trc promoter, and T7 promoter, etc.; more preferably, the recombinant nucleic acid molecules contain trc promoter.
In this Invention, microorganism transformed by recombinant nucleic acid molecules transform are selected from free type (that is to say, recombinant nucleic acid molecules are mounted into plasmids) and integrated type (that is to say, recombinant nucleic acid molecules are integrated into the genomes of microorganism). Preferably, recombinant nucleic acid molecules are integrated into the genomes of microorganism.
In another preferably optimized implementation scheme, the microorganism contains at least one genetic modification of the natural endogenous promoter to the gene encoding Glucosamine-6-Phosphate Synthase (GlmS). Preferably, the WSLEGAL\068076\00030\21038773v1 natural endogenous promoter with the gene encoding Glucosamine-6-Phosphate Synthase (GlmS) is replaced by a promoter with a higher expression level, such as HCE promoter, gap promoter, trc promoter, or T7 promoter, etc.; more preferably, the natural endogenous promoter with the gene encoding Glucosamine-6-Phosphate Synthase (GlmS) is replaced by trc promoter.
In this Invention, the genetic modifications decreasing the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism are selected from a) decreasing effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism; and/or b) reducing expression of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, including but not limited to: Partial or complete deletion, or partial or complete deactivation of the endogenous gene encoding D-Glucosamine-6-Phosphate Deaminase (NagB), and/or partial or complete deletion, or partial or complete deactivation of the natural endogenous promoter with the gene encoding Glucosamine-6-Phosphate Deaminase (NagB).
Preferably, the genetic modification decreasing the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism is complete deletion (loss) of the natural endogenous promoter with the gene encoding D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism.
In a specific implementation scheme, the microorganism is transformed by molecules of at least one recombinant nucleic acid, containing at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NanB) in microorganism.
In respect to the above (5), the genetic modification increasing the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism is selected from a) increasing the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism; and/or b) overexpression of UDP-N-Acetyl -D-Glucosamine- 2-Epimerase (WecB) in microorganism.
A technician in this field may understand that, to increase the effects of WSLEGAL\068076\00030\21038773v1 UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism, it may be realized by screening for a gene mutant of UDP-N-Acetyl- D-Glucosamine-2 -Epimerase (WecB), encoding UDP-N-Acetyl-D-Gluco s amine-2-Ep imeras e (WecB) with increased activities. The screening for a WecB gene mutant may be achieved by error-prone PCR technology to produce a high-frequency mutant gene.
To increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism, it may also be realized by increasing its gene copies or replacing it with a promoter with a higher expression level than that of the natural promoter, for overexpression of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB). In a specific implementation scheme, the microorganism is transfotmed by molecules of at least recombinant nucleic acid molecules, containing at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism.
In a preferably optimized implementation scheme, the microorganism is transformed by molecules of recombinant nucleic acid, containing one nucleotide sequence encoding UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB).
On the other hand, the nucleotide sequence encoding UDP-N-Acetyl- D-Glucosamine-2-Epimerase (WecB) contains at least one genetic modification that may increase the activities of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB). Preferably the said genetic modification contains one or more substitutions at the following corresponding sites of SEQ ID NO: 50:
Substitution of cysteine at Site 34 by senile, substitution of histidine at site 145 by aspartate, substitution of cysteine at Site 226 by phenylalanine, and substitution of valine at Site 245 by glycine. More preferably, the nucleic acid sequence encoding UDP-N-Acetyl-D-Glucosamine- 2-Epimerase (WecB) is SEQ ID NO: 58; the amino acid sequence of the said UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) is SEQ ID NO: 59.
On the other hand, at least approximately 30% (more preferably at least WSLEGAL\068076\00030\21038773v1 approximately 50%, further more preferably at least approximately 70%, further more preferably at least approximately 80%, and further more at least approximately 90%, and most preferably at least approximately 95%) of the amino acid sequence of the said UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) is the same as that of SEQ ID NO: 50, where the said UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) is active.
On the other hand, the said UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) has the amino acid sequence of SEQ ID NO: 50.
On the other hand, the gene copies in the recombinant nucleic acid molecules, encoding UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB), are increased.
On the other hand, the recombinant nucleic acid molecules contain an endogenous promoter, with a higher expression level of promoters, enhancers, and fusion sequences, etc., than those of natural endogenous promoters.
Preferably, the recombinant nucleic acid molecules contains a higher expression level of promoters than that of natural endogenous promoters, such as HCE promoter, gap promoter, trc promoter, and T7 promoter, etc.; more preferably, the recombinant nucleic acid molecules contain trc promoter.
In this Invention, microorganism transformed by recombinant nucleic acid molecules transform are selected from free type (that is to say, recombinant nucleic acid molecules are mounted into plasmids) and integrated type (that is to say, recombinant nucleic acid molecules are integrated into the genomes of microorganism). Preferably, recombinant nucleic acid molecules are integrated into the genomes of microorganism.
In another preferably optimized implementation scheme, the microorganism contains at least one genetic modification of the natural endogenous promoter to the gene encoding UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB).
Preferably, the natural endogenous promoter with the gene encoding UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) is replaced by a promoter WSLEGAL\068076\00030\21038773v1 with a higher expression level, such as HCE promoter, gap promoter, trc promoter, or T7 promoter, etc.; more preferably, the natural endogenous promoter with the gene encoding UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) is replaced by trc promoter.
Based on the preferably optimized implementation scheme, the said microorganism contains one or more of the following genetic modifications:
(1) Contain at least genetic modification that may decrease the effects of Mannose transporter EIIM, P/IIIm"(Man)(YZ) in microorganism;
(2) Contain at least one genetic modification that may decrease the effects of N-Acetylneuraminate Lyase (NanA) in microorganism;
(3) Contain at least one genetic modification that may decrease the effects of N-Acetyl-D-Glucosamine-6-Phosphate Deactylase (NagA) in microorganism;
(4) Contain at least one genetic modification that may decrease the effects of N-Acetyl-D-Glucosamine Specific Enzyme Irag (NagE) in microorganism;
(5) Contain at least one genetic modification that may increase the effects of PhosphoGlucosamine Mutase (G1mM) in microorganism;
(6) Contain at least one genetic modification that may increase the effects of bifunctional N-acetyl Glucosamine- 1-Phosphate Uridyltransferase (GlmU) in microorganism;
In respect to the above (1), the genetic modifications decreasing the effects of Mannose transporter EIIM, PAH' (ManXYZ) in microorganism include but not limited to: Partial or complete deletion, or partial or complete deactivation of the endogenous gene encoding Mannose transporter EIIM, PAH' (ManXYZ), and/or partial or complete deletion, or partial or complete deactivation of the natural endogenous promoter with the gene encoding Mannose transporter EIIM, PAH' (ManXYZ). Preferably, the genetic modification decreasing the effects of Mannose transporter EIIM, P/IIIm"(Man(YZ) in microorganism is complete deletion (loss) of the endogenous gene encoding EIIM, P/IIIm"(ManXYZ) in microorganism. In a WSLEGAL\068076\00030\21038773v1 specific implementation scheme, the microorganism is transfolined by molecules of at least one recombinant nucleic acid, containing at least one genetic modification that may decrease the effects of Mannose transporter EIIM, P/IIIman (ManXYZ) in microorganism.
In respect to the above (2), the genetic modifications decreasing the effects of N-Acetylneuraminate Lyase (NanA) in microorganism include but not limited to:
Partial or complete deletion, or partial or complete deactivation of the endogenous gene encoding N-Acetylneuraminate Lyase (NanA), and/or partial or complete deletion, or partial or complete deactivation of the natural endogenous promoter with the gene encoding N-Acetylneuraminate Lyase (NanA). Preferably, the genetic modification decreasing the effects of N-Acetylneuraminate Lyase (NanA) in microorganism is complete deletion (loss) of the natural endogenous gene encoding N-Acetylneuraminate Lyase (NanA) in microorganism. In a specific implementation scheme, the microorganism is transformed by molecules of at least recombinant nucleic acid, containing at least one genetic modification that may decrease the effects of N-Acetylneuraminate Lyase (NanA) in microorganism.
In respect to the above (3), the genetic modifications decreasing the effects of N-Acetyl-D-Glucosamine-6-Phosphate Deactylase (NagA) in microorganism include but not limited to: Partial or complete deletion, or partial or complete deactivation of the endogenous gene encoding N-Acetyl-D-Glucosamine-6-Phosphate Deactylase (NagA), and/or partial or complete deletion, or partial or complete deactivation of the natural endogenous promoter with the gene encoding N-Acetyl-D-Glucosamine-6-Phosphate Deactylase (NagA). Preferably, the genetic modification decreasing the effects of N-Acetyl-D-Glucosamine-6-Phosphate Deactylase (NagA) in microorganism is complete deletion (loss) of the natural endogenous promoter with the gene encoding N-Acetyl-D-Glucosamine-6-Phosphate Deactylase (NagA) in microorganism. In a specific implementation scheme, the microorganism is WSLEGAL\068076\00030\21038773v1 transformed by molecules of at least one recombinant nucleic acid, containing at least one genetic modification that may decrease the effects of N-Acetyl-D-Glucosamine-6-Phosphate Deactylase (NagA) in microorganism.
In respect to the above (4), the genetic modifications decreasing the effects of N-Acetyl-D-Glucosamine Specific Enzyme IINag (NagE) in microorganism include but not limited to: Partial or complete deletion, or partial or complete deactivation of the endogenous gene encoding N-Acetyl-D-Glucosamine Specific Enzyme IINag (NagE), and/or partial or complete deletion, or partial or complete deactivation of the natural endogenous promoter with the gene encoding N-Acetyl-D-Glucosamine Specific Enzyme IINag (NagE). Preferably, the genetic modification decreasing the effects of N-Acetyl-D-Glucosamine Specific Enzyme IINag (NagE) in microorganism is complete deletion (loss) of the natural endogenous promoter with the gene encoding N-Acetyl-D-Glucosamine Specific Enzyme IINag (NagE) in microorganism. In a specific implementation scheme, the microorganism is transformed by molecules of at least one recombinant nucleic acid, containing at least one genetic modification that may decrease the effects of N-Acetyl-D-Glucosamine Specific Enzyme IINag (NagE) in microorganism.
In respect to the above (5), the genetic modification increasing the effects of PhosphoGlucosamine Mutase (G1mM) in microorganism is selected from a) increasing the effects of PhosphoGlucosamine Mutase (G1mM) in microorganism;
and/or b) overexpression of PhosphoGlucosamine Mutase (G1mM) in microorganism.
A technician in this field may understand that, to increase the effects of PhosphoGlucosamine Mutase (G1mM) in microorganism, it may be realized by screening for a gene mutant of PhosphoGlucosamine Mutase (G1mM), encoding PhosphoGlucosamine Mutase (G1mM) with increased activities. The screening for a GlmM gene mutant may be achieved by error-prone PCR technology to produce a high-frequency mutant gene. To increase the effects of PhosphoGlucosamine WSLEGAL\068076\00030\21038773v1 Mutase (G1mM) in microorganism, it may also be realized by increasing its gene copies or replacing it with a promoter with a higher expression level than that of the natural promoter, for overexpression of PhosphoGlucosamine Mutase (G1mM).
In a specific implementation scheme, the microorganism is transformed by molecules of at least one recombinant nucleic acid, containing at least one genetic modification that may increase the effects of PhosphoGlucosamine Mutase (G1mM) in microorganism.
In a preferably optimized implementation scheme, the microorganism is transformed by molecules of at least recombinant nucleic acid, containing one nucleotide sequence encoding PhosphoGlucosamine Mutase (G1mM).
On the other hand, the nucleotide sequence encoding PhosphoGlucosamine Mutase (G1mM) contains at least one genetic modification that may increase the activities of PhosphoGlucosamine Mutase (G1mM).
On the other hand, the gene copies in the recombinant nucleic acid molecules, encoding PhosphoGlucosamine Mutase (G1mM), are increased.
On the other hand, the recombinant nucleic acid molecules contain an endogenous promoter, with a higher expression level of promoters, enhancers, and fusion sequences, etc., than those of natural endogenous promoters.
Preferably, the recombinant nucleic acid molecules contains a higher expression level of promoters than that of natural endogenous promoters, such as HCE promoter, gap promoter, trc promoter, and 17 promoter, etc.; more preferably, the recombinant nucleic acid molecules contain trc promoter.
In this Invention, microorganism transformed by recombinant nucleic acid molecules transform are selected from free type (that is to say, recombinant nucleic acid molecules are mounted into plasmids) and integrated type (that is to say, recombinant nucleic acid molecules are integrated into the genomes of microorganism). Preferably, recombinant nucleic acid molecules are integrated into the genomes of microorganism.

WSLEGAL\068076\0003021038773v1 In another preferably optimized implementation scheme, the microorganism contains at least one genetic modification of the natural endogenous promoter to the gene encoding PhosphoGlucosamine Mutase (G1mM). Preferably, the natural endogenous promoter with the gene encoding PhosphoGlucosamine Mutase (G1mM) is replaced by a promoter with a higher expression level, such as HCE
promoter, gap promoter, trc promoter, or T7 promoter, etc.; more preferably, the natural endogenous promoter with the gene encoding PhosphoGlucosamine Mutase (G1mM) is replaced by trc promoter.
In respect to the above (6), the genetic modification increasing the effects of bifunctional N-acetyl Glucosamine-l-Phosphate Uridyltransferase (GlmU) in microorganism is selected from a) increasing the effects of bifunctional N-acetyl Glucosamine-1 -Phosphate Uridyltransferase (GlmU) in microorganism; and/or b) overexpression of bifunctional N-acetyl Glucosamine-l-Phosphate Uridyltransferase (GlmU) in microorganism.
A technician in this field may understand that, to increase the effects of bifunctional N-acetyl Glucosamine-l-Phosphate Uridyltransferase (GlmU) in microorganism, it may be realized by screening for a gene mutant of bifunctional N-acetyl Glucosamine-1 -Phosphate Uridyltransferase (GlmU), encoding of bifunctional N-acetyl Glucosamine-1-Phosphate Uridyltransferase (GlmU) with increased activities. The screening for a GlmU gene mutant may be achieved by error-prone PCR technology to produce a high-frequency mutant gene. To increase the effects of bifunctional N-acetyl Glucosamine-1 -Phosphate Uridyltransferase (GlmU) in microorganism, it may also be realized by increasing its gene copies or replacing it with a promoter with a higher expression level than that of the natural promoter, for overexpression of bifunctional N-acetyl Glucosamine-1 -Phosphate Uridyltransferase (GlmU). In a specific implementation scheme, the microorganism is transformed by molecules of at least recombinant nucleic acid molecules, containing at least one genetic modification that may increase the WSLEGAL\068076100030\21038773v1 effects of bifunctional N-acetyl Glucosamine- 1 -Phosphate Uridyltransferase (GlmU) in microorganism.
In a preferably optimized implementation scheme, the microorganism is transformed by molecules of at least recombinant nucleic acid, containing one nucleotide sequence encoding bifunctional N-acetyl Glucosamine- 1 -Phosphate Uridyltransferase (GlmU).
On the other hand, the nucleotide sequence encoding bifunctional N-acetyl Glucosamine- 1 -Phosphate Uridyltransferase (GlmU) contains at least one genetic modification that may increase the activities of bifunctional N-acetyl Glucosamine- 1-Phosphate Uridyltransferase (GlmU).
On the other hand, the gene copies in the recombinant nucleic acid molecules, encoding bifunctional N-acetyl Glucosamine- 1 -Phosphate Uridyltransferase (GlmU), are increased.
On the other hand, the recombinant nucleic acid molecules contain an endogenous promoter, with a higher expression level of promoters, enhancers, and fusion sequences, etc., than those of natural endogenous promoters.
Preferably, the recombinant nucleic acid molecules contains a higher expression level of promoters than that of natural endogenous promoters, such as HCE promoter, gap promoter, trc promoter, and T7 promoter, etc.; more preferably, the recombinant nucleic acid molecules contain trc promoter.
In this Invention, microorganism transformed by recombinant nucleic acid molecules transform are selected from free type (that is to say, recombinant nucleic acid molecules are mounted into plasmids) and integrated type (that is to say, recombinant nucleic acid molecules are integrated into the genomes of microorganism). Preferably, recombinant nucleic acid molecules are integrated into the genomes of microorganism.
In another preferably optimized implementation scheme, the microorganism contains at least one genetic modification of the natural endogenous promoter to WSLEGAL\068076\00030\21038773v1 the gene encoding bifunctional N-acetyl Gluco s amine-1 -Phosphate Uridyltransferase (GlmU). Preferably, the natural endogenous promoter with the gene encoding bifunctional N-acetyl Glucosamine- 1 -Phosphate Uridyltransferase (GlmU) is replaced by a promoter with a higher expression level, such as HCE
promoter, gap promoter, trc promoter, or T7 promoter, etc.; more preferably, the natural endogenous promoter with the gene encoding bifunctional N-acetyl Glucosamine-l-Phosphate Uridyltransferase (GlmU) is replaced by trc promoter.
This Invention is further involved with the following preferably optimized implementation schemes:
1. Based on one preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), and at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
2. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (GleNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), and at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) WSLEGAL\068076\00030\21038773v1 in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
3. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), and at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
Preferably, the said microorganism also contains at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
4. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, and at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the WSLEGAL\068076\00030\21038773v1 cultivation step A).
5. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
6. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, and at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
7. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:

WSLEGAL\068076\00030\21038773v1 A) Cultivation of microorganism in the fennentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, and at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deatninase (NagB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
Preferably, the said microorganism also contains at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
8. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, and at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
9. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial WSLEGAL\068076\00030\21038773v1 fermentation, which includes:
A) Cultivation of microorganism in the femientation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
10. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism, and at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
Preferably, the said microorganism also contains at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
11. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:

WSLEGAL068076\00030\21038773v1 A) Cultivation of microorganism in the feimentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism, at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, and at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
12. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
13. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express WSLEGAL\068076\00030\21038773v1 vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
Preferably, the said microorganism also contains at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
14. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fennentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
15. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said WSLEGAL\068076\00030\21038773v1 microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism, and at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
Preferably, the said microorganism also contains at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
16. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism, at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, and at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).

WSLEGAL\068076\00030\21038773v1
17. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial felinentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
18. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).

WSLEGAL\068076\00030\21038773v1 Preferably, the said microorganism also contains at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
19. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, at least one genetic modification that may increase the effects of Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
20. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism, at least one genetic modification that may increase the effects of WSLEGAL068076\00030\21038773v1 D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
Preferably, the said microorganism also contains at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
21. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the fermentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism, at least one genetic modification that may increase the effects of Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
22. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
WSLEGAL\068076\00030\21038773v1 A) Cultivation of microorganism in the fellnentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine- 6-Phosphate Epimerase (NanE) in microorganism, at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
Preferably, the said microorganism also contains at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
23. Based on another preferably optimized implementation scheme of the Invention, the Inveition is involved with the method for producton of N-Acetyl-D-Glucosamine (G1cNAc) and/or D-Glucosamine Salt by microbial fermentation, which includes:
A) Cultivation of microorganism in the feimentation medium, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism, at least one genetic modification that may increase the effects of Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate WSLEGAL\068076\00030\21038773v1 Deaminase (NagB) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism; and B) Collection of N-Acetyl-D-Glucosamine (G1cNAc) produced in the cultivation step A).
In the above preferably optimized implementation schemes, further include C) Deacetylation of N-Acetyl-D-Glucosamine (G1cNAc) to produce D-Glucosamine Salt.
In the above preferably optimized implementation schemes, the microorganism further contain: At least one genetic modification that may decrease the effects of Mannose transporter EIIM, P/IIIman (ManXYZ) in microorganism; at least one genetic modification that may decrease the effects of N-Acetylneuraminate Lyase (NanA) in microorganism; at least one genetic modification that may decrease the effects of N-Acetyl-D-Glucosamine-6-Phosphate Deactylase (NagA) in microorganism; at least one genetic modification that may decrease the effects of N-Acetyl-D-Glucosamine Specific Enzyme IINag (NagE) in microorganism.
On one hand for any of the above implementation schemes, the above recombinant nucleic acid molecules may be induced, including but not limited to induction yb lactose; for example, it may realize expression induced by lactase, by adding lactose to the culture solution.
A technician in this field may understand that, various known common fermentation media in this field may be used in this Invention. On the one hand, the fermentation media contain carbon source. On the other hand, the fermentation media contain nitrogen sources. On the other hand, the fermentation media contain both carbon sources and nitrogen sources. On the other hand, the fermentation media contain carbon sources, nitrogen sources, and inorganic salts.
A technician in this field may understand that, various known carbon sources WSLEGAL068076\00030\21038773v1 in this field may be used in this Invention, including organic and/or inorganic carbon sources. Preferably, carbon sources are selected from one or more of glucose, fructose, sucrose, galactose, dextrin, glycerin, starch, syrup, and molasses.
Preferably, the concentration of a carbon source is maintained in the range of approximately 0.1 % - approximately 5 %. A technician in this field may understand that, various known nitrogen sources in this field may be used in this Invention, including organic and/or inorganic nitrogen sources. Preferably, nitrogen sources are selected from one or more of ammonia water, ammonium chloride, ammonium sulfate, ammonium nitrate, ammonium acetate, sodium nitrate, urea, yeast extract, meat extract, peptone, fish meal, bean flour, malt, corn syrup, and cotton seed meal.
Preferably, this Invention uses feed-batch fermentation method. Base on one aspect of this Invention, the carbohydrate supplement solution contains glucose and ribose; preferably, the concentration of glucose is 10%-85% (w/v), and that of ribose is 0.5%-15% (w/v); further preferably, the concentration of glucose is 55%-75% (w/v), and that of ribose is 5%-7% (w/v). Base on one aspect of this Invention, the carbohydrate supplement solution contains glucose and gluconate;
preferably, the concentration of glucose is 10%-85% (w/v), and that of gluconate is 0.5%-15% (w/v); further preferably, the concentration of glucose is 55%-75%
(w/v), and that of gluconate is 2%-3% (w/v); Base on one aspect of this Invention, the carbohydrate supplement solution contains glucose, ribose, and gluconate;
preferably, the concentration of glucose is 10%-85% (w/v), that of gluconate is 0.5%-15% (w/v), and that of gluconate is 0.5%-15% (w/v); further preferably, the concentration of glucose is 55%-75% (w/v), that of gluconate is 5%-7% (w/v), and that of gluconate is 2%-3% (w/v); Preferably, gluconate is sodium gluconate.
In preferably optimized implementation schemes, the said cultivation step is carried out at approximately 20 C ¨ approximately 45 C; further preferably, the said cultivation step is carried out at approximately 33 C ¨ approximately 37 C.

WSLEGAL\068076\00030\21038773v1 In preferably optimized implementation schemes, the said cultivation stem is carried out at approximately pH4.5 ¨ approximately pH8.5. Further preferably, the said cultivation step is carried out at approximately pH6.7 ¨ approximately pH7.2.
A technician in this field may understand that, various known common methods may be used to collect N-Acetyl-D-Glucosamine in this Invention.
Preferably, N-Acetyl-D-Glucosamine may be collected from extracellular products in the fermentation medium. Furthe preferably, the collection step includes one selected from the following steps: (a) N-Acetyl-D-Glucosamine is precipitated in the feimentation liquid in which microorganism are removed; (b) N-Acetyl-D-Glucosamine is crystallized from the fermentation liquid in which microorganism are removed.
Based on this Invention, the collection step further includes a decoloration step of the fermentation liquid. The decoloration step may include but not limited to conduction prior to precipigation or crystallization of the fermentation liquid, and after one or multiple redissolution of precipitates or crystals in the feimentation liquid; the decoloration include activated charcoal treatment and/or chromatographic decoloration. The said chromatographic decoloration includes a step for exposure of the said fermentation liquid to an ion exchange resin.
The said ion exchange resins include but not limited to anion exchange resin and/or cation exchange resin; for example, the fermentation liquid is exposed to a mixed bed containing anion and cation exchange resins.
Based on this Invention, N-Acetyl-D-Glucosamine may be deacetylated to produce a D-Glucosamine salt. The said salts include but not limited to hydrochlride, sulfate, sodium salt, phosphate, and bisulfate, etc. For example, N-Acetyl-D- Glucosamine may be deacetylated and hydrolized under acidic and heating conditions a D-Glucosamine salt. Preferably, N-Acetyl-D-Glucosamine may be deacetylated and hydrolized in 30%-70% hydrochloric acid and at 60-90 C

to produce N-Glucosamine Hydrochloride; N-Acetyl-D-Glucosamine may also be WSLEGAL\068076\00030\21038773v1 hydrolyzed under UDP-3-0-N-Acetylglucosamine Deacetylase to produce D-Glucosamine and further to produce a salt.
Based on another implementation scheme of this Invention, this Invention is involved with one microorganism, where the said microorganism contains at least one genetic modification that may express vitreoscilla hemoglobin (Vhb). The above text has described detailedly the genetic modification.
Based on the preferably optimized implementation scheme, the said microorganism contains one or more of the following genetic modifications:
(1) Contain at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism;
(2) Contain at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism;
(3) Contain at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and preferably contain at least one genetic modification that may decrease the effects of Glucosamine-6-Phosphate Synthase (GlmS);
(4) Contain at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, and preferably contain at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) (5) Contain at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism; The above text has described detailedly the genetic modifications.
Based on the preferably optimized implementation scheme, the said microorganism contains one or more of the following genetic modifications:
(1) Contain at least genetic modification that may decrease the effects of Mannose transporter EIIM, P/III"(ManXYZ) in microorganism;
WSLEGAL\068076\00030\21038773v1 (2) Contain at least one genetic modification that may decrease the effects of N-Acetylneuraminate Lyase (NanA) in microorganism;
(3) Contain at least one genetic modification that may decrease the effects of N-Acetyl-D-Glucosamine-6-Phosphate Deactylase (NagA) in microorganism;
(4) Contain at least one genetic modification that may decrease the effects of N-Acetyl-D-Glucosamine Specific Enzyme IINag (NagE) in microorganism;
(5) Contain at least one genetic modification that may increase the effects of PhosphoGlucosamine Mutase (G1mM) in microorganism;
(6) Contain at least one genetic modification that may increase the effects of bifunctional N-acetyl Glucosamine- 1-Phosphate Uridyltransferase (GlmU) in microorganism; The above text has described detailedly the genetic modifications.
This Invention is further involved with the following preferably optimized implementation schemes:
1. Based on one preferably optimized implementation scheme of this Invention, this Invention is involved with one microorganism, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), and at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism.
2. Based on another preferably optimized implementation scheme of this Invention, this Invention is involved with one microorganism, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), and at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism.
3. Based on another preferably optimized implementation scheme of this Invention, this Invention is involved with one microorganism, where the said microorganism contains: At least one genetic modification that may express WSLEGAL\068076\00030\21038773v1 vitreoscilla hemoglobin (Vhb), and at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism.
Preferably, the said microorganism also contains at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
4. Based on another preferably optimized implementation scheme of this Invention, this Invention is involved with one microorganism, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, and at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism.
5. Based on another preferably optimized implementation scheme of this Invention, this Invention is involved with one microorganism, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism.
6. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, and at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism.
7. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At WSLEGAL\068076\00030\21038773v1 least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, and at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism.
Preferably, the said microorganism also contains at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
8. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, at least one genetic modification that may increase the effects of Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, and at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism.
9. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism.
10. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine- 6-Phosphate Epimerase (NanE) in microorganism, and at least one WSLEGAL\068076\00030\21038773v1 genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism.
Preferably, the said microorganism also contains at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
11. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine- 6-Phosphate Epimerase (NanE) in microorganism, at least one genetic modification that may increase the effects of Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, and at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism.
12. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine- 6-Phosphate Epimerase (NanE) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2- Epimerase (WecB) in microorganism.
13. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism.

WSLEGAL\068076\00030\21038773v1 Preferably, the said microorganism also contains at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
14. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism.
15. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism, and at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism.
Preferably, the said microorganism also contains at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
16. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of WSLEGAL\068076\00030\21038773v1 N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism, at least one genetic modification that may increase the effects of Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, and at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism.
17. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism.
18. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism.
Preferably, the said microorganism also contains at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.

WSLEGAL\068076\00030\21038773v1 19. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, at least one genetic modification that may increase the effects of Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, at least one genetic modification that may decrease the effects of D-Glucosamine-6- Phosphate Deaminase (NagB) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine- 2-Epimerase (WecB) in microorganism.
20. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6- Phosphate Epimerase (NanE) in microorganism, at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism.
Preferably, the said microorganism also contains at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
21. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine- 6-Phosphate Epimerase (NanE) in microorganism, at least one genetic modification that may increase the effects of WSLEGAL\068076\00030\21038773v1 Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine- 2-Epimerase (WecB) in microorganism.
22. Based on one implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism, at least one genetic modification that may increase the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine- 2-Epimerase (WecB) in microorganism.
Preferably, the said microorganism also contains at least one genetic modification that may decrease the effects of D-Glucosamine-6-Phosphate Synthase (GlmS) in microorganism.
23. Based on another implementation scheme of this Invention, this Invention is involved with one microorganisms, where the said microorganism contains: At least one genetic modification that may express vitreoscilla hemoglobin (Vhb), at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism, at least one genetic modification that may increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase (NanE) in microorganism, at least one genetic modification that may increase the effects of Glucosamine-6-Phosphate Synthase (GlmS) in microorganism, at least one genetic WSLEGAL\068076\00030\21038773v1 modification that may decrease the effects of D-Glucosamine-6-Phosphate Deaminase (NagB) in microorganism, and at least one genetic modification that may increase the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism.
In the above preferably optimized implementation schemes, the microorganism further contain: At least one genetic modification that may decrease the effects of Mannose transporter EIIM, Willman (ManXYZ) in microorganism; at least one genetic modification that may decrease the effects of N-Acetylneuraminate Lyase (NanA) in microorganism; at least one genetic modification that may decrease the effects of N-Acetyl-D-Glucosamine-6-Phosphate Deactylase (NagA) in microorganism; at least one genetic modification that may decrease the effects of N-Acetyl-D-Glucosamine Specific Enzyme IINag (NagE) in microorganism.
Based on another implementation scheme of this Invention, this Invention is involved with one vitreoscilla hemoglobin (Vhb) with higher activities, which has the amino acid sequence as shown in SEQ ID NO:65. This Invention is further involved with nucleic acid molecules encoding the above vitreoscilla hemoglobin (Vhb), where the said nucleic acid molecules have the nucleic acid sequence as shown in SEQ ID NO: 64. This Invention is further involved with a carrier containnig the above nucleic acid molecules. This Invention is further involved with a microorganism containing the above carrier. This Invention is further involved with a microorganism with genomes containing above nucleic acid molecules.
In this Invention, microorganism may be any one (such as bacteria, protozoan, algae, fungi, or other microorganisms). In a preferably optimized implementation scheme, the microorganisms include but not limited to bacteria, yeast, or fungi.
Preferably, the said microorganism is selected from bacteria or yeasts.
Further preferably, the bacteria include but not limited to bacteria selected from WSLEGAL\068076\00030\21038773v1 Escherichia, Bacillus, Lactobacillus, Pseudomonas, or Streptomyces; more preferably, the bacteria include but not limited to bacteria selected from Escherichia coli, Bacillus subtilis, Bacillus licheniformis, Lactobacillus brevis, Pseudomonas aeruginosa, or Streptomyces lividans. More preferably, the yeasts include but not limited to yeasts selected from Saccharomyces, Schizosaccharomyces, Candida, Hansenula, Pichia, Kluveromyces, and Phaffia;
more preferably, the yeasts include but not limited to yeasts selected from Saccharomyce scerevisiae, Schizosaccharo mycespombe, Candida albicans, Hansenulapolymorpha, Pichia pastoris, Pichia canadensis, Kluyveromyces marxianus, or Phaffia rohodozyma. Preferably, the said microorganism is a fungus;
more preferably, the said fungi include but not limited to fungi selected from Aspergillus, Absidia, Rhizopus, Cluysosporium, Neurospora, or Trichoderma;
more preferably, the fungi include but not limited to those selected from Aspergillus niger, Aspergillus nidulans, Absidia coerulea, Rhizopus oryzae, Chrysosporium lucknowense, Neurospora crassa, Neurospora intermedia, or Trichoderma reesei. Particularly more preferably, the Escherichia coli strains include K-12, B, and W, and most preferably, include K-12. Although Escherichia coli are used as preferably optimized microorganism, and are used as example of the various implementation schemes of this Invention, it should be understood that this Invention may use any other microorganisms that may produce N-Acetyl-D-Glucosamine and may increase output of N-Acetyl-D-Glucosamine by a genetic modification. The microorganism used in this Invention may also be called as production organism.
In this Invention, the term N-Acetyl-D-Glucosamine may be called as 2-acetami do-2-deoxy-D-glu co se. The terms N-Acetyl-D-Glucosamine, N-Acetyl-D- Gluco samine-6-Phosphate and N-Acetyl-D-Gluco samine-1 -Phosphate may be abbreviated to GlcNAc, GlcNAc-6-P, and GlcNAc- 1 -P, respectively. N-Acetyl-D- Glucosamine may also WSLEGAL\068076\00030\21038773v1 be abbreviated to NAG. Similar to N-Acetyl-D-Glucosamine and its derivatives, the terms D-Glucosamine, D-Glucosamine-6-Phosphate, and D-Glucosamine-l-Phophate may also be abbreviated to GlcN, G1cN-6-P, and GlcN-1-P. Similarly, the terms N-Acetyl-D-Mannosamine, N-Acetyl-D-Mannosamine-6-Phosphate, glucose, Glucose-6-Phosphate, and Fructose-6-Phosphate may also be abbreviated to ManNAc, ManNAc-6-P, Glc, Glc-6-P, and Fru-6-P, respectively.
The telin "increasing the effects of an enzyme in microorganism" means increased activities the enzyme and/or overexpression of the enzyme, thus to increase output of the product manufactured from the substrate catalyzed by the enzyme in microorganism.
The term "decreasing the effects of an enzyme in microorganism" means decreased activities the enzyme and/or reduced expression of the enzyme, thus to decrease output of the product manufactured from the substrate catalyzed by the enzyme in microorganism.
The tenn "increased activities of an enzyme" means increased capacity of the enzyme to catalyze a certain chemical reaction. It encompasses increased capacity of the enzyme to catalyze a chemical reaction where the inhibition of the enzyme by the product, and the affinity of the enzyme to the substrate remain unchanged, and/or increased capacity resulted from decreased inhibition of the enzyme by the product, and/or from increased affinity of the enzyme to the substrate. The term "decreased inhibition of the enzyme by the product" means decreased activities of the enzyme to catalyze a reaction, due to specific inhibition of the enzyme by its end product. The term "increased affinity of the enzyme to the substrate"
means increased affinity of the enzyme to the substrate to be catalyzed.
In Figure 1, using Escherichia coli as example, it illustrates the major aspect of the genetic modification in the Glucosamine metabolic pathway used to manufacture N-Acetyl-D-Glucosamine in large scale, as disclosed in this Invention.

WSLEGAL\068076\00030\21038773v1 In regard to Figure 1, the bold arrow means metabolic produced and/or increased through genetic modification in this Invention. Figure 1 discloses several synthetic methods used to synthesize N-Acetyl-D-Glucosamine, which include a modification to Vhb, may further include a modification to NanK, NagE, NagB, GlmS, or WecB, or their combination, and may also further include a modification to ManXYZ, NanA, NagA, NagE, GlmM, or GlmU, or their combination. A
technician in this Field may understand that, other microorganisms have a similar carbohydrate metabolic pathway, and in such a metabolic pathway, the genes and proteins have similar structure and function. Therefore, the contents discussed in this Invention are applicable for both Escherichia coli and other microorganisms, and other microorganisms are obviously included in this Invention.
The enzyme known with the same biological activities in this field may have different names, dependent on the microorganism from which the enzyme is originated. Optional names of many enzymes and the name of a specific gene encoding such enzymes are provided below. The names of those enzymes may be used interchangeably, or may be used for a given sequence or organism if appropriate; however, this Invention is intended to include an enzyme with the specific function, originated from any organism.
For example, the enzyme generally called as "N-Acetyl-D-Mannosamine .. Kinase" in this article catalyzes phosphorylation of N-Acetyl-D-Mannosamine into N-Acetyl-D-Mannosamine-6-P. N-Acetyl-D-Mannosamine Kinase originated from Escherichia coli is generally called as NanK. N-Acetyl-D-Mannosamine Kinase originated from various organisms is well known in this field, and may be used in the genetic modification strategy in this Invention. For example, this article describes that N-Acetyl-D-Mannosamine Kinase originated from Escherichia coli has the nucleic acid sequence codes represented by SEQ ID NO: 16, and the amino acid sequence represented by SEQ ID NO: 17.
The enzyme generally called as "N-Acetyl-D-Mannosamine-6-P Epimerase"

WSLEGAL\068076\00030\21038773v1 in this article catalyzes transformation of N-Acetyl-D-Mannosamine-6-P into N-Acetyl-D-Gluco samine- 6-P. N-Acetyl-D-Mannosamine-6-P
Epimerase originated from Escherichia coli is generally called as NanE.
N-Acetyl-D-Mannosamine-6-P Epimerase originated from various organisms is well known in this field, and may be used in the genetic modification strategy in this Invention. For example, this article describes that N-Acetyl-D-Mannosamine-6-P Epimerase originated from Escherichia coli has the nucleic acid sequence codes represented by SEQ ID NO: 28, and the amino acid sequence represented by SEQ ID NO: 29.
The enzyme generally called as "UDP-N-Acetyl-D-Glucosamine-2-Epimerase" in this article catalyzes transformation of UDP-N-Acetyl-D-Glucosamine into N-Acetyl-D-Mannosamine.
UDP-N-Acetyl-D-Glucosamine-2-Epimerase originated from Escherichia coli is generally called as WecB. UDP-N-Acetyl- D-Glucosamine-2- Epimerase originated from various organisms is well known in this field, and may be used in the genetic modification strategy in this Invention. For example, this article describes that UDP-N-Acetyl-D-Glucosamine-2-Epimerase originated from Escherichia coli has the nucleic acid sequence codes represented by SEQ ID NO:

49, and the amino acid sequence represented by SEQ ID NO: 50.
The enzyme generally called as "D-Glucosamine-6-Phosphate Deaminase" in this article catalyzes a reversible reaction of D-Glucosamine-6-Phosphate and water to produce Glucose-6-Phosphate and ammonium. The enzyme is also called as D-Glucosamine-6-Phosphate Epimerase , GlcN6P Deaminase, Phospho-D-Glucosamine Epimerase, Phospho-D- Glucosamine Epimerase, D-Glucosamine Phosphate Ester Deaminase, and 2-Amino-2-Deoxy-D-Glucose-6- Phosphate Ketol Epimerase (deamination). D-Glucosamine-6-Phosphate Deaminase originated from various organisms is well known in this field, and may be used in the genetic modification strategy in this Invention. The enzyme is generally called as NagB in WSLEGAL068076\00030\21038773v1 Escherichia coli or other bacteria.
The enzyme generally called as "D-Glucosamine-6-Phosphate Synthase" in this article catalyzes Glucose-6-Phosphate and Glutamine to produce D-Glucosamine- 6- Phosphate and glutamic acid. The enzyme is also called as D-Glucosamine-Fructose -6 - Phosphate Aminotransferase (isomerization), Phosphohexose Aminotransferase, D- Fructose-6-Phosphate Transamidase, D-Gluco samine-6-Pho sphate Epimerase (to produce glutamin), L-Glutamine-Fructose-6-Phosphate Transamidase, and GlcN6P Synthase.
D-Glucosamine-6-Phosphate Synthase originated from various organisms is well known in this field, and may be used in the genetic modification strategy in this Invention. D-Glucosamine-6-Phosphate Synthase originated from Escherichia coli or other bacteria is generaally called as GlmS.
The enzyme generally called as "N-Acetyl-D-Glucosamine-6-Phosphate Deacetylase" may hydrolyze N-Acetyl-D-Glucosamine-6-Phosphate nto D-Glucosamine - 6- Phosphate and acetate ester. N-Acetyl-D- Glucosamine-6-Phosphate Deacetylase originated from various organisms is well known in this field, and may be used in the genetic modification strategy in this Invention.
For example, this article describes the enzyme called as NagA, originated from Escherichia coli.
The enzyme generally called as "N-Acetylneuraminate Lyase" catalyze degradation of N-Acetyl-D-Mannosamine into N-Acetylneuraminic Acid.N-Acetylneuraminate Lyase originated from various organisms is well known in this field, and may be used in the genetic modification strategy in this Invention.
For example, this article describes that N-Acetylneuraminate Lyase originated from Escherichia coli is called as NagA.
The enzyme generally called as "PhosphoGlucosamine Mutase" in this article catalyzes transformation of D-Glucosamine-6-Phosphate into D-Glucosamine- 1 -Phosphate. Phospho-D-Glucosamine Mutase originated from various organisms is WSLEGAL068076\00030\21038773v1 well known in this field and may be used in the genetic modification strategy of this Invention. The enzyme PhosphoGlucosamine Mutase is generally called as GlmM in Escherichia coli or other bacteria.
The enzyme generally called as "D-Gluco samine-1 -PhosphateN-Acetyltransferase" in this article catalyzes Transformation of D-Glucosamine-1-Phosphate and Acetyl Coenzyme A nito N-Acetyl-D-Glucosamine-1 -Phosphate, and release of CoA. As a bifunctinal enzyme, it also has the function of N-Acetyl-D-Glucosamine- 1-Phosphate Uridyltransferase, and is also called as UDP-N-Acetyl-D-Glucosamine Pyrophosphorylase, UDP-N-Acetyl-D-Glucosamine Diphosphorylase, and catalyze further transformation of N-Acetyl-D-Glucosamine- 1-Phosphate into UDP-N-Acetyl-D-Glucosamine. D-Glucosamine-1- PhosphateN- Acetyltransferase and N-Acetyl-D-Glucosamine-1 -Phosphate Uridyltransferase originated from various organisms are well known in this field, and may be used in the genetic modification strategy in this Invention. The enzyme is generally called as GlmU in Escherichia coli or other bacteria.
Through a crafty design, "Trc promoter" may be used for prokaryotic expression, such as Escherichia coli expression system. Trc promoter is well known in this field and may be used in the genetic modification strategy of this Invention. For example, this article describes that Trc promoter has a nucleotide sequence represented by SEQ ID NO: 32.
As disclosed by the W02004/003175 Invention, D-Glucosamine is very unstable in the common pH range for growth of Escherichia coli. D-Glucosamine and/or its degradation products produce toxic effects to the strains. Toxic effects may be evenly observed when D-Glucosamine in a low concentration of up to 20 g/L is preincubated in the culture medium (pH7.0), prior to cell inoculation.
Toxic effects are partially caused by the degradation products of D-Glucosamine in the culture medium with an initial pH 7Ø GleN is more stable in low pH
conditions, WSLEGAL\068076\00030\21038773v1 and D-Glucosamine may not be degraded below p114.7. However, Escherichia coli grow slowly under pH 6-7 conditions. Therefore, the scheme is difficult to implement production of D-Glucosamine in the feimentation tank under relatively low pH.
Based on this Invention, by expression of vitreoscilla hemoglobin (Vhb) in microorganism, it may increase the microorganism's utilization ability for dissolved oxygen, accelerate synthesis of proteins and metabolic products, promote microbial growth, increase fermentation potency and level. Moreover, D-Glucosamine-6-P (G1cN-6-P) is catalyzed by GlmM and GlmU to produce UDP-N-Acetyl-D- Glucosamine (UDP-G1cNAc) in cells, and is catalyzed by UDP-N-Acetyl- Glucosamine-2-Epimerase (WecB) to produce N-Acetyl-D-Mannosamine (ManNAc). Through overexpression of NanK and NanE, it is further transformed into N-Acetyl-D-Glucosamine-6-Phosphate (G1cNAc-6-P), and dephosphorylated under action of phosphatase and then excreted out of cells to produce N-Acetyl-D-Glucosamine (G1cNAc) The method in this Invention may avoid production of D-Glucosamine, and thus avoid toxic effects of D-Glucosamine and/or its degradation products to the strains.
Therefore, the beneficial effects of this Invention Based on this Invention lie in: This invention has demonstrated that, by expression of vitreoscilla hemoglobin (Vhb) in microorganism, it may increase the microorganism's utilization ability for dissolved oxygen, accelerate synthesis of proteins and metabolic products, promote microbial growth, and increase fermentation potency and level, so as to produce wholly natural N-Acetyl-D-Glucosamine by microbial fermentation method. The new production method has no risk for contamination by heavy metals, and no risk for residue of antibiotics or drugs; the production is not influenced by supply of raw materials, and may produce stably for a long term, with high yield and low cost; The produced N-Acetyl-D-Glucosamine and D-Glucosamine products are characterized by non-animal source. The production does not use chitin from WSLEGAL\068076\00030\21038773v1 shrimp shell, and does use glucose, etc., as carbohydrate source for fermentation.
The products are vegetarian products, without any allergens of aquatic products.
The whole contents of the public literatures and references cited or described in this article are attached for reference in this article.
Descriptions for Attached Figures Figure 1, Biosynthesis Strategy and Metabolic Engineering Strategy for N-Acetyl-D-Glucosamine in Escherichia Coli Actual Implementation Modes Hereafter this Invention is further described detailedly in combination with the implementation examples. The following examples are just used as ones to clarify and explain this Invention, and cannot be explained as any limitation to the protection range of this Invention. The technology realized, based on the contents of this Invention, are covered in the protection range of this Invention.
Unless otherwise specified, the raw materials and reagents used in the implementation examples are commercially available goods.
The list of various modified microorganisms involved in and/or described by this Invention is provided below.
Strain No. Genotype Description Remarks AT-001 ATCC 27325, F-IN(rmD-rmE)1 lambda-, a Parent strain of engineering prototrophic derivative strain of Escherichia coli K-12 bacterial, obtained from American Type Culture Collection (ATCC) AT-002-01 AT-001, AmanXYZ::fKanrf Example 1 AT-002-02 AT-001, AmanXYZ Example 1 AT-003-01 AT-002-02, AnanA::fKanrf Example 1 WSLEGAL\068076\00030\21038773v1 Strain No. Genotype Description Remarks AT-003-02 AT-002-02, AnanA Example 1 AT-004-01 AT-003-02, AnagA::fKanrf Example 1 AT-004-02 AT-003-02, AnagA Example 1 AT-005-01 AT-004-02, AnagE::fKanrf Example 1 AT-005-02 AT-004-02, AnagE Example 1 AT-006-01 AT-004-02, AnagE::pTrc-nanK-fKand Example 2a AT-006-02 AT-004-02, AnagE::pTrc-nanK Example 2a AT-007-01 AT-004-02, A nagE::pTrc-nanKM-fKanrf Example 2b AT-007-02 AT-004-02, A nagE::pTrc-nanKM Example 2b AT-052 AT-007-02, vhb/pTrc99A Example 2.c AT-053 AT-007-02, vhbM/pTrc99A Example 2.c AT-030-01 AT-004-02, AnagE::pTrc-nanE-fKanrf Example 3.a AT-030-02 AT-004-02, A nagE::pTrc-nanE Example 3.a AT-031-01 AT-004-02, AnagE::pTrc-nanEM-fKamf Example 3.b AT-031-02 AT-004-02, AnagE::pTrc-nanEM Example 3.b AT-054 AT-031-02, vhb/pTrc99A Example 3.c AT-055 AT-031-02, vhbM/pTrc99A Example 3.c AT-042-01 AT-004-02, AnagE::pTrc-wecB-fKanrf Example 4.a AT-042-02 AT-004-02, AnagE::pTrc-wecB Example 4.a AT-043-01 AT-004-02, AnagE::pTrc-wecBM-fKand Example 4.b AT-043-02 AT-004-02, AnagE::pTrc-wecB Example 4.b AT-056 AT-043-02, vhb/pTrc99A Example 4.c WSLEGAL\068076\00030\21038773v1 Strain No. Genotype Description Remarks AT-057 AT-043-02, vhbM/pTrc99A Example 4.c AT-048 AT-005-02, AnagB promotor::Trc promoter Example 5.a AT-049 AT-048, A glmS promotor Example 5.a AT-050 AT-005-02, A glmS promotor::Trc promoter Example 5.b AT-051 AT-050, AnagB promotor Example 5.b AT-058 AT-049, vhb/pTrc99A Example 5.c AT-059 AT-049, vhbM/pTrc99A Example 5.c AT-060 AT-051, vhb/pTrc99A Example 5.c AT-061 AT-051, vhbM/pTrc99A Example 5.c AT-009 AT-007-02, A nanE promotor::Trc promoter Example 6 AT-062 AT-009, vhb/pTrc99A Example 6 AT-063 AT-009, vhbM/pTrc99A Example 6 AT-010 AT-007-02, AnagB promotor::Trc promoter Example 7 AT-011 AT-010, A glmS promotor Example 7 AT-012 AT-007-02, A glmS promotor::Trc promoter Example 7 AT-013 AT-012, AnagB promotor Example 7 AT-064 AT-011, vhb/pTrc99A Example 7 AT-065 AT-011, vhbM/pTrc99A - Example 7 AT-066 AT-013, vhb/pTrc99A Example 7 AT-067 AT-013, vhbM/pTrc99A Example 7 AT-019 AT-007-02, AwecB promotor::Trc promoter Example 8 AT-068 AT-019, vhb/pTrc99A Example 8 AT-069 AT-019, vhbM/pTrc99A Example 8 AT-032 AT-031-02, AnagB promotor::Trc promoter Example 9 AT-033 AT-032, A glmS promotor Example 9 WSLEGAL\068076\00030\21038773v1 Strain No. Genotype Description Remarks AT-034 AT-031-02, A glmS promotor::Trc promoter Example 9 AT-035 AT-034, .LnagB promotor Example 9 AT-070 AT-033, vhb/pTrc99A Example 9 AT-071 AT-033, vhbM/pTrc99A Example 9 AT-072 AT-035, vhb/pTrc99A Example 9 AT-073 AT-035, vhbM/pTrc99A Example 9 AT-037 AT-031-02, AwecB promotor::Trc promoter Example 10 AT-074 AT-037, vhb/pTrc99A Example 10 AT-075 AT-037, vhbM/pTrc99A Example 10 AT-044 AT-043-02, AnagB promotor::Trc promoter Example 11 AT-045 AT-044, AglmS promotor Example 11 AT-046 AT-043-02, AglmS promotor::Trc promoter Example 11 AT-047 AT-046, AnagB promotor Example 11 AT-076 AT-045-02, vhb/pTrc99A Example 11 AT-077 AT-045-02, vhbM/pTrc99A Example 11 AT-078 AT-047-02, vhb/pTrc99A Example 11 AT-079 AT-047-02, vhbM/pTrc99A Example 11 AT-015 AT-011, AnanE promotor::Trc promoter Example 12 AT-017 AT-013, AnanE promotor::Trc promoter Example 12 AT-027 AT-015, AwecB promotor::Trc promoter Example 12 AT-029 AT-017, AwecB promotor::Trc promoter Example 12 AT-080 AT-027, vhb/pTrc99A Example 12 AT-081 AT-027, vhbM/pTrc99A Example 12 AT-082 AT-035, vhb/pTrc99A Example 12 AT-083 AT-035, vhbM/pTrc99A Example 12 Example 1 This implementation describes construction of a mutant strain of Escherichia coli, for which the relevant metabolic pathways for intake of WSLEGAL\068076\00030\21038773v1 N-Acetyl-D-Glucosamine is blocked and degradation of beneficial intermediate products are blocked.
The said parent strain of the production strain is AT-001 (Escherichia coli ATCC 27325), belonging to K-12 derivative strain of Escherichia coli, and is obtained from American Type Culture Collection.
Blockage of intake of N-Acetyl-D-Glucosamine into the strain, and of degradation of intermediate products may reduce consumption during metabolism, and increase accumulationof the target product (N-Acetyl-D-Glucosamine).
To construct such mutant host strain, manXYZ, nanA, nagA, and nagE gene .. sequences in its chromosomal genomes may be deleted completely or partially, to deactivate its function, and thus result in accumulation of N-Acetyl-D-Glucosamine.
Such deletion of gene sequence in the chromosome may be accomplished by Red recombinant technology. Red recombination is an homologous recombination technology, based on Red operon in A., phage, and mediated by RecE/RecT system in Rac phage. By the technology, it may carry out simply and rapidly multiple modifications such as insertion, knockout, and mutation to any large DNA
molecules. Simply speaking, for Red recombination technology, pKD46 plasmids with the recombinase-expressing gene are introduced into thalli, then the prepared linear DNA segment for targeting is electrotransfouned, positive clones are screened, and finally the resistance gene in the strain is removed.
The specific operational process is described hereafter:
1. Deletion of manXYZ gene sequence Mannose transporter EIIM, P/III" (mannose transporter EIIM, P/IIIman, .. ManXYZ) may be used as a second transporter of N-Acetyl-D-Glucosamine; it may transport hexose such as N-Acetyl-D-Glucosamine into cells, and thus the target product excreted out of cells and accumulated is transported into cells for degradation. Deletion of manXYZ gene sequence may block transportation of WSLEGAL\068076\00030\21038773v1 extracellular N-Acetyl-D-Glucosamine into cells for degradation.
(1) Preparation of Linear DNA Full-length PCR Segment for Targeting of Red Recombination 1) fKanrf segment amplified by PCR
fKanrf, i.e. FRT-Kanr-FRT segment means a FRT site base sequence for specific recognition of FLP recombinase, mounted at both ends of kalamycin resistance gene (Kanr).
Primer Design: Forward primer (mfKanf-F) SEQ ID No.1, and reverse primer (mfKanf-R) SEQ ID No.2.
Template: pPic9K.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
fKanrf size: 1.28kb. Its nucleotide sequence is SEQ ID No.3.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
2) PCR Amplification of Linear DNA Full-length PCR Segment for Targeting of Red Recombination Design of Homologous Arm Primer: According to the manXYZ sequence SEQ ID No.4, it is designed to delete the homologous ami forward primer (manXYZKO-F) SEQ ID No.5 and reverse primer (manXYZKO-R) SEQ ID No.6 of the manXYZ sequence.
Template: Amplification of fKanrf PCR Segment.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product: Homologous Arm + fKanrf + Homologous Ann.
The PCR product is separated by agarose gel electrophoresis, and purified and WSLEGAL\068076\00030\21038773v1 recovered to obtain 100 ng/ 1_, linear DNA full-length PCR segment for targeting of Red recombination.
(2) Red Recombination Operation First, pKD46 carrier is introduced into the AT-001 strain of Escherichia coli. Then, the prepared linear DNA segment for targeting is electrotransformed, and positive clones are screened. Finally, the resistance gene is removed.
1) Transformation of pKD46 Plasmid pKD46 carrier is a plasmid with Red recombinase-expressing gene, which is 3-gene segment expressing Exo, Bet, and Gam; the 3 genes are placed below the arabinose promoter, and may express in a large amount by induction of L-arabinose. It is necessary to transform pKD46 plasmid into Escherichia coli, to achieve purpose to modify the target gene in the chromosome by Red recombination.
()Preparation of Competence: First, inoculate the bacterial suspension of Escherichia coli ATCC 27325 stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C and 225 rpm for 2-3 h.
then add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaCl2 on an ice bath for 5 min. Finally, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath. Allow to stand at -4 C
for 12 h for spontaneous sedimentation. Here, preparation of 0.1M CaCl2:
Prepare a 1M CaCl2 solution with anhydrous CaCl2, autoclave at a steam pressure of 15 lbf/in2 for 20 min, and dispense 1.5 mL and store at -20 C; for use, allow to thaw, and then dilute in a ratio of 1:10 to produce a 0.1M CaCl2 solution.
OPlasmid Transformation: Transfer 250 pt of spontaneously sedimented thalli, add 5 tiL of 0(1346 plasmid, and cultivate at -4 C for 30min. Then heat WSLEGAL\068076\00030\21038773v1 on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h. Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate. Cultivate overnight (for 12-16 h) at 30 C. Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification. Store the positive strain for use.
2)Electrotransform linear DNA segment for targeting, and screen positive clone ()Preparation of electrotransfoimed competence: Inoculate the AT-001 strain of Escherichia coli ATCC 27325, containing pKD46, into a test tube of LB
medium containing Ampicillin (Amp), and shake-cultivate overnight at 250 rpm;
On the next day, inoculate in a ratio of 1% into LB medium containing Amp, and cultivate at 30 C; when 0D600 reaches approximately 0.2, add 0.2%
L-Arabinose, and induce at 30 C for 35 min until 0D600 reaches approximately 0.4. Cool on an ice bath. Wash once with ultrapure water, wash twice with 10% glycerin, and finally resuspend with 10% glycerin; the amount of glyerin used is to produce a final concentration of the thalli concentrated by 500-1000 folds.
Transfot ________________________________________________________________________ mation by electric shock: Take out a 2-mm electrotransformation cup from 70% ethanol, wash with sterilized ultrapure water, and irradiate by UV lamp for 30 min. Precool at 4 C for 30 min.
Transfer 90 Fit of finally resuspended cells to a precooled centrifuge tube, add 5 tit (more than 100 ng) of the full-length PCR segement (linear DNA) obtained in Step (1), suction gently by a gun, and maintain on an ice bath for min. Electrotransformation Parameters: 2500V, 200n, 25 F.

()Resuscitate and screen positive clones: add 1 mL of LB broth medium, and cultivate at 37 C and 100rpm for 1 h. Then smear one kanamycin (Kan) plate with every 200 tiL, 5 plates in total. Smear evenly and allow to air-dry.
Cultivate at 30 C for 24 h. Pick up clones grown under kanamycin resistance, WSLEGAL\068076\00030\21038773v1 and carry out PCR identification to screen positive clones.
No. of the obtained strain: AT-002-01 (AT-001, AmanXYZ:: fKanrf).
(3) Removal of the Resistance Gene To facilitate subsequent work, the resistance gene in the obtained strain (positive clones) may be removed. Removal of the resistance gene may be accomplished by pCP20 plasmid. pCP20 is a plasmid with ampicillin and chloramphenicol resistance genes, and may express FLP recombinase after thennal induction, which may identify specifically FRT sites. The sequence between FRT

sites may be deleted by recombination, to retain only one FRT site.
Introduce pCP20 into the above kanamycin-resistant clones, cultivate at 30 C
for 8 h, then increase to 42 C and cultivate overnight, and thermally induce to express FLP recombinase; the plasmids are lost gradually. Streak the plate of antibiotics-free culture medium by an inoculating loop dipped in the bacterial suspension, pick up grown monoclones and dot on the kanamycin-resistant plate;
those that cannot grown are clones of which the kanamycin resistance gene has been removed by FLP recombination. Carry out PCR with identification primer to identify clones losing kanamycin resistance.
No. of the obtained strain: AT-002-02 (AT-001, AmanXYZ).
2. Deletion of nanA Gene Sequence N-Acetylneuraminate Lyase (N-acetylneuraminate lyase, NanA) can degrade N-Acetyl-D-Mannosamine (1VIanNAc) in microorganism to produce N-Acetyl-D-Neuraminic Acid (Neu5Ac). Deletion of the nanA gene sequence in nanKETA operon may block degradation of N-Acetyl-D-Mannosamine (ManNAc) into N-Acetyl-D-Neuraminic Acid (Neu5Ac).
(1) Preparation of Linear DNA Full-length PCR Segment for Targeting of Red Recombination Design of Homologous Arm Primer: According to the nanA sequence SEQ ID
No.7 in the former segment of nanE-nanK, the homologous arm primers for WSLEGAL\068076\00030\21038773v1 deletion of nanA sequence are designed: Forward primer (nanAKO-F) SEQ ID
No.8 and reverse primer (nanAKO-R) SEQ ID No.9.
Template: Amplification of fKanrf PCR Segment.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product: Homologous Arm + fKanrf + Homologous Aim.
The PCR product is separated by agarose gel electrophoresis, and purified and recovered to obtain 100 ng/ L linear DNA full-length PCR segment for targeting of Red recombination.
(2) Red Recombination Operation First, pKD46 carrier is introduced into the AT-002-02 strain of Escherichia coil. Then, the prepared linear DNA segment for targeting is electrotransformed, and positive clones are screened. Finally, the resistance gene is removed.
1) Transfoimation of pKD46 Plasmid 0 Preparation of Competence: First, inoculate the bacterial suspension of Escherichia coli AT-002-02 (AT-001, AmanXYZ) stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C and 225rpm for 2-3 h. then add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g X 5min, discard the supernatant, and suspend with 5 mL 0.1M CaC12 on an ice bath for 5 min. Finally, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaC12 on an ice bath. Allow to stand at -4 C for 12 h for spontaneous sedimentation.
0 Plasmid Transformation: Transfer 250 !IL of spontaneously sedimented thalli, add 5 [IL of pKD46 plasmid, and cultivate at -4 C for 30 min. Then heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C
for 2 h. Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate.

WSLEGAL\068076\00030\21038773v1 Cultivate overnight (for 12-16 h) at 30 C. Pick up monoclone, add 5 mL of LB
broth medium and cultivate, and withdraw plasmid for identification. Store the positive strain for use.
2) Electrotransform linear DNA segment for targeting, and screen positive clone ()Preparation of Electrotransformed Competence: Inoculate the AT-002-02 strain of Escherichia coli, containing pKD46, into a test tube of LB medium containing Ampicillin (Amp), and shake-cultivate at 250 rpm. On the next day, inoculate in a ratio of 1% into LB medium containing Amp, and cultivate at 30 C; when 0D600 reaches approximately 0.2, add 0.2% L-Arabinose, and induce at 30 C for 35 min until OD600 reaches approximately 0.4. Cool on an ice bath. Wash once with ultrapure water, wash twice with 10% glycerin, and finally resuspend with 10% glycerin; the amount of glyerin used is to produce a final concentration of the thalli concentrated by 500-1000 folds.
Transformation by electric shock: Take out a 2-mm electrotransformation cup from 70% ethanol, wash with sterilized ultrapure water, and irradiate by UV lamp for 30 min. Precool at 4 C for 30 min.
Transfer 90 L of finally resuspended cells to a precooled centrifuge tube, add 5 ILL (more than 100 ng) of the full-length PCR segement (linear DNA) obtained in Step (1), suction gently by a gun, and maintain on an ice bath for min. Electrotransformation Parameters: 2500V, 200n, 25 F.
()Resuscitate and screen positive clones: add 1 mL of LB broth medium, and cultivate at 37 C and 100rpm for 1 h. Then smear one kanamycin (Kan) plate with every 200 L, 5 plates in total. Smear evenly and allow to air-dry.

Cultivate at 30 C for 24 h. Pick up clones grown under kanamycin resistance, and carry out PCR identification to screen positive clones.
No. of the obtained strain: AT-003-01 (AT-002-02, AnanA::fKanrf).
(3) Removal of the Resistance Gene WSLEGAL\068076\00030\21038773v1 Introduce pCP20 into the above kanamycin-resistant clones, cultivate at 30 C
for 8 h, then increase to 42 C and cultivate overnight, and thermally induce to express FLP recombinase; the plasmids are lost gradually. Streak the plate of antibiotics-free culture medium by an inoculating loop dipped in the bacterial suspension, pick up grown monoclones and dot on the kanamycin-resistant plate;
those that cannot grown are clones of which the kanamycin resistance gene has been removed by FLP recombination. Carry out PCR with identification primer to identify clones losing kanamycin resistance.
No. of the obtained strain: AT-003-02 (AT-002-02, AnanA).
3.Deletion of nagA Gene Sequence N-Acetyl-D-Glucosamine-6-Phosphate Deacetylase (NagA) can transform N-Acetyl-D-Glucosamine-6-Phosphate (G1cNAc-6-P) in microorganism into D-Glucosamine-6-Phosphate (G1cN-6-P). Deletion of the nagA gene sequence in nag operon (nagE-nagBACD) may block transformation of N-Acetyl-D-Glucosamine-6-Phosphate (G1cNAc-6-P) into D-Glucosamine-6-Phosphate (G1cN-6-P).
(1) Preparation of Linear DNA Full-length PCR Segment for Targeting of Red Recombination Design of Homologous Arm Primers: From NCBI, look up NC 000913, nagA sequence SEQ ID No.10 for N-Acetyl-D-Glucosamine-6-Phosphate Deacetylase, Escherichia coli str. K-12, design the homologous ami primers for deletion of the nagA gene sequence: Forward primer (nagAKO-F) SEQ ID No.11 and reverse primer (nagAKO-R) SEQ ID No.12.
Template: Amplification of fKanrf PCR Segment.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product: Homologous Arm + fKanf + Homologous Arm.

WSLEGAL\068076\00030\21038773v1 The PCR product is separated by agarose gel electrophoresis, and purified and recovered to obtain 100 ng/1.11_, linear DNA full-length PCR segment for targeting of Red recombination.
(2) Red Recombination Operation First, pKD46 carrier is introduced into the AT-003-02 strain of Escherichia coli. Then, the prepared linear DNA segment for targeting is electrotransformed, and positive clones are screened. Finally, the resistance gene is removed.
1) Transformation of pKD46 Plasmid ()Preparation of Competence: First, inoculate the bacterial suspension of Escherichia coli AT-003-02 (AT-002-02, AnanA) stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C and 225 rpm for 2-3 h. then add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL
0.1M CaCl2 on an ice bath for 5 min. Finally, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath.
Allow to stand at -4 C for 12 h for spontaneous sedimentation.
()Plasmid Transfoimation: Transfer 250 lit of spontaneously sedimented thalli, add 5 tit of pKD46 plasmid, and cultivate at -4 C for 30min. Then heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h. Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate. Cultivate overnight (for 12-16 h) at 30 C. Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification. Store the positive strain for use.
2) Electrotransform linear DNA segment for targeting, and screen positive clone Preparation of Electrotransformed Competence: Inoculate the AT-003-02 WSLEGAL\068076\00030\21038773v1 strain of Escherichia con, containing 0(1)46, into a test tube of LB medium containing Ampicillin (Amp), and shake-cultivate at 250 rpm, on the next day, inoculate in a ratio of 1% into LB medium containing Amp, and cultivate at 30 C; when 0D600 reaches approximately 0.2, add 0.2% L-Arabinose, and induce at 30 C for 35 min until 0D600 reaches approximately 0.4. Cool on an ice bath. Wash once with ultrapure water, wash twice with 10% glycerin, and finally resuspend with 10% glycerin; the amount of glyerin used is to produce a final concentration of the thalli concentrated by 500-1000 folds.
0 Transformation by electric shock: Take out a 2-mm electrotransformation cup from 70% ethanol, wash with sterilized ultrapure water, and irradiate by UV lamp for 30 min. Precool at 4 C for 30 min.
Transfer 90 tit of finally resuspended cells to a precooled centrifuge tube, add 5 tit (more than 100 ng) of the full-length PCR segement (linear DNA) obtained in Step (1), suction gently by a gun, and maintain on an ice bath for 30 min. Electrotransformation Parameters: 2500V, 200SI, 25 F.
0 Resuscitate and screen positive clones: add 1 mL of LB broth medium, and cultivate at 37 C and 100rpm for 1 h. Then smear one kanamycin (Kan) plate with every 200 pt, 5 plates in total. Smear evenly and allow to air-dry.

Cultivate at 30 C for 24 h. Pick up clones grown under kanamycin resistance, and carry out PCR identification to screen positive clones.
No. of the obtained strain: AT-004-01 (AT-003-02, AnagA::fKanrf).
(3) Removal of the Resistance Gene Introduce pCP20 into the above kanamycin-resistant clones, cultivate at 30 C
for 8 h, then increase to 42 C and cultivate overnight, and thermally induce to express FLP recombinase; the plasmids are lost gradually. Streak the plate of antibiotics-free culture medium by an inoculating loop dipped in the bacterial suspension, pick up grown monoclones and dot on the kanamycin-resistant plate;
WSLEGAL\068076\00030\21038773v1 those that cannot grown are clones of which the kanamycin resistance gene has been removed by FLP recombination. Carry out PCR with identification primer to identify clones losing kanamycin resistance.
No. of the obtained strain: AT-004-02 (AT-003-02, A nagA).
4. Deletion of nagE Gene Sequence Deletion of the gene sequence nagE for N-Acetyl-D-Glucosamine Specific Enzyme IINag (NagE) may block transport of extracellular GlcNAc into cells for degradation.
(1) Preparation of Linear DNA Full-length PCR Segment for Targeting of Red Recombination Design of Homologous Arm Primers: From NCBI, look up NC 000913, nagB
promoter and nagA gene sequence SEQ ID No.13, Escherichia coli str. K-12, and design the homologous aim primers for deletion of the nagA gene sequence:
Forward primer (nagEKO-F1) SEQ ID No.14 and reverse primer (nagEKO-R1) SEQ ID No.15.
Template: Amplification of fKanrfPCR Segment.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product: Homologous Arm + fKanrf + Homologous Arm.
The PCR product is separated by agarose gel electrophoresis, and purified and recovered to obtain 100 ng/pt linear DNA full-length PCR segment for targeting of Red recombination.
(2)Red Recombination Operation First, pKD46 carrier is introduced into the AT-004-02 strain of Escherichia coil. Then, the prepared linear DNA segment for targeting is electrotransformed, and positive clones are screened. Finally, the resistance gene is removed.

WSLEGAL\068076\00030\21038773v1 1) Transfaimation of pKD46 Plasmid Preparation of Competence: First, inoculate the bacterial suspension of Escherichia coli AT-004-02 (AT-003-02, AnagA) stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C and 225 rpm for 2-3 h. then add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaCl2 on an ice bath for 5 min. Finally, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath. Allow to stand at -4 C for 12 h for spontaneous sedimentation.
0 Plasmid Transformation: Transfer 250 ttL of spontaneously sedimented thalli, add 5 tit of pKD46 plasmid, and cultivate at -4 C for 30 min. Then heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h. Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate. Cultivate overnight (for 12-16 h) at 30 C. Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification. Store the positive strain for use.
2) Electrotransform linear DNA segment for targeting, and screen positive clone 0 Preparation of Electrotransformed Competence: Inoculate the AT-004-02 strain of Escherichia coil, containing pKD46, into a test tube of LB medium containing Ampicillin (Amp), and shake-cultivate at 250 rpm, on the next day, inoculate in a ratio of 1% into LB medium containing Amp, and cultivate at C; when 0D600 reaches approximately 0.2, add 0.2% L-Arabinose, and induce at 30 C for 35 min until 0D600 reaches approximately 0.4. Cool on an ice bath. Wash once with ultrapure water, wash twice with 10% glycerin, and finally resuspend with 10% glycerin; the amount of glyerin used is to produce a final concentration of the thalli concentrated by 500-1000 folds.

WSLEGAL\068076\00030\21038773v1 @ Transformation by electric shock: Take out a 2-mm electrotransformation cup from 70% ethanol, wash with sterilized ultrapure water, and irradiate by UV lamp for 30 min. Precool at 4 C for 30 min.
Transfer 90 1_, of finally resuspended cells to a precooled centrifuge tube, add 5 111, (more than 100 ng) of the full-length PCR segement (linear DNA) obtained in Step (1), suction gently by a gun, and maintain on an ice bath for 30 min. Electrotransformation Parameters: 2500V, 200t2, 251iF.
0 Resuscitate and screen positive clones: add 1 mL of LB broth medium, and cultivate at 37 C and 100rpm for 1 h. Then smear one kanamycin (Kan) plate with every 200 L, 5 plates in total. Smear evenly and allow to air-dry.

Cultivate at 30 C for 24 h. Pick up clones grown under kanamycin resistance, and carry out PCR identification to screen positive clones.
No. of the obtained strain: AT-005-01 (AT-004-02, AnagE::fKanrf).
(3) Removal of the Resistance Gene Introduce pCP20 into the above kanamycin-resistant clones, cultivate at 30 C
for 8 h, then increase to 42 C and cultivate overnight, and thermally induce to express FLP recombinase; the plasmids are lost gradually. Streak the plate of antibiotics-free culture medium by an inoculating loop dipped in the bacterial suspension, pick up grown monoclones and dot on the kanamycin-resistant plate;
those that cannot grown are clones of which the kanamycin resistance gene has been removed by FLP recombination. Carry out PCR with identification primer to identify clones losing kanamycin resistance.
No. of the obtained strain: AT-005-02 (AT-004-02, AnagE).
Example 2.a This example describes gene nanK cloning of N-Acetyl-D-Mannosamine Kinase (NanK), and transfoimed nanK/pTrc99A plasmids in Escherichia coli, as well as integration of ptrc- nanK gene cassette into the chromosome of Escherichia WSLEGAL\068076\00030\21038773v1 coli.
1. nanK Gene Cloning, Transformation of nanK/pTrc99A plasmid in Escherichia coli, and its Influence on the Output of N-Acetyl-D-Glucosamine Amplification of the gene nanK of Escherichia coli NanK (N-acetylmannosamine kinase, N-Acetyl-D-Mannosamine Kinase), that is controlloed by Trc promoter to transfolin the strain for overexpression of the enzyme, may strengthen phosphorylation of ManNAc (N-Acetyl-D-mannosamine, N-Acetyl-D-Mannosamine or N-Acetyl-D-Mannosamine) into ManNAc-6-P
(N-Acetyl-D-mannosamine-6-P, N-Acetyl-D-Mannosamine-6-Phosphate).
1) nanK Gene Cloning of Escherichia coli From NCBI, look up U00096, to obtain the nucleotide sequence SEQ ID
No.16 of the nanK gene of Escherichia coli, which amino acid sequence is SEQ
ID
No.17.
Primer Design: Forward primer (nanK-F) SEQ ID No.18 and reverse primer (nanK-R) SEQ ID No.19.
Template: Escherichia coli AT-001.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product Size: 0.9kb.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
Ligate the obtained PCR amplification segment with pUC57-T carrier, and carry out sequencing for identification, to obtain nanK/ pUC57.
2) Construction and Transformation of Plasmid in which nanK gene is controlled by Trc promoter 0 Plasmid Construction: Amplify plasmid nanK/ pUC57, digest enzymatically nanK/pUC57 and carrier pTrc99A with Nco I and Hind III, WSLEGAL\068076\00030\21038773v1 separate by agarose gel electrophoresis, purify to recover nanK segment and pTrc99A segment, ligate overnight with T4 DNA ligase at 16 C, and carry out identification to obtain nanK/pTrc99A plasmid.
()Preparation of Competence: First, inoculate the bacterial suspension of AT-005-02 stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C and 225 rpm for 2-3 h. then add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaCl2 on an ice bath for 5 min. Finally, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath. Allow to stand at -4 C for 12 h for spontaneous sedimentation.
Plasmid Transformation: Transfer 250 tiL of spontaneously sedimented thalli, add 5 1_, of nanK/pTrc99A plasmid, and cultivate at -4 C for 30min.
Then heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h. Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate. Cultivate overnight (for 12-16 h) at 30 C. Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification. Store the positive strain for use. Obtain Recombinant Strain nanK/pTrc99A (AT-005-02) 3) Influence of nanK/pTrc99A plasmid transformation on the output of N-Acetyl-D-Glucosamine Carry out a shake-flask feimentation trial with the recombinant strain and nanK/pTrc99A (AT-005-02) reference strain. Transfer the monoclonal strain freshly cultivated in culture medium of the LB plate, inoculate into a test tube (13 x150mm) containing 3 mL of the LB broth culture medium, and shake-cultivate at 30 C and 225rpm for 8 h. Components of LB Broth Medium: 5 g/L yeast powder, 10 g/L peptone, and 10 g/L NaCl. Then transfer the seed culture solution, WSLEGAL\068076\00030\21038773v1 inoculate in 3% into a 250-mL shake-flask containing 50 mL of the feimentation culture solution (M9 culture solution). The initial Mao is approximately 0.5;
shake-cultivate at 37 C and 225rpm. The fermentation cycle is 72 h. At 24 h and 48 h, adjust to pH 7.0 with 10M NaOH. According to glucose consumption in the .. fermentation broth, add 65% glucose solution to maintain a glucose concentration of 20 g/L. After completion of fermentation, transfer 1 mL of the felmentation broth and centrifugate. Measure the content of N-Acetyl-D-Glucosamine by HPLC
method.
HPLC Method to Measure the Content of N-Acetyl-D-Glucosamine Buffer: Add 3.5 g of dipotassium hydrogen phosphate to 1-L volumetric flask, add water to dissolve, add 0.25 mL of ammonia water, then dilute with water and mix well, adjust to pH 7.5, and add wate to volume.
Mobile Phase: Acetonitrile:Buffer (75:25).
Diluent: Acetonitrile and water (50:50).
Standard Solution: Dissolve 1.0 mg/mL USP N-Acetyl-D-Glucosamine Reference Substance (RS) in the diluent.
Sample Solution: Dissolve 1.0 mg/mL N-Acetyl-D-Glucosamine sample in the diluent.
Liquid Phase Conditions:
Model: LC
Detector: UV 195 nm Chromatographic Column: 4.6-mmx15-cm; 3-pm packing L8 Flow Rate: 1.5 mL/min Column Temperature: 35 C
Injection Volume: 10 Li 0 Preparation of M9 Culture Solution First prepare 5xM9 culture medium: To approximately 800 mL of double distilled water (ddH20), add 64 g of Na2HPO4.7H20, 15g of KH2PO4, 2.5g of WSLEGAL\068076\00030\21038773v1 NaC1, and 5.0 g of NH4C1, and after dissolution, add water to 1000 mL.
Sterilize at 121 C for 30 min. Then prepare 1M MgSO4, 1M CaCl2, and 20% glucose, respectively, and sterilize them separately. Then prepare M9 culture solution according to Table 1, while 1000x microelement solution is prepared according to Table 2.
Table 1. Components of M9 Culture Solution Ingredients Amount used (mL/L) 5xm9 200 1M MgSO4 2 1M CaC12 0.1 20% Glucose 20 1000x Microelement 1 Solution ddH20 to 1000 pH 6.9 Table 2, Components of 1000x Microelement Solution Ingredients Amount used (g/L) CoC12 .61120 0.01 CuSO4. SH20 0.01 MnS 04* H20 0.033 FeSO4.7H20 0.50 ZnSO4=7H20 0.38 H3B03 0.01 NaMo04-2H20 0.01 pH 3 WSLEGAL\ 068076 \00030 \21038773v1 Influence of nanK/pTrc99A plasmid transfomiation on the output of N-Acetyl-D-Glucosamine from shake-flask fermentation See Table 3 for the output from shake-flask femientation. The results show that: The output by the reference strain AT-005-02 is very low and is not detected, while the output from overexpression by nanK gene of nanK/pTrc99A
(AT-005-02), controlled by Trc promoter, is increased obviously.
Table 3. Output from Shake-flask Fetnientation by the Recombinant nanK/pTrc99A (AT-005-02) species Output of N-Acetyl-D-Glucosamine (g/L) AT-005-02 (AT-004-02, Not detected A nagE) (Reference) NanK/pTrc99A (AT-005-02) 2.9 0.4 2.Integration of pTrc-nanK Gene Cassette into the Chromosome of Escherichia Coli Using the nagE gene site as integration site of pTrc-nanK gene cassette into the chromosome. To achieve integration of pTrc-nanK gene cassette into the chromosome of Escherichia coli, first amplify the nanK segment (i.e. pTrc-nanK) with Trc promoter, as well as the kanamycin resistance gene segment with FLP
recognition site (FRT site) at its both ends: FRT-Kanr-FRT (fKanrf), and splice them. Then design homologous primers for deletion of the nagE gene sequence, and using the spliced segment of pTrc-nanK and fKanrf as template, amplify the linear DNA full-length segment for targeting of Red recombination.
The specific operating process is provided below:
(1) PCR Amplification of pTrc-nanK segment Template: nanK/pTrc99A.
Primer Design: Forward primer (Trcff-F) SEQ ID No.20, and reverse primer (Trcff-R) SEQ ID No.21.

WSLEGAL\068076\00030\21038773v1 PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Produce Size: 1.05kb.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(2)fKanrf segment amplified by PCR
Primer Design: Forward primer (mfKanf-F) SEQ ID No.1, and reverse primer (mfKanf-R) SEQ ID No.2.
Template: pPic9K.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
fKanrf size: 1.28kb. Its nucleotide sequence is SEQ ID No.3.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(3) Amplification of fKanrf spliced with pTrc-nanK
Primer Design: Forward primer (fKanf-F) SEQ ID No.22, and reverse primer (fKanf-R) SEQ ID No.23.
Template: fKanrf.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
fKanrf size from secondary amplificatino: 1.3kb.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(4)Preparation of Linear DNA Full-length PCR Segment for Targeting of Red WSLEGAL\068076\00030\21038773v1 Recombination Design of Homologous Arm Primers: Design again homologous arm primers for deletion of the nagE gene sequence: Forward primer (nagEKO-F2) SEQ ID
No.24, and reverse primer (nagEKO-R2) SEQ ID No.25.
Template: Mix pTrc-nanK PCR segment, and fKanrf PCR segment from secondary amplification in the ratio of 1:1.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product: Homologous Arm + pTrc-nanK-fKand + Homologous Arm The PCR product is separated by agarose gel electrophoresis, and purified and recovered to obtain 100 ng/1.1L linear DNA full-length PCR segment for targeting of Red recombination.
(5)Red Recombination Operation First, pKD46 carrier is introduced into the AT-004-02 strain of Escherichia coil. Then, the prepared linear DNA segment for targeting is electrotransformed, and positive clones are screened. Finally, the resistance gene is removed.
1) Transformation of pKD46 Plasmid ()Preparation of Competence: First, inoculate the bacterial suspension of Escherichia coil AT-004-02 stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C and 225 rpm for 2-3 h. then add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaC12 on an ice bath for 5 min. Finally, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath. Allow to stand at -4 C
WSLEGAL\068076\00030\21038773v1 for 12 h for spontaneous sedimentation.
0 Plasmid Transformation: Transfer 250 lit of spontaneously sedimented thalli, add 5 tiL of pl(D46 plasmid, and cultivate at -4 C for 30min. Then heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h. Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate. Cultivate overnight (for 12-16 h) at 30 C. Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification. Store the positive strain for use.
2) Electrotransform linear DNA segment for targeting, and screen positive clone ()Preparation of Electrotransformed Competence: Inoculate the AT-004-02 strain of Escherichia coil, containing pl(D46, into a test tube of LB medium containing Ampicillin (Amp), and shake-cultivate at 250 rpm, on the next day, inoculate in a ratio of 1% into LB medium containing Amp, and cultivate at 30 C; when 0D600 reaches approximately 0.2, add 0.2% L-Arabinose, and induce at 30 C for 35 min until 0D600 reaches approximately 0.4. Cool on an ice bath. Wash once with ultrapure water, wash twice with 10% glycerin, and finally resuspend with 10% glycerin; the amount of glyerin used is to produce a final concentration of the thalli concentrated by 500-1000 folds.
O Transformation by electric shock: Take out a 2-mm electrotransformation cup from 70% ethanol, wash with sterilized ultrapure water, and irradiate by UV lamp for 30 min. Precool at 4 C for 30 min.
Transfer 90 tit of finally resuspended cells to a precooled centrifuge tube, add 5 fit (more than 100 ng) of the full-length PCR segement (linear DNA) obtained in Step (4), suction gently by a gun, and maintain on an ice bath for min. Electrotransformation Parameters: 2500V, 2001,1 25 F.
0 Resuscitate and screen positive clones: add 1 mL of LB broth medium, WSLEGAL\068076\00030\21038773v1 and cultivate at 37 C and 100rpm for 1 h. Then smear one kanamycin (Kan) plate with every 200 L, 5 plates in total. Smear evenly and allow to air-dry.

Cultivate at 30 C for 24 h. Pick up clones grown under kanamycin resistance, and carry out PCR identification to screen positive clones.
No. of the obtained strain: AT-006-01 (AT-004-02, A nagE::pTrc-nanK-fKanrf).
(6) Removal of the Resistance Gene Introduce pCP20 into the above kanamycin-resistant clones, cultivate at 30 C
for 8 h, then increase to 42 C and cultivate overnight, and thermally induce to express FLP recombinase; the plasmids are lost gradually. Streak the plate of antibiotics-free culture medium by an inoculating loop dipped in the bacterial suspension, pick up grown monoclones and dot on the kanamycin-resistant plate;

those that cannot grown are clones of which the kanamycin resistance gene has been removed by FLP recombination. Carry out PCR with identification primer to identify clones losing kanamycin resistance.
No. of the obtained strain: AT-006-02 (AT-004-02, A nagE::pTrc-nanK).
3.Influence of pTrc-nanK gene cassette integration on the output of N-Acetyl-D-Glucosamine Carry out a shake-flask fermentation trial with the recombinant strain AT-006-02 of which the nagE gene site in the chromosome is integrated with pTrc-nanK gene cassette, and the reference strain. Transfer the monoclonal strain freshly cultivated in culture medium of the LB plate, inoculate into a test tube (13x150mm) containing 3 mL of the LB broth culture medium, and shake-cultivate at 30 C and 225rpm for 8 h. Then transfer the seed culture solution, inoculate in 3%
into a 250-mL shake-flask containing 50 mL of the fermentation culture solution (M9 culture solution). The initial 0D600 is approximately 0.5; shake-cultivate at 37 C and 225rpm. The fermentation cycle is 72 h. At 24 h and 48 h, adjust to pH

WSLEGAL068076\00030\21038773v1 7.0 with 10M NaOH. According to glucose consumption in the feunentation broth, add 65% glucose solution to maintain a glucose concentration of 20 g/L. After completion of fermentation, transfer 1 mL of the fermentation broth and centrifugate. Measure the content of N-Acetyl-D-Glucosamine by HPLC method.
See Table 4 for the output from shake-flask fermentation. The results show that: The outputs by the reference strains AT-001 and AT-005-02 are very low and are not detected, while the output by the recombinant strain integrated with pTrc-nanK gene cassette is increased obviously, and is also increased significantly than that by the recombinant strain nanK/pTrc99A (AT-005-02) not integrated with the gene cassette.
Table 4, Output from Shake-flask Feanentation by the Recombinant Strain integrated with pTrc-nanK Gene Cassette Species Output of N-Acetyl-D-Glucosamine (g/L) AT-001 (Reference) Not detected AT-005-02 (AT-004-02, AnagE) (Reference) Not detected nanK/pTrc99A ( AT-005-02 ) 2.8 0.5 AT-006-02 (AT-004-02, AnagE::pTrc-nanK) 4.2 0.5 Example 2.b This implementation example describes screening for a gene mutant of N-Acetyl-D-Mannosamine Kinase (NanK); the said gene encodes N-Acetyl-D-Mannosamine Kinase (NanK) with increased activities.
To further increase synthetic quantity of N-Acetyl-D-Glucosamine by the production strain, screen a gene mutant encoding N-Acetyl-D-Mannosamine Kinase (NanK) with increased activities. To achieve the purpose, amplify the cloned gene by error-prone PCR technology; used for amplified DNA polymerase, WSLEGAL\068076\00030\21038773v1 amplify the said gene under conditions leading to high-frequency mismatch, so as to obtain a high-frequency mutation in PCR products.
The specific operating process is provided below:
1. Amplification of the Gene nanK of N-Acetyl-D-Mannosamine Kinase in Escherichia coli by Error-prone PCR
By means of Taq DNA polymerase without the property of 3' -5' proofreading function, control the frequency of random mutation under high magnesium ion concentration (8 mmol/L) and different dNTP concentrations (where, the concentration of dATP and dGTP is 1.5 mmol/L, and the concentration of dTTP
and dCTP is 3.0 mmol/L), introduce random mutations into the target gene, and construct a mutant library; the template concentration A260 value is 1000 ng/mL, the enzyme concentration is 5 U/ L, and the primer concentration is 100 M.
Error-prone PCR reaction system (50 L): 10xPCR reaction buffer 50, dNTP
(2.5 mM) 5 !,.t.L, MgCl2 (25 mM) 5 L, Forward primer (nanK-F, SEQ ID No.18) 1 L, reverse primer (nanK-R, SEQ ID No.19) 1 L, DNA template (nanK/pUC57) 0.1 L, Taq DNA polymerase 0.5 L, and ddH20 32.4 L.
PCR procedure: Predegenerate at 96 C for 4 min; degenerate at 94 C for 1 min, anneal at 56 C for 1 min, extend at 75 C for 2 min, and repeat for 45 cycles;
finally extend at 75 C for 15 min, recover PCR product (product size: 0.9 kb) by gel recovery method; transfer 5 L of the product and carry out 1% agarose gel electrophoresis test; the product is store at -20 C for use.
2. Construction of the gene mutant library of N-Acetyl-D-Mannosamine Kinase Digest the above PCR product by two enzymes of restriction endonuclease Nco I and Hind III, carry out a ligation reaction with pTrc99A digested by Nco I
and Hind III, then transform Escherichia coli AT-005-02 with the mixture of the ligated products to obtain a large amount of cloned transformants, and construct a mutant library of transformed thalli.

WSLEGAL\068076\00030\21038773v1 3. Screening for Mutants with High Enzyme Activities Using the wild type NanK/pTrc99A (AT-005-02) as reference, pick up randomly 300 mutant clones from the mutant library of transfouned thalli, inoculate into 5 mL of LB medium containing 50 pg/mL Ampicillin (Amp), shake-cultivate at 37 C and 150 rpm for 18 h, and then centrifugate at 10000 rpm for 5 mim and collect thalli. Discard the supernatant, then resuspend at 4 C
in 1 mL of PBS solution (pH 7.5, 10 mmol/L), carry out ultrasonicate at a voltage of 300 V for 10 min (ultrasonicate for 3 s and pause for 6 s), centrifugate, transfer the supernatant as crude extract of enzyme, and carry out a method for determination .. of enzyme activity.
Determination of N-Acetyl-D-Mannosamine Kinase (NanK) Activity: Based on the phosphorylated amount of N-Acetyl-D-Mannosamine (ManNAc); that is to say, using the reduced amount of N-Acetyl-D-Mannosamine as test marker.
Definition of Enzyme Activity Unit: Under the enzymatic reaction conditions, the enzyme amount reduced by the reducing sugar, equivalent to 1 pmol N-Acetyl-D-Mannosamine per minute, is defined as one enzyme activity unit (IU).
The specific procedure is provided as follows: Transfer 5 mL of the reaction system as the system for determination of enzyme activity, which contains 500 mmol/L N-Acetyl-D-Mannosamine, 5 mmol/L glucose, 100 mmol/L Tris-HC1 (pH8.0), and 100 pL of crude enzyme solution. Carry out the reaction for determination of enzyme activity on a water bath at 37 C, maintain for 4 h, and then place the enzymatic hydrolysate at 70 C for 10 min to stop the reaction.
Centrifugate at 3000 rpm for 10 min, and transfer the supernatant. Measure the content of N-Acetyl-D-Mannosamine by HPLC method.
The results show that: The enzyme activity of the mutant strain with maximum activity is 77.5 IU/mL, and the enzyme activity of the reference control is 16.3 IU/mL. Transfrom NanK by error-prone PCR, to obtain a mutant strain with enzyme activity increased by 5 folds. Pick up the mutant strain with WSLEGAL\068076\00030\21038773v1 maximum enzyme activity and extract plasmids for sequencing. The results show that: The gene sequence of the mutant of N-Acetyl-D-Mannosamine Kinase is shown as SEQ ID No.26, and the corresponding amino acid is shown as SEQ ID
No.27. By sequence alignment with the gene sequence of wild the type N-Acetyl-D-Mannosamine Kinase, 4 base point mutations occur in total: 107A/G, 309T/G, 669G/C, and 783A/G; There occur 3 missense mutations of amino acids, of which the mutation points are: Q36R (lysine at Site 36 is relaced by arginine), 1103M (isoleucine at Site 103 is replaced by methionine), and R223S (arginine at Site 223 is replaced by serine) The mutant gene is named as nanKM.
4. Integration of pTrc-nanK Gene Cassette into the nagE Gene Site in the Chromosome of Escherichia Coli Using the nagE gene site as integration site of pTrc-nanKM gene cassette into the chromosome. To achieve integration of pTrc-nanKM gene cassette into the chromosome of Escherichia coli, first amplify the nanK segment (i.e. pTrc-nanKM) of Trc promoter, as well as the kanamycin resistance gene segment with FLP
recognition site (FRT site) at its both ends: FRT-Kanr-FRT (fKanrf), and splice them. Then design homologous primers for deletion of the nagE gene sequence, and using the spliced segment of pTrc-nanKM and fKand as template, amplify the linear DNA full-length segment for targeting of Red recombination.
The specific operating process is provided below:
(1) PCR Amplification of pTrc-nanKM Segment Template: nanKM/pTrc99A.
Primer Design: Forward primer (Trcff-F) SEQ ID No.20, and reverse primer (Trcff-R) SEQ ID No.21.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Produce Size: 1.05kb.

WSLEGAL\068076\00030\21038773v1 The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(2) fKanrf segment amplified by PCR
Primer Design: Forward primer (mfKanf-F) SEQ ID No.1, and reverse primer (mfKanf-R) SEQ ID No.2.
Template: pPic9K.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
fKanrf size: 1.28kb. Its nucleotide sequence is SEQ ID No.3.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(3) Amplification of fKanrf spliced with pTrc-nanKM
Primer Design: Forward primer (fKanf-F) SEQ ID No.22, and reverse primer (fKanf-R) SEQ ID No.23.
Template: fKanrf.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
fKanrf size from secondary amplificatino: 1.3kb.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(4) Preparation of Linear DNA Full-length PCR Segment for Targeting of Red Recombination Design of Homologous Arm Primers: Design again homologous arm primers for deletion of the nagE gene sequence: Forward primer (nagEKO-F2) SEQ ID
No.24, and reverse primer (nagEKO-R2) SEQ ID No.25.

WSLEGAL\068076\00030\21038773v1 Template: Mix pTrc-nanKM PCR segment, and fKanrf PCR segment from secondary amplification in the ratio of 1:1.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product: Homologous Aim + pTrc-nanKM-fKanrf +
Homologous Arm The PCR product is separated by agarose gel electrophoresis, and purified and recovered to obtain 100 ng/IAL linear DNA full-length PCR segment for targeting of Red recombination.
(5) Red Recombination Operation First, pKD46 carrier is introduced into the AT-004-02 strain of Escherichia coli. Then, the prepared linear DNA segment for targeting is electrotransformed, and positive clones are screened. Finally, the resistance gene is removed.
1) Transformation of pKD46 Plasmid ()Preparation of Competence: First, inoculate the bacterial suspension of Escherichia coli AT-004-02 stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C and 225 rpm for 2-3 h. Then add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaCl2 on an ice bath for 5 min. Finally, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaC12 on an ice bath. Allow to stand at -4 C
for 12 h for spontaneous sedimentation.
0 Plasmid Transformation: Transfer 250 lit of spontaneously sedimented thalli, add 5 pt of 0(046 plasmid, and cultivate at -4 C for 30min. Then heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake WSLEGAL\068076\00030\21038773v1 at 30 C for 2 h. Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate. Cultivate overnight (for 12-16 h) at 30 C. Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification. Store the positive strain for use.
2) Electrotransfoun linear DNA segment for targeting, and screen positive clone ()Preparation of Electrotransfouned Competence: Inoculate the AT-004-02 strain of Escherichia coil, containing pKD46, into a test tube of LB medium containing Ampicillin (Amp), and shake-cultivate at 250 rpm, on the next day, inoculate in a ratio of 1% into LB medium containing Amp, and cultivate at 30 C; when 0D600 reaches approximately 0.2, add 0.2% L-Arabinose, and induce at 30 C for 35 min until 0D600 reaches approximately 0.4. Cool on an ice bath. Wash once with ultrapure water, wash twice with 10% glycerin, and finally resuspend with 10% glycerin; the amount of glyerin used is to produce a final concentration of the thalli concentrated by 500-1000 folds.
() Transformation by electric shock: Take out a 2-mm electrotransformation cup from 70% ethanol, wash with sterilized ultrapure water, and irradiate by UV lamp for 30 mm. Precool at 4 C for 30 min.
Transfer 90 tiL of finally resuspended cells to a precooled centrifuge tube, add 5 pt (more than 100 ng) of the full-length PCR segement (linear DNA) obtained in Step (4), suction gently by a gun, and maintain on an ice bath for min. Electrotransformation Parameters: 2500V, 200S2, 250'.
Resuscitate and screen positive clones: add 1 mL of LB broth medium, and cultivate at 37 C and 100rpm for 1 h. Then smear one kanamycin (Kan) plate with every 200 pt, 5 plates in total. Smear evenly and allow to air-dry.

Cultivate at 30 C for 24 h. Pick up clones grown under kanamycin resistance, and carry out PCR identification to screen positive clones.
No. of the obtained strain: AT-007-01 (AT-004-02, WSLEGAL\068076\00030\21038773v1 AnagE::pTrc-nanKM-fKanrf).
(6) Removal of the Resistance Gene Introduce pCP20 into the above kanamycin-resistant clones, cultivate at 30 C
for 8 h, then increase to 42 C and cultivate overnight, and thermally induce to express FLP recombinase; the plasmids are lost gradually. Streak the plate of antibiotics-free culture medium by an inoculating loop dipped in the bacterial suspension, pick up grown monoclones and dot on the kanamycin-resistant plate;

those that cannot grown are clones of which the kanamycin resistance gene has been removed by FLP recombination. Carry out PCR with identification primer to identify clones losing kanamycin resistance.
No. of the obtained strain: AT-007-02 (AT-004-02, AnagE::pTrc-nanKM).
5.Influence of pTrc-nanKM gene cassette integration on the output of N-Acetyl-D-Glucosamine Carry out a shake-flask fermentation trial with the recombinant strain AT-007-02 of which the nagE gene site in the chromosome is integrated with pTrc-nanKM gene cassette, and the reference strain. Transfer the monoclonal strain freshly cultivated in culture medium of the LB plate, inoculate into a test tube (13 x150mm) containing 3 mL of the LB broth culture medium, and shake-cultivate at 30 C and 225rpm for 8 h. Then transfer the seed culture solution, inoculate in 3% into a 250-mL shake-flask containing 50 mL of the fermentation culture solution (M9 culture solution). The initial 0D600 is approximately 0.5;
shake-cultivate at 37 C and 225rpm. The fermentation cycle is 72 h. At 24 h and 48 h, adjust to pH 7.0 with 10M NaOH. According to glucose consumption in the fermentation broth, add 65% glucose solution to maintain a glucose concentration of 20 g/L. After completion of fermentation, transfer 1 mL of the fermentation broth and centrifugate. Measure the content of N-Acetyl-D-Glucosamine by 'PLC
method.
WSLEGAL\068076\00030\21038773v1 See Table 5 for the output from shake-flask fermentation. The results show that: The output by the reference strain AT-005-02 is very low and is not detected, while the output by the recombinant strain AT-007-02 integrated with pTrc-nanKM gene cassette is increased obviously, and is also increased significantly than that by the unmutant reference strain (AT-006-02).
Table 5, Output from Shake-flask Fermentation by the Recombinant Strain integrated with pTrc-nanKM Gene Cassette species Output of N-Acetyl-D-Glucosamine (g/L) AT-005-02 (AT-004-02, AnagE) (Reference) Not detected AT-006-02 (AT-004-02, AnagE::pTrc-nanK) 4.5+0.4 AT-007-02 (AT-004-02, 11.2+1.2 AnagE::pTrc-nanKM) The above results show that: The output of N-Acetyl-D-Glucosamine may be increased obviously by overexpression of N-Acetyl-D-Mannosamine Kinase;
moreover, the output of N-Acetyl-D-Glucosamine may also be greatly by the mutant screened by error-prone PCR technology, due to increased activities of the obtained mutant of the enzyme.
Example 2.c This implementation example describes Escherichia coli strains integrated with pTrc-nanKM gene cassette, and the gene vhb thereof and its mutant for expression of vitreoscilla hemoglobin (Vhb) as well as influence on the output of N-Acetyl-D-Glucosamine.
Amplify the gene vhb for vitreoscilla hemoglobin (Vhb), insert into pTrc99A, so that vhb is controlled by Trc promoter to transform the strains, or screen a mutant of the gene vhb for vitreoscilla hemoglobin (Vhb) and insert into pTrc99A
to transform the strains, to increase the microorganism's utilization ability for dissolved oxygen and increase the fermentation production the output of WSLEGAL\068076\00030\21038773v1 N-Acetyl-Glucosamine.
1. Escherichia coli strains integrated with pTrc-nanK1VI gene cassette, and the gene vhb for expression of vitreoscilla hemoglobin (Vhb) (1) Amplify the vhb Gene and Insert into pTrc99A
The nucleotide sequence the gene encoding vitreoscilla hemoglobin (Vhb) is SEQ ID No.60, and the amino acid sequence is SEQ ID No.61. Based on the preference cocon bases of Escherichia coli, optimize and synthesize the gene for vitreoscilla hemoglobin (Vhb), and load into pUC57 carrier. Obtain a carrier named as: pVS/pUC57.
Primer Design: Forward primer (vhb-F) SEQ ID No.62, and reverse primer (vhb-R) SEQ ID No.63.
Template: pVS/pUC57.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product Size: 441bp.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
Digest enzymatically the obtained PCR amplification segment and carrier pTrc99A with Nco I and Hind III, separate by agarose gel electrophoresis, purify and recover vhb segment and pTrc99A segment, ligate overnight with T4 DNA
ligase at 16 C, and carry out identification to obtain vhb/pTrc99A plasmid.
(2) Transform Escherichia coli strains integrated with pTrc-NanKM gene gassette by vhb/pTrc99A
1) Preparation of Competence ()Inoculate the bacterial suspension of AT-007-02 stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C

WSLEGAL\068076\00030\21038773v1 and 225 rpm for 2-3 h.
()Add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaCl2 on an ice bath for 5 min.
0 Centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath. Allow to stand at -4 C for 12 h for spontaneous sedimentation.
2) Plasmid Transfoilliation () Transfer 250 pi of spontaneously sedimentated thalli, add 5 }IL of vhb/pTrc99A plasmid, and cultivate at -4 C for 30min.
()Heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h.
0 Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate.
() Cultivate overnight (for 12-16 h) at 30 C.
0 Pick up mono clone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification.
()Positive clones are stored for use.
No. of the obtained strain: AT-052 (AT-007-02, vhb/pTrc99A).
2. Escherichia coli strains integrated with pTrc-nanK1VI gene cassette, and the gene vhb mutant for expression of vitreoscilla hemoglobin (Vhb) To further increase synthetic quantity of N-Acetyl-D-Glucosamine by the production strain, screen a gene mutant encoding vitreoscilla hemoglobin (Vhb) with increased activities. To achieve the purpose, amplify the cloned gene by error-prone PCR technology; used for amplified DNA polymerase, amplify the said gene under conditions leading to high-frequency mismatch, so as to obtain a high-frequency mutation in PCR products.
The specific operating process is provided below:

WSLEGAL\068076\00030\21038773v1 (1) Error-prone PCR amplification of the gene vhb for vitreoscilla hemoglobin (Vhb) in Escherichia coli By means of Taq DNA polymerase without the property of 3' -5' proofreading function, control the frequency of random mutation under high magnesium ion concentration (8 mmol/L) and different dNTP concentrations (where, the concentration of dATP and dGTP is 1.5 mmol/L; and the concentration of dTTP
and dCTP is 3.0 mmol/L), introduce random mutations into the target gene, and construct a mutant library; the template concentration A260 value is 1000 ng/mL, the enzyme concentration is 5 U/ L, and the primer concentration is 100 M.
Error-prone PCR reaction system (50 !IL): 10xPCR reaction buffer 50, dNTP
(2.5 mM) 5 !IL, MgC12 (25 mM) 5 !AL, Forward primer (vhb-F, SEQ ID No.62) 1 IAL, reverse primer (vhb-R, SEQ ID No.63) 1 4, DNA template (nanK/pUC57) 0.1 juL, Taq DNA polymerase 0.5 liL, and ddH20 32.44.
PCR procedure: Predegenerate at 96 C for 4 min; degenerate at 94 C for 1 min, anneal at 56 C for 1 min, extend at 75 C for 2 min, and repeat for 45 cycles;
finally extend at 75 C for 15 min, recover PCR product (product size: 0.44kb) by gel recovery method; transfer 5 L of the product and carry out 1% agarose gel electrophoresis test; the product is store at -20 C for use.
(2) Construction of the gene mutant library for vitreoscilla hemoglobin (Vhb) Digest the above PCR product by two enzymes of restriction endonuclease Nco I and Hind III, carry out a ligation reaction with pTrc99A digested by Nco I
and Hind III, then transform Escherichia coli AT-005-02 with the mixture of the ligated products to obtain a large amount of cloned transformants, and construct a mutant library of transformed thalli.
(3) Screening for mutants with higher activities Using the wild type vhb/pTrc99A (AT-005-02) as reference, pick up randomly 420 mutant clones from the mutant library of transformed thalli, inoculate into 5 mL of LB medium containing 50 [tg/rnL Ampicillin (Amp), WSLEGAL\068076\00030\21038773v1 shake-cultivate at 37 C and 150 rpm for 18 h, and then centrifugate at 10000 rpm for 5 min and collect thalli. Discard the supernatant, then resuspend at 4 C
in 1 mL of PBS solution (pH 7.5, 10 mmol/L), carry out ultrasonicate at a voltage of 300 V for 10 mm (ultrasonicate for 3 s and pause for 6 s), centrifugate, transfer the supernatant as crude extract, and carry out a method for deteimination of activity.
Determination of vitreoscilla hemoglobin activities: Carry out the CO-differential chromatography for determination of vitreoscilla hemoglobin activities. As the conjugate of CO and vitreoscilla hemoglobin may produce a strong absorption peak at the wavelength of 420 nm, and form a typical characteristic curve of Vhb, so the activities of Vhb may be reflected by test results of the absorption peak intensity. Test Method: Based on the feed-batch fermentation trial of different batches of the above different types of recombinant Escherichia coli under limited oxygen cultivation and low oxygen (dissolved oxygen <=20%) conditions, transfer 6 mL each of the culture solution, and .. centrifugate and collect thalli. Wash the precipitate once with saline solution (100 mmol/L Tris-HC1, 50 mmol/L NaC1, pH7.5), then resuspend in 3 mL of the buffer, ultrasonicate, and centrifugate at 4 C and 10 000 rpm for 15 mm. Transfer the supernatant, dilute by 2 folds with 3 mL of the buffer, and add Sodium Hydrosulfite (Na2S204) to a final concentration of 2.5 mg/mL, and then introduce CO gas into the solution. After 3 min later, scan by the ultraviolet-visible spectrometer at the wave band of 400-500 nm, and determine vitreoscilla hemoglobin activities from the maximum absorption peak (Abs) of the ultraviolet spectrum.
Screen to obtain one mutant strain with the maximum activities. Pick up the strain and extract plasmid, and carry out sequencing. The results show that:
The mutant gene sequence of vitreoscilla hemoglobin is shown as SEQ ID No.64, and the corresponding amino acid sequence is shown as SEQ ID No.65. By sequence alignment with the gene sequence of the wild type N-Acetyl-D-Mannosamine WSLEGAL\068076\00030\21038773v1 Kinase, 3 base point mutations occur in total: 133A/C, 256T/G, and 284A/C.
There occur 3 missense mutations of amino acids, of which the mutation points are:
M45L (methionine at Site 45 is replaced by leucine), C86G (cysteine at Site 86 is replaced by glycine), and Y95S (tyrosine at Site 95 is replaced by serine).
The mutant gene is named as vhbM.
(4) Transform Escherichia coli strains integrated with pTrc-NanKM gene gassette by vhbM/pTrc99A
1) Preparation of Competence 0 Inoculate the bacterial suspension of AT-007-02 stored at -20 C into 10 .. mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C
and 225 rpm for 2-3 h.
0 Add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaCl2 on an ice bath for 5 min.
0 Centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath. Allow to stand at -4 C for 12 h for spontaneous sedimentation.
2) Plasmid Transformation 0 Transfer 250 tit of spontaneously sedimentated thalli, add 5 tiL of vhbM/pTrc99A plasmid, and cultivate at -4 C for 30min.
()Heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h.
0 Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate.
Cultivate overnight (for 12-16 h) at 30 C.
()Pick up monoclone, add 5 niL of LB broth medium and cultivate, and withdraw plasmid for identification.

WSLEGAL\068076\00030\21038773v1 0 Positive clones are stored for use.
No. of the obtained strain: AT-053 (AT-007-02, vhbM/pTrc99A).
2. Escherichia coli strains integrated with pTrc-nanKM gene cassette, and the gene vhb thereof and its mutants for expression of vitreoscilla hemoglobin (Vhb) as well as influence on the output of N-Acetyl-D-Glucosamine Carry out a shake-flask fermentation trial with the strains integrated with pTrc-nanKM gene cassette, and the mutant strains AT-052 and AT-053 with the gene vhb for expression of vitreoscilla hemoglobin (Vhb). Transfer the monoclonal strain freshly cultivated in culture medium of the LB plate, inoculate into a test tube (13x 150mm) containing 3 mL of the LB broth culture medium, and shake-cultivate at 30 C and 225rpm for 8 h. Then transfer the seed culture solution, inoculate in 3% into a 250-mL shake-flask containing 50 mL of M9 culture solution. The initial 0D600 is approximately 0.5; shake-cultivate at 37 C and 225rpm. The feimentation cycle is 72 h. At 24 h and 48 h, adjust to pH 7.0 with 10M NaOH. According to glucose consumption in the fermentation broth, add 65%
glucose solution to maintain a glucose concentration of 20 g/L. After completion of fennentation, transfer 1 mL of the fettnentation broth and centrifugate.
Measure the content of N-Acetyl-D-Glucosamine by HPLC method.
See Table 6 for the output from shake-flask fermentation by recombinant strains. The results show that: The output may be increased obviously from expression of vhb by the recombinant strains both with transformed vhb/
pTrc99A
and with transformed vhbM/ pTrc99A plasmid; moreover, the output is increased more significant by the recombinant strain with with transformed vhbM/ pTrc99A
plasmid.
Table 6. Output from Shake-flask Fermentation by the Recombinant Strains for Expression of vhb and vhbM
species Output of WSLEGAL\068076\00030\21038773v1 N-Acetyl-D-Glucosamine (g/L) AT-007-02 (Reference) 11.4+1.2 _ AT-052 (AT-007-02, vhb/pTrc99A) 16.5+1.1 AT-053 (AT-007-02, vhbM/pTrc99A) 20.7+1.5 Example 3.a This example describes gene nanE cloning of N-Acetyl-D-Mannosamine-6-P
Epimerase (NanE), and transfoimed nanK/pTrc99A plasmids in Escherichia coli, as well as integration of ptrc- nanE gene cassette into the chromosome of Escherichia coli.
1. nanE Gene Cloning, Transformation of nanE/pTrc99A plasmid in Escherichia coli, and its Influence on the Output of N-Acetyl-D-Glucosamine Amplify the gene nanE of Escherichia coli NanE (N-Acetyl-D-Mannosamine- 6-P Epimerase), insert into pTrc so that nanE is controlled by Trc promoter to transfonn the strains for overexpression, to strengthen transformation of N-Acetyl-D-Mannosamine-6-Phosphate (ManNAc-6-P) into N-Acetyl-D-Glucosamine-6-Phosphate (G1cNAc-6-P).
1) nanE Gene Cloning of Escherichia coli From NCBI, look up U00096, to obtain the nucleotide sequence SEQ ID
No.28 of the nanE gene of Escherichia coli, which amino acid sequence is SEQ
ID
No.29.
Primer Design: Forward primer (nanE-F) SEQ ID No.30, and reverse primer (nanE-R) SEQ ID No.31.
Template: AT-001 (Escherichia coli ATCC 27325) Genome.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product Size: 690kb.

WSLEGAL\068076\00030\21038773v1 The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
Ligate the obtained PCR amplification segment with pUC57-T carrier, and carry out sequencing for identification to obtain nanE/ pUC57.
2) Construction and Transformation of Plasmid in which nanE gene is controlled by Trc promoter 0 Plasmid Construction: Amplify plasmid nanE/ pUC57, digest enzymatically nanE/pUC57 and carrier pTrc99A with Nco I and Hind III, separate by agarose gel electrophoresis, purify to recover nanE segment and pTrc99A segment, ligate overnight with T4 DNA ligase at 16 C, and carry out identification to obtain nanE/pTrc99A plasmid.
()Preparation of Competence: First, inoculate the bacterial suspension of AT-005-02 stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C and 225 rpm for 2-3 h. then add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaCl2 on an ice bath for 5 min. Finally, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath. Allow to stand at -4 C for 12 h for spontaneous sedimentation.
0 Plasmid Transformation: Transfer 250 pL of spontaneously sedimented thalli, add 5 pL of nanE/pTrc99A plasmid, and cultivate at -4 C for 30min.
Then heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h. Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate. Cultivate overnight (for 12-16 h) at 30 C. Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification. Store the positive strain for use. Obtain Recombinant Strain nanE/pTrc99A (AT-005-02) WSLEGAL\068076\00030\21038773v1 3) Influence of nanE/pTrc99A plasmid transformation on the output of N-Acetyl-D-Glucosamine Carry out a shake-flask fermentation trial with the recombinant strain nanE/pTrc99A (AT-005-02) and the reference strain. Transfer the monoclonal strain freshly cultivated in culture medium of the LB plate, inoculate into a test tube (13 x150mm) containing 3 mL of the LB broth culture medium, and shake-cultivate at 30 C and 225rpm for 8 h. Components of LB Broth Medium: 5 g/L yeast powder, 10 g/L peptone, and 10 g/L NaCl. Then transfer the seed culture solution, inoculate in 3% into a 250-mL shake-flask containing 50 mL of the fermentation culture solution (M9 culture solution). The initial 0D600 is approximately 0.5; shake-cultivate at 37 C and 225rpm. The fermentation cycle is 72 h. At 24 h and 48 h, adjust to pH 7.0 with 10M NaOH. According to glucose consumption in the fermentation broth, add 65% glucose solution to maintain a glucose concentration of 20 g/L. After completion of fermentation, transfer 1 mL
of the fermentation broth and centrifugate. Measure the content of N-Acetyl-D-Glucosamine by HPLC method.
See Table 7 for the output from shake-flask fermentation. The results show that: The output by the reference strain AT-005-02 is very low and is not detected, while the output from overexpression by nanE gene of nanE/pTrc99A (AT-005-02), controlled by Trc promoter, is increased obviously.
Table 7. Output from Shake-flask Fermentation by the Recombinant Strain nanE/pTrc99A (AT-005-02) species Output of N-Acetyl-D-Glucosamine (g/L) AT-005-02 (AT-004-02, AnagE) Not detected (Reference) nanE/pTrc99A (AT-005-02) 1.4 0.4 WSLEGAL\068076\00030\21038773v1 2. Integration of pTrc-nanE Gene Cassette into the Chromosome of Escherichia Coli Using the nagE gene site as integration site of pTrc-nanE gene cassette into the chromosome. To achieve integration of pTrc-nanE gene cassette into the chromosome of Escherichia coli, first amplify the nanE segment (i.e. pTrc-nanE) with Trc promoter, as well as the kanamycin resistance gene segment with FLP
recognition site (FRT site) at its both ends: FRT-Kanr-FRT (fKanrf), and splice them. Then design homologous primers for deletion of the nagE gene sequence, and using the spliced segment of pTrc-nanE and fKanrf as template, amplify the linear DNA full-length segment for targeting of Red recombination.
The specific operating process is provided below:
(1) PCR Amplification of pTrc-nanE Segment Template: nanE/pTrc99A.
Primer Design: Forward primer (Treff-F) SEQ ID No.20, and reverse primer (Trcff-R) SEQ ID No.21.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Product Size: 0.86kb.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(2) fKanrf segment amplified by PCR
Primer Design: Forward primer (mfKanf-F) SEQ ID No.1, and reverse primer (mfKanf-R) SEQ ID No.2.
Template: pPic9K.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out WSLEGAL\068076\00030\21038773v1 cycles; Step 3: Extend at 72 C for 10 min.
fKanrf size: 1.28kb. Its nucleotide sequence is SEQ ID No.3.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(3) Amplification of fKanrf spliced with pTrc-nanE
Primer Design: Forward primer (fKanf-F) SEQ ID No.22, and reverse primer (fKanf-R) SEQ ID No.23.
Template: fKanrf.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 mm.
fKanrf size from secondary amplificatino: 1.3kb.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(4) Preparation of Linear DNA Full-length PCR Segment for Targeting of Red Recombination Design of Homologous Arm Primers: Design again homologous arm primers for deletion of the nagE gene sequence: Forward primer (nagEKO-F2) SEQ ID
No.24, and reverse primer (nagEKO-R2) SEQ ID No.25.
Template: Mix pTrc-nanE PCR segment, and fKanrf PCR segment from secondary amplification in the ratio of 1:1.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product: Homologous Arm + pTrc-nanE-fKanrf + Homologous Arm The PCR product is separated by agarose gel electrophoresis, and purified and WSLEGAL\068076\00030\21038773v1 recovered to obtain 100 ng/fil, linear DNA full-length PCR segment for targeting of Red recombination.
(5) Red Recombination Operation First, pKD46 carrier is introduced into the AT-004-02 strain of Escherichia coli. Then, the prepared linear DNA segment for targeting is electrotransformed, and positive clones are screened. Finally, the resistance gene is removed.
1) Transformation of pKD46 Plasmid 0 Preparation of Competence: First, inoculate the bacterial suspension of Escherichia coli AT-004-02 stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C and 225 rpm for 2-3 h. then add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaC12 on an ice bath for 5 min. Finally, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath. Allow to stand at -4 C
for 12 h for spontaneous sedimentation.
0Plasmid Transformation: Transfer 250 L of spontaneously sedimented thalli, add 5 pt of pKD46 plasmid, and cultivate at -4 C for 30min. Then heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h. Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate. Cultivate overnight (for 12-16 h) at 30 C. Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification. Store the positive strain for use.
2) Electrotransform linear DNA segment for targeting, and screen positive clone 0 Preparation of Electrotransformed Competence: Inoculate the AT-004-02 strain of Escherichia coli, containing 00)46, into a test tube of LB medium WSLEGAL\068076\00030\21038773v1 containing Ampicillin (Amp), and shake-cultivate at 250 rpm, on the next day, inoculate in a ratio of 1% into LB medium containing Amp, and cultivate at 30 C; when 0D600 reaches approximately 0.2, add 0.2% L-Arabinose, and induce at 30 C for 35 min until 0D600 reaches approximately 0.4. Cool on an ice bath. Wash once with ultrapure water, wash twice with 10% glycerin, and finally resuspend with 10% glycerin; the amount of glyerin used is to produce a final concentration of the thalli concentrated by 500-1000 folds.
()Transformation by electric shock: Take out a 2-mm electrotransformation cup from 70% ethanol, wash with sterilized ultrapure water, and irradiate by UV lamp for 30 min. Precool at 4 C for 30 min.
Transfer 90 tit of finally resuspended cells to a precooled centrifuge tube, add 5 tit (more than 100 ng) of the full-length PCR segement (linear DNA) obtained in Step (4), suction gently by a gun, and maintain on an ice bath for 30 min. Electrotransformation Parameters: 2500V, 200, 25 F.
()Resuscitate and screen positive clones: add 1 mL of LB broth medium, and cultivate at 37 C and 100rpm for 1 h. Then smear one kanamycin (Kan) plate with every 200 tiL, 5 plates in total. Smear evenly and allow to air-dry.
Cultivate at 30 C for 24 h. Pick up clones grown under kanamycin resistance, and carry out PCR identification to screen positive clones.
No. of the obtained strain: AT-030-01 (AT-004-02, A nagE::pTrc-nanE-fKanrf).
(6)Removal of the Resistance Gene Introduce pCP20 into the above kanamycin-resistant clones, cultivate at 30 C
for 8 h, then increase to 42 C and cultivate overnight, and thermally induce to express FLP recombinase; the plasmids are lost gradually. Streak the plate of antibiotics-free culture medium by an inoculating loop dipped in the bacterial WSLEGAL\068076\00030\21038773v1 suspension, pick up grown monoclones and dot on the kanamycin-resistant plate;

those that cannot grown are clones of which the kanamycin resistance gene has been removed by FLP recombination. Carry out PCR with identification primer to identify clones losing kanamycin resistance.
No. of the obtained strain: AT-030-02 (AT-004-02, nagE::pTrc-nanE).
3. Influence of the integration of pTrc-nanE gene cassette on the output of N-Acetyl-D-Glucosamine Carry out a shake-flask fermentation trial with the recombinant strain AT-030-02 of which the nagE gene site in the chromosome is integrated with pTrc-nanE gene cassette, and the reference strain. Transfer the monoclonal strain freshly cultivated in culture medium of the LB plate, inoculate into a test tube (13 x150mm) containing 3 mL of the LB broth culture medium, and shake-cultivate at 30 C and 225rpm for 8 h. Then transfer the seed culture solution, inoculate in 3%
into a 250-mL shake-flask containing 50 mL of the feimentation culture solution (M9 culture solution). The initial 0D600 is approximately 0.5; shake-cultivate at 37 C
and 225rpm. The fermentation cycle is 72 h. At 24 h and 48 h, adjust to pH 7.0 with 10M NaOH. According to glucose consumption in the fermentation broth, add 65% glucose solution to maintain a glucose concentration of 20 g/L. After completion of fermentation, transfer 1 mL of the fermentation broth and centrifugate. Measure the content of N-Acetyl-D-Glucosamine by HPLC method.
See Table 8 for the output from shake-flask fermentation. The results show that: The outputs by the reference strains AT-001 and AT-005-02 are very low and are not detected, while the output by the recombinant strain integrated with pTrc-nanE gene cassette is increased obviously, and is also increased significantly than that by the recombinant strain nanE/pTrc99A (AT-005-02) not integrated with the gene cassette.

WSLEGAL\068076\00030\21038773v1 Table 8, Output from Shake-flask Fermentation by the Recombinant Strain integrated with pTrc-nanE Gene Cassette species Output of N-Acetyl-D-Glucosamine (g/L) AT-001 (Reference) Not detected AT-005-02 (AT-004-02, AnagE) (Reference) Not detected nanE/pTrc99A (AT-005-02) 1.2 0.3 AT-030-02 (AT-004-02, AnagE::pTrc-nanE) 2.5 0.5 Example 3.b This implementation example describes screening for a gene mutant of N-Acetyl-D-Mannosamine-6-P Epimerase (NanE); the said gene encodes N-Acetyl-D-Mannosamine-6-P Epimerase (NanE) with increased activities.
To further increase synthetic quantity of N-Acetyl-D-Glucosamine by the production strain, screen a gene mutant encoding N-Acetyl-D-Mannosamine-6-P
Epimerase with increased activities. To achieve the purpose, amplify the cloned gene by error-prone PCR technology; used for amplified DNA polymerase, amplify the said gene under conditions leading to high-frequency mismatch, so as to obtain a high-frequency mutation in PCR products.
The specific operating process is provided below:
1. Amplification of the Gene nanE of N-Acetyl-D-Mannosamine-6-P
Epimerase in Escherichia coli by Error-prone PCR
By means of Taq DNA polymerase without the property of 3' -5' proofreading function, control the frequency of random mutation under high magnesium ion concentration (8 mmol/L) and different dNTP concentrations (where, the concentration of dATP and dGTP is 1.5 mmol/L; and the concentration of dTTP

WSLEGAL\068076\00030\21038773v1 and dCTP is 3.0 mmol/L), introduce random mutations into the target gene, and construct a mutant library; the template concentration A260 value is 1000 ng/mL, the enzyme concentration is 5 U/lit, and the primer concentration is 100 ilM.
Error-prone PCR reaction system (50 L): 10xPCR reaction buffer 5 1, dNTP
(2.5 mM) 5 L, MgCl2 (2.5 mM) 5 vt,L, Forward primer (nanE-F, SEQ ID No.30) 1 L, reverse primer (nanE-R, SEQ ID No.31) 1 !AL, DNA template (nanE/pUC57) 0.1 viL, Taq DNA polymerase 0.5 pL, and ddH20 32.4 L.
PCR procedure: Predegenerate at 96 C for 4 min; degenerate at 94 C for I
min, anneal at 56 C for 1 mM, extend at 75 C for 2 min, and repeat for 45 cycles;
finally extend at 75 C for 15 min, recover PCR product (product size: 0.7 kb) by gel recovery method; transfer 5 I, of the product and carry out 1% agarose gel electrophoresis test; the product is store at -20 C for use.
2. Construction of the gene mutant library of N-Acetyl-D-Mannosamine-6-P
Epimerase Digest the above PCR product by two enzymes of restriction endonuclease Nco I and Hind III, carry out a ligation reaction with pTrc99A digested by Nco I
and Hind III, then transform Escherichia coli AT-005-02 with the mixture of the ligated products to obtain a large amount of cloned transformants, and construct a mutant library of transformed thalli.
3. Screening for Mutants with High Enzyme Activities Using the wild type NanE/pTrc99A (AT-005-02) as reference, pick up randomly 350 mutant clones from the mutant library of transformed thalli, inoculate into 5 mL of LB medium containing 50 Kg/mL Ampicillin (Amp), shake-cultivate at 37 C and 150 rpm for 18 h, and then centrifugate at 10000 rpm for 5 mim and collect thalli. Discard the supernatant, then resuspend at 4 C
in 1 mL of PBS solution (pH 7.5, 10 mmol/L), carry out ultrasonicate at a voltage of WSLEGAL\068076\00030\21038773v1 300 V for 10 min (ultrasonicate for 3 s and pause for 6 s), centrifugate, transfer the supernatant as crude extract of enzyme, and carry out a method for determination of enzyme activity.
Determination of N-Acetyl-D-Mannosamine-6-P Epimerase Activity: Based on the amount of N-Acetyl-D-Mannosamine-6-Phosphate (ManNAc-6-P) transformed into N-Acetyl-D-Glucosamine-6-Phosphate (G1cNAc-6-P); that is to say, using the reduced amount of N-Acetyl-D-Mannosamine-6-Phosphate as test marker. Definition of Enzyme Activity Unit: Under the enzymatic reaction conditions, the enzyme amount reduced, equivalent to 1 [imol N-Acety1-D-Mannosamine-6-Phosphate per minute, is defined as one enzyme activity unit (IU). The specific procedure is provided as follows: First, prepare isotope-labelled ManNAc-6-P as substrate. Prepare a reaction solution in a total volume of 225 uL, containing ManNAc Kinase (NanK) crude solution (containing 1-5 mg protein), 20 mM ATP disodium, 60 mM Tris-HCl, pH8.1, 20 mM MgC12, 5 mM ManNAc, and 50nCi [14C]ManNAc. Incubate at 37 C for 30 min. Add 350 uL of alcohol to stop the reaction. The product is eluted and lyophilized with water.
Secondly, prepare a reaction solution in a total volume of 26.5 uL as the determination system for enzyme activity, containing 1 mM isotope-labelled ManNAc-6-P, 37 mM Tris-HC1, pH 8.0, and 19 mM MgCl2. Incubate at 37 C for 30 min, heat the reaction solution to boil for 3 min, then add 0.1 volume of alkaline phosphatase buffer to adjust pH and 20 U of alkaline phosphatase. Incubate at for 1 h, draw a sample and add on a dry chromatography paper, and presoak with 1%
sodium tetraborate. The used solvent system is a mixture of ethyl acetate:isopropanol:pyridine:water (50:22:14:14). Separate radioactive compounds by paper chromatography. Measure the radioactive intensity by a liquid scintillation counter, and calculate the activity units of N-Acetyl-D-Mannosamine-6-P Epimerase, based on the amount of ManNAc-6-P
transformed into GlcNAc-6-P.

WSLEGAL\068076\00030\21038773v1 The results show that: The enzyme activity of the mutant strain with maximum activity is 72 IU/mL, and the enzyme activity of the reference control is 9.5 IU/mL. Transform NanE by error-prone PCR, to obtain a mutant strain with enzyme activity increased greatly. Pick up the mutant strain with maximum enzyme activity and extract plasmids for sequencing. The results show that:
The mutant gene sequence of N-Acetyl-D-Mannosamine-6-P Epimerase is shown as SEQ ID No.56, and the corresponding amino acid sequence is shown as SEQ ID
No.57. Through gene sequence alignment with the wild type of N-Acetyl-D-Mannosamine-6-P Epimerase, 3 base point mutations occur in total:
198C/T, 397T/C, and 559T/C. There occur 2 missense mutations of amino acids, of which the mutation points are: Q133R (cysteine at Site 133 is replaced by arginine), and Y18711 (tyrosine at Site 187 is replaced by histidine). The mutant gene is named as nanEM.
4. Integration of pTrc-nanEM Gene Cassette into the nagE Gene Site in the Chromosome of Escherichia Coli Using the nagE gene site as integration site of pTrc-nanEM gene cassette into the chromosome. To achieve integration of pTrc-nanEM gene cassette into the chromosome of Escherichia coli, first amplify the nanEM segment (i.e.
pTrc-nanEM) of Trc promoter, as well as the kanamycin resistence gene segment with FLP recognition site (FRT site) at its both ends: FRT-Kanr-FRT (fKanrf), and splice them. Then design homologous primers for deletion of the nagE gene sequence, and using the spliced segment of pTrc-nanEM and fKand as template, amplify the linear DNA full-length segment for targeting of Red recombination.
The specific operating process is provided below:
(1) PCR Amplification of pTrc-nanEM Segment Template: nanEM/pTrc99A.
Primer Design: Forward primer (Trcff-F) SEQ ID No.20, and reverse primer (Trcff-R) SEQ ID No.21.

WSLEGAL\068076\00030\21038773v1 PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Product Size: 0.86kb.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(2) fKanrf segment amplified by PCR
Primer Design: Forward primer (mfKanf-F) SEQ ID No.1, and reverse primer (mfKanf-R) SEQ ID No.2.
Template: pPic9K.
PCR reaction conditions: Step 1: Degenerate at 94 C for I min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
fKanrf size: 1.28kb. Its nucleotide sequence is SEQ ID No.3.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(3) Amplification of fKanrf spliced with pTrc-nanEM
Primer Design: Forward primer (fKanf-F) SEQ ID No.22, and reverse primer (fKanf-R) SEQ ID No.23.
Template: fKanrf.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
fKanrf size from secondary amplificatino: 1.3kb.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(4) Preparation of Linear DNA Full-length PCR Segment for Targeting of WSLEGAL\068076\00030\21038773v1 Red Recombination Design of Homologous Ann Primers: Design again homologous arm primers for deletion of the nagE gene sequence: Forward primer (nagEKO-F2) SEQ ID
No.24, and reverse primer (nagEKO-R2) SEQ ID No.25.
Template: Mix pTrc-nanEM PCR segment, and fKanrf PCR segment from secondary amplification in the ratio of 1:1.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product: Homologous Aim + pTrc-nanEM-fKand +
Homologous Arm The PCR product is separated by agarose gel electrophoresis, and purified and recovered to obtain 100 ng/i.IL linear DNA full-length PCR segment for targeting of Red recombination.
(5) Red Recombination Operation First, 0(1)46 carrier is introduced into the AT-004-02 strain of Escherichia coil. Then, the prepared linear DNA segment for targeting is electrotransformed, and positive clones are screened. Finally, the resistance gene is removed.
1) Transformation of pKD46 Plasmid Preparation of Competence: First, inoculate the bacterial suspension of Escherichia coil AT-004-02 stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C and 225 rpm for 2-3 h. Then add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaCl2 on an ice bath for 5 min. Finally, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath. Allow to stand at -4 C

WSLEGAL\068076\00030\21038773v1 for 12 h for spontaneous sedimentation.
C)Plasmid Transformation: Transfer 250 tit of spontaneously sedimented thalli, add 5 fit of pKD46 plasmid, and cultivate at -4 C for 30min. Then heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake .. at 30 C for 2 h. Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate. Cultivate overnight (for 12-16 h) at 30 C. Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification. Store the positive strain for use.
2) Electrotransfoim linear DNA segment for targeting, and screen positive clone Preparation of Electrotransformed Competence: Inoculate the AT-004-02 strain of Escherichia coli, containing 0(.1)46, into a test tube of LB medium containing Ampicillin (Amp), and shake-cultivate at 250 rpm, on the next day, inoculate in a ratio of 1% into LB medium containing Amp, and cultivate at 30 C;
when 0D600 reaches approximately 0.2, add 0.2% L-Arabinose, and induce at 30 C
for 35 min until 0D600 reaches approximately 0.4. Cool on an ice bath. Wash once with ultrapure water, wash twice with 10% glycerin, and finally resuspend with 10% glycerin; the amount of glyerin used is to produce a final concentration of the thalli concentrated by 500-1000 folds.
co Transformation by electric shock: Take out a 2-mm electrotransformation cup from 70% ethanol, wash with sterilized ultrapure water, and irradiate by UV lamp for 30 min. Precool at 4 C for 30 min.
Transfer 90 tit of finally resuspended cells to a precooled centrifuge tube, add 5 tit (more than 100 ng) of the full-length PCR segement (linear DNA) obtained in Step (4), suction gently by a gun, and maintain on an ice bath for min. Electrotransformation Parameters: 2500V, 2005,I 251tf.
()Resuscitate and screen positive clones: add 1 mL of LB broth medium, WSLEGAL\068076\00030\21038773v1 and cultivate at 37 C and 100rpm for 1 h. Then smear one kanamycin (Kan) plate with every 200 p,L, 5 plates in total. Smear evenly and allow to air-dry.
Cultivate at 30 C for 24 h. Pick up clones grown under kanamycin resistance, and carry out PCR identification to screen positive clones.
No. of the obtained strain: AT-031-01 (AT-004-02, AnagE::pTrc-nanEM-fKanrf).
(6) Removal of the Resistance Gene Introduce pCP20 into the above kanamycin-resistant clones, cultivate at 30 C
for 8 h, then increase to 42 C and cultivate overnight, and themially induce to express FLP recombinase; the plasmids are lost gradually. Streak the plate of antibiotics-free culture medium by an inoculating loop dipped in the bacterial suspension, pick up grown monoclones and dot on the kanamycin-resistant plate;

those that cannot grown are clones of which the kanamycin resistance gene has been removed by FLP recombination. Carry out PCR with identification primer to identify clones losing kanamycin resistance.
No. of the obtained strain: AT-031-02 (AT-004-02, AnagE::pTrc-nanEM).
5. Influence of the integration of pTrc-nanEM gene cassette on the output of N-Acetyl-D-Glucosamine Carry out a shake-flask felluentation trial with the recombinant strain AT-031-02 of which the nagE gene site in the chromosome is integrated with pTrc-nanEM gene cassette, and the reference strain. Transfer the monoclonal strain freshly cultivated in culture medium of the LB plate, inoculate into a test tube (13x150mm) containing 3 mL of the LB broth culture medium, and shake-cultivate at 30 C and 225rpm for 8 h. Then transfer the seed culture solution, inoculate in 3%
into a 250-mL shake-flask containing 50 mL of the fermentation culture solution (M9 culture solution). The initial 0D600 is approximately 0.5; shake-cultivate at 37 C and 225rpm. The fermentation cycle is 72 h. At 24 h and 48 h, adjust to pH

WSLEGAL\068076\00030\21038773v1 7.0 with 10M NaOH. According to glucose consumption in the fermentation broth, add 65% glucose solution to maintain a glucose concentration of 20 g/L. After completion of fermentation, transfer 1 mL of the feimentation broth and centrifugate. Measure the content of N-Acetyl-D-Glucosamine by HPLC method.
See Table 9 for the output from shake-flask feimentation. The results show that: The output by the reference strain AT-005-02 is very low and is not detected, while the output by the recombinant strain AT-031-02 integrated with pTrc-nanEM
gene cassette is increased obviously, and is also increased significantly than that by the unmutant reference strain AT-030-02.
Table 9, Output from Shake-flask Fermentation by the Recombinant Strain integrated with pTrc-nanEM Gene Cassette species Output of N-Acetyl-D-Glucosamine (g/L) AT-005-02 (AT-004-02, AnagE) (Reference) Not detected AT-030-02 (AT-004-02, AnagE::pTrc-nanE) 2.6+0.5 AT-031-02 (AT-004-02, A nagE: :pTrc-nanEM) 5.9+0.8 The above results show that: The output of N-Acetyl-D-Glucosamine may be increased obviously by overexpression of N-Acetyl-D-Mannosamine-6-P
Epimerase; moreover, the output of N-Acetyl-D-Glucosamine may also be greatly by the mutant screened by error-prone PCR technology, due to increased activities of the obtained mutant of the epimerase.
Example 3.c This implementation example describes Escherichia coli strains integrated with pTrc-nanEM gene cassette, and the gene vhb thereof and its mutant for expression of vitreoscilla hemoglobin (Vhb) as well as influence on the output of N-Acetyl-D- Glucosamine.

WSLEGAL\068076\00030\21038773v1 Amplify the gene vhb for vitreoscilla hemoglobin (Vhb), insert into pTrc99A, so that vhb is controlled by Trc promoter to transform the strains, or screen a mutant of the gene vhb for vitreoscilla hemoglobin (Vhb) and insert into pTrc99A
to transform the strains, to increase the microorganism's utilization ability for dissolved oxygen and increase the fermentation production the output of N-Acetyl-Glucosamine.
1. Escherichia coil strains integrated with pTrc-nanEM gene cassette, and the gene vhb for expression of vitreoscilla hemoglobin (Vhb) (1) Amplify the vhb Gene and Insert into pTrc99A
The nucleotide sequence the gene encoding vitreoscilla hemoglobin (Vhb) is SEQ ID No.60, and the amino acid sequence is SEQ ID No.61. Based on the preference cocon bases of Escherichia coli, optimize and synthesize the gene for vitreoscilla hemoglobin (Vhb), and load into pUC57 carrier. Obtain a carrier named as: vhb/pUC57.
Primer Design: Forward primer (vhb-F) SEQ ID No.62, and reverse primer (vhb-R) SEQ ID No.63.
Template: vhb/pUC57.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 mm; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product Size: 441bp.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
Digest enzymatically the obtained PCR amplification segment and carrier pTrc99A with Nco I and Hind III, separate by agarose gel electrophoresis, purify and recover vhb segment and pTrc99A segment, ligate overnight with T4 DNA
ligase at 16 C, and carry out identification to obtain vhb/pTrc99A plasmid.

WSLEGAL\068076\00030\21038773v1 (2) Transform Escherichia coli strains integrated with pTrc-NanEM gene gassette by vhb/pTrc99A
1) Preparation of Competence 0 Inoculate the bacterial suspension of AT-031-02 stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C
and 225 rpm for 2-3 h.
()Add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaCl2 on an ice bath for 5 min.
0 Centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaC12 on an ice bath. Allow to stand at -4 C for 12 h for spontaneous sedimentation.
2) Plasmid Transformation 0 Transfer 250 fiL of spontaneously sedimentated thalli, add 5 L of vhb/pTrc99A plasmid, and cultivate at -4 C for 30min.
()Heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h.
0 Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate.
0 Cultivate overnight (for 12-16 h) at 30 C.
0 Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification.
0 Positive clones are stored for use.
No. of the obtained strain: AT-054 (AT-031-02, vhb/pTrc99A).
2. Escherichia coli strains integrated with pTrc-nanEM gene cassette, and the gene vhb mutant for expression of vitreoscilla hemoglobin (Vhb) WSLEGAL\068076\00030\21038773v1 1) Preparation of Competence ()Inoculate the bacterial suspension of AT-031-02 stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C
and 225 rpm for 2-3 h.
0 Add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaCl2 on an ice bath for 5 min.
0 Centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath. Allow to stand at -4 C for 12 h for spontaneous sedimentation.
2) Plasmid Transfoluiation ()Transfer 250 jut of spontaneously sedimentated thalli, add 5 L of vhbM/pTrc99A plasmid, and cultivate at -4 C for 30min.
()Heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h.
0 Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate.
0 Cultivate overnight (for 12-16 h) at 30 C.
()Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification.
0 Positive clones are stored for use.
No. of the obtained strain: AT-055 (AT-031-02, vhbM/pTrc99A).
2. Escherichia coil strains integrated with pTrc-nanEM gene cassette, and the gene vhb thereof and its mutants for expression of vitreoscilla hemoglobin (Vhb) as well as influence on the output of N-Acetyl-D-Glucosamine Carry out a shake-flask fermentation trial with the strains integrated with WSLEGAL\068076\00030\21038773v1 pTrc-nanEM gene cassette, and the mutant strains AT-052 and AT-053 with the gene vhb for expression of vitreoscilla hemoglobin. Transfer the monoclonal strain freshly cultivated in culture medium of the LB plate, inoculate into a test tube (13 x150mm) containing 3 mL of the LB broth culture medium, and shake-cultivate at 30 C for 8 h. Then transfer the seed culture solution, inoculate in 3% into a 250-mL shake-flask containing 50 mL of M9 culture solution. The initial 0D600 is approximately 0.5; shake-cultivate at 37 C and 225rpm. The fermentation cycle is 72 h. At 24 h and 48 h, adjust to pH 7.0 with 10M NaOH. According to glucose consumption in the fermentation broth, add 65% glucose solution to maintain a glucose concentration of 20 g/L. After completion of feimentation, transfer 1 mL
of the fermentation broth and centrifugate. Measure the content of N-Acetyl-D-Glucosamine by HPLC method.
See Table 10 for the output from shake-flask fermentation by recombinant strains. The results show that: The output may be increased obviously from expression of vhb by the recombinant strains both with transformed vhb/
pTrc99A
and with transformed vhbM/ pTrc99A plasmid; moreover, the output is increased more significant by the recombinant strain with with transformed vhbM/ pTrc99A

plasmid.
Table 10. Output from Shake-flask Fermentation by the Recombinant Strains for Expression of vhb and vhbM
species Output of N-Acetyl-D-Glucosamine (g/L) _ AT-031-02 (Reference) 6.0 0.8 AT-054 (AT-031-02, vhb/pTrc99A) 17.1 1.2 _ AT-055 (AT-031-02, vhbM/pTrc99A) 20.7 1.3 Example 4.a WSLEGAD068076\00030\21038773v1 This example describes gene wecB cloning of UDP-N-Acetyl-D -Gluco samine-2-Epimerase (WecB), and trans fol __ ined wecB/pTrc99A plasmids in Escherichia coli, as well as integration of ptrc-wecB

gene cassette into the chromosome of Escherichia coli.
1. wecB Gene Cloning, Transformation of wecB/pTrc99A Plasmid in Escherichia coli, and its Influence on the Output of N-Acetyl-D-Glucosamine The gene wecB of UDP-N-AcetylGlucosamine-2-Epimerase (WecB) is controlled by Trc promoter to transform strains for overexpression of the enzyme, to strengthen production of ManNAc (N-Acetyl-D-mannosamine, N-Acetyl-D-Mannosamine or N-Acetyl-D-Mannosamine) from UDP-G1cNAc (UDP-N-Acetyl Glucosamine, UDP-N-Acetyl-D-Glucosamine).
1) wecB Gene Cloning of Escherichia Coli According to NCBI, look up the nucleotide sequence SEQ ID No.49 of the wecB gene of Escherichia coli, and its amino acid sequence is SEQ ID No.50.
Primer Design: Forward primer (TrcwecB-F) SEQ ID No.51, and reverse primer (TrcwecB-R) SEQ ID No.52.
Template: AT-001 (Escherichia coli ATCC 27325) Genome.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product Size: 1.13kb.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
Ligate the obtained PCR amplification segment with pUC57-T carrier, and carry out sequencing for identification, to obtain wecB/ pUC57.
2) Construction and Transformation of Plasmid in which wecB gene is WSLEGAL\068076\00030\21038773v1 controlled by Trc promoter (DPlasmid Construction: Amplify plasmid wecB/ pUC57, digest enzymatically wecB/pUC57 and carrier pTrc99A with Nco I and Hind III, separate by agarose gel electrophoresis, purify to recover wecB segment and pTrc99A segment, ligate overnight with T4 DNA ligase at 16 C, and carry out identification to obtain wecB/pTrc99A plasmid.
()Preparation of Competence: First, inoculate the bacterial suspension of AT-005-02 stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C and 225 rpm for 2-3 h. then add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaC12 on an ice bath for 5 min. Finally, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath. Allow to stand at -4 C for 12 h for spontaneous sedimentation.
()Plasmid Transfoimation: Transfer 250 tit of spontaneously sedimentated thalli, add 5 1_, of wecB/pTrc99A plasmid, and cultivate at -4 C for 30min.
Then heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h. Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate. Cultivate overnight (for 12-16 h) at 30 C. Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification. Store the positive strain for use. Obtain Recombinant Strain wecB/pTrc99A (AT-005-02) 3) Influence of wecB/pTrc99A plasmid transformation on the output of N-Acetyl-D-Glucosamine Carry out a shake-flask fermentation trial with the recombinant strain wecB/pTrc99A (AT-005-02) and the reference strain. Transfer the monoclonal strain freshly cultivated in culture medium of the LB plate, inoculate into a test WSLEGAL\068076\00030\21038773v1 tube (13x150mm) containing 3 mL of the LB broth culture medium, and shake-cultivate at 30 C and 225rpm for 8 h. Components of LB Broth Medium: 5 g/L yeast powder, 10 g/L peptone, and 10 g/L NaCl. Then transfer the seed culture solution, inoculate in 3% into a 250-mL shake-flask containing 50 mL of the fetmentation culture solution (M9 culture solution). The initial 0D600 is approximately 0.5; shake-cultivate at 37 C and 225rpm. The fetmentation cycle is 72 h. At 24 h and 48 h, adjust to pH 7.0 with 10M NaOH. According to glucose consumption in the fermentation broth, add 65% glucose solution to maintain a glucose concentration of 20 g/L. After completion of fermentation, transfer 1 mL
of the fermentation broth and centrifugate. Measure the content of N-Acetyl-D-Glucosamine by HPLC method.
See Table 11 for the output from shake-flask fermentation. The results show that: The output by the reference strain AT-005-02 is very low and is not detected, while the output from overexpression by wecB gene of wecB/pTrc99A
(AT-005-02), controlled by Trc promoter, is increased obviously.
Table 11. Output from Shake-flask Fermentation by the Recombinant Strain wecB/pTrc99A (AT-005-02) species Output of N-Acetyl-D-Gluco s amine (g/L) AT-005-02 (AT-004-02, AnagE) Not detected (Reference) wecB/pTrc99A (AT-005-02) 4.2+0.4 2. Integration of pTrc-wecB Gene Cassette into the Chromosome of Escherichia Coli WSLEGAL\068076\00030\21038773v1 Using the nagE gene site as integration site of pTrc-wecB gene cassette into the chromosome. To achieve integration of pTrc-wecB gene cassette into the chromosome of Escherichia coli, first amplify the wecB segment (i.e. pTrc-wecB) of Trc promoter, as well as the kanamycin resistance gene segment with FLP
recognition site (FRT site) at its both ends: FRT-Kanr-FRT (fKanrf), and splice them. Then design homologous primers for deletion of the nagE gene sequence, and using the spliced segment of pTrc-wecB and fKanrf as template, amplify the linear DNA full-length segment for targeting of Red recombination.
The specific operating process is provided below:
(1)PCR Amplification of pTrc-wecB Segment Template: wecB/pTrc99A.
Primer Design: Forward primer (Trcff-F) SEQ ID No.20, and reverse primer (Trcff-R) SEQ ID No.21.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Product Size: 1.3kb.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(2)fKanrf segment amplified by PCR
Primer Design: Forward primer (mfKanf-F) SEQ ID No.1, and reverse primer (mfKanf-R) SEQ ID No.2.
Template: pPic9K.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
fKanrf size: 1.28kb. Its nucleotide sequence is SEQ ID No.3.

WSLEGAL\068076\00030\21038773v1 The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(3)Amplification of fKanrf spliced with pTrc-wecB
Primer Design: Forward primer (fKanf-F) SEQ ID No.22, and reverse primer (fKanf-R) SEQ ID No.23.
Template: fKanrf.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
fKanrf size from secondary amplificatino: 1.3kb.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(4)Preparation of Linear DNA Full-length PCR Segment for Targeting of Red Recombination Design of Homologous Arm Primers: Design again homologous arm primers for deletion of the nagE gene sequence: Forward primer (nagEKO-F2) SEQ ID
No.24, and reverse primer (nagEKO-R2) SEQ ID No.25.
Template: Mix pTrc-wecB PCR segment, and fKanrf PCR segment from secondary amplification in the ratio of 1:1.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product: Homologous Aim + pTrc-wecB-fKanrf +
Homologous Ann The PCR product is separated by agarose gel electrophoresis, and purified and recovered to obtain 100 ng/i.tL, linear DNA full-length PCR segment for targeting of Red recombination.

WSLEGAL\068076\00030\21038773v1 (5) Red Recombination Operation First, pKD46 carrier is introduced into the AT-004-02 strain of Escherichia coli. Then, the prepared linear DNA segment for targeting is electrotransformed, and positive clones are screened. Finally, the resistance gene is removed.
1) Transfonnation of pKD46 Plasmid ()Preparation of Competence: First, inoculate the bacterial suspension of Escherichia coli AT-004-02 stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C and 225 rpm for 2-3 h. then add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaCl2 on an ice bath for 5 min. Finally, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaC12 on an ice bath. Allow to stand at -4 C
for 12 h for spontaneous sedimentation.
Plasmid Transformation: Transfer 250 iiiL of spontaneously sedimented thalli, add 5 ILL of pKD46 plasmid, and cultivate at -4 C for 30min. Then heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h. Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate. Cultivate overnight (for 12-16 h) at 30 C. Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification. Store the positive strain for use.
2) Electrotransform linear DNA segment for targeting, and screen positive clone Preparation of Electrotransformed Competence: Inoculate the AT-004-02 strain of Escherichia coli, containing pKD46, into a test tube of LB medium containing Ampicillin (Amp), and shake-cultivate at 250 rpm, on the next day, inoculate in a ratio of 1% into LB medium containing Amp, and cultivate at 30 C;

WSLEGAL\068076\00030\21038773v1 when 0D600 reaches approximately 0.2, add 0.2% L-Arabinose, and induce at 30 C

for 35 min until 0D600 reaches approximately 0.4. Cool on an ice bath. Wash once with ultrapure water, wash twice with 10% glycerin, and finally resuspend with 10% glycerin; the amount of glyerin used is to produce a final concentration of the thalli concentrated by 500-1000 folds.
0 Transformation by electric shock: Take out a 2-mm electrotransformation cup from 70% ethanol, wash with sterilized ultrapure water, and irradiate by UV lamp for 30 min. Precool at 4 C for 30 min.
Transfer 90 tiL of finally resuspended cells to a precooled centrifuge tube, add 5 pit (more than 100 ng) of the full-length PCR segement (linear DNA) obtained in Step (4), suction gently by a gun, and maintain on an ice bath for 30 min. Electrotransformation Parameters: 2500V, 200, 250.
()Resuscitate and screen positive clones: add 1 mL of LB broth medium, and cultivate at 37 C and 100rpm for 1 h. Then smear one kanamycin (Kan) plate with every 200 L, 5 plates in total. Smear evenly and allow to air-dry.
Cultivate at 30 C for 24 h. Pick up clones grown under kanamycin resistance, and carry out PCR identification to screen positive clones.
No. of the obtained strain: AT-042-01 (AT-004-02, AnagE::pTrc-wecB-fKanrf).
(6) Removal of the Resistance Gene Introduce pCP20 into the above kanamycin-resistant clones, cultivate at 30 C
for 8 h, then increase to 42 C and cultivate overnight, and thermally induce to express FLP recombinase; the plasmids are lost gradually. Streak the plate of antibiotics-free culture medium by an inoculating loop dipped in the bacterial suspension, pick up grown monoclones and dot on the kanamycin-resistant plate;
those that cannot grown are clones of which the kanamycin resistance gene has been removed by FLP recombination. Carry out PCR with identification primer to WSLEGAL\068076\00030\21038773v1 identify clones losing kanamycin resistance.
No. of the obtained strain: AT-042-02 (AT-004-02, AnagE::pTrc-wecB).
3. Influence of the integration of pTrc-wecB gene cassette on the output of N-Acetyl-D-Glucosamine Carry out a shake-flask fermentation trial with the recombinant strain AT-042-02 of which the nagE gene site in the chromosome is integrated with pTrc-wecB gene cassette, and the reference strain. Transfer the monoclonal strain freshly cultivated in culture medium of the LB plate, inoculate into a test tube (13x150mm) containing 3 mL of the LB broth culture medium, and shake-cultivate at 30 C and 225rpm for 8 h. Then transfer the seed culture solution, inoculate in 3%
into a 250-mL shake-flask containing 50 mL of the fermentation culture solution (M9 culture solution). The initial 0D600 is approximately 0.5; shake-cultivate at 37 C
and 225rpm. The fermentation cycle is 72 h. At 24 h and 48 h, adjust to pH 7.0 with 10M NaOH. According to glucose consumption in the fermentation broth, add 65% glucose solution to maintain a glucose concentration of 20 g/L. After completion of fermentation, transfer 1 mL of the fermentation broth and centrifugate. Measure the content of N-Acetyl-D-Glucosamine by HPLC method.
See Table 12 for the output from shake-flask fermentation. The results show that: The outputs by the reference strains AT-001 and AT-005-02 are very low and are not detected, while the output by the recombinant strain integrated with pTrc-wecB gene cassette is increased obviously, and is also increased significantly than that by the recombinant strain wecB/pTrc99A (AT-005-02) not integrated with the gene cassette.
Table 12, Output from Shake-flask Fermentation by the Recombinant Strain integrated with pTrc-wecB Gene Cassette species Output of N-Acetyl-D-Glucosamine (g/L) AT-001 (Reference) Not detected WSLEGAL\068076\00030\21038773v1 AT-005-02 (AT-004-02, AnagE) Not detected (Reference) wecB/pTrc99A (AT-005-02) 4.1+0.5 AT-042-02 (AT-004-02, 7.0+0.8 A nagE::pTrc-wecB) Example 4.b This implementation example describes screening for a gene mutant of UDP-N-AcetylGlucosamine-2-Epimerase (WecB); the said gene encodes UDP-N-AcetylGlucosamine-2-Epimerase (WecB) with increased activities.
To further increase synthetic quantity of N-Acetyl-D-Glucosamine by the production strain, screen a gene mutant encoding UDP-N-AcetylGlucosamine -2-Epimerase with increased activities. To achieve the purpose, amplify the cloned gene by error-prone PCR technology; used for amplified DNA polymerase, amplify the said gene under conditions leading to high-frequency mismatch, so as to obtain a high-frequency mutation in PCR products.
The specific operating process is provided below:
1. Amplification of UDP-N-AcetylGlucosamine-2-Epimerase gene wecB by Error-prone PCR.
By means of Taq DNA polymerase without the property of 3' -5' proofreading function, control the frequency of random mutation under high magnesium ion concentration (8 mmol/L) and different dNTP concentrations (where, the concentration of dATP and dGTP is 1.5 mmol/L; and the concentration of dTTP
and dCTP is 3.0 mmol/L), introduce random mutations into the target gene, and construct a mutant library; the template concentration A260 value is 1000 ng/mL, the enzyme concentration is 5 U/lut, and the primer concentration is 100 M.
Error-prone PCR reaction system (50111): 10xPCR reaction buffer 50, dNTP
(2.5 mM) 5 L, MgC12 (25 mM) 5 pL, Forward primer (TrcwecB-F, SEQ ID

WSLEGAL\068076\00030\21038773v1 No.51) 1 L, reverse primer (TrcwecB-R, SEQ ID No.52) 1 ILtL, DNA template (wecB/pUC57) 0.1 L, Taq DNA polymerase 0.5 vtL, and ddH20 32.4 L.
PCR procedure: Predegenerate at 96 C for 4 min; degenerate at 94 C for 1 min, anneal at 56 C for 1 min, extend at 75 C for 2 min, and repeat for 45 cycles;
finally extend at 75 C for 15 min, recover PCR product (product size: 1.13 kb) by gel recovery method; transfer 5 vEL of the product and carry out 1% agarose gel electrophoresis test; the product is store at -20 C for use.
2. Construction of the gene mutant library of UDP-N-Acetyl Glucosamine-2-Epimerase Digest the above PCR product by two enzymes of restriction endonuclease Nco I and Hind III, carry out a ligation reaction with pTrc99A digested by Nco I
and Hind III, then transform Escherichia coli AT-005-02 with the mixture of the ligated products to obtain a large amount of cloned transfonnants, and construct a mutant library of transformed thalli.
3. Screening for Mutants with High Enzyme Activities Using the wild type WecB/pTrc99A (AT-005-02) as reference, pick up randomly 640 mutant clones from the mutant library of transformed thalli, inoculate into 5 mL of LB medium containing 50 g/mL Ampicillin (Amp), shake-cultivate at 37 C and 150 rpm for 18 h, and then centrifugate at 10000 rpm for 5 mim and collect thalli. Discard the supernatant, then resuspend at 4 C
in 1 mL of PBS solution (pH 7.5, 10 mmol/L), carry out ultrasonicate at a voltage of 300 V for 10 min (ultrasonicate for 3 s and pause for 6 s), centrifugate, transfer the supernatant as crude extract of enzyme, and carry out a method for deteanination of enzyme activity.
Determination of UDP-N-AcetylGlucosamine-2-Epimerase Activity: Based WSLEGAL\068076\00030\21038773v1 on the amount of UDP-N-Acetyl-D-Glucosamine transformed into N-Acetyl-D-Mannosamine. That is to say, the reduced amount of UDP-N-Acetyl-D-Glucosamine is used as test marker. Definition of Enzyme Activity Unit: Under the enzymatic reaction conditions, the enzyme amount reduced, equivalent to 1 mol UDP-N-Acetyl-D-Glucosamine per minute, is defined as one enzyme activity unit (IU). The specific procedure is provided as follows: Transfer 20 mL of the reaction system as the system for determination of enzyme activity, which contains 45 mmol/L phosphate buffer (pH7.5), 10 mM
MgC12 and 100 nCi of UDPG1cNAc, and 5 mg crude enzyme solution. Carry out the enzyme activity reaction by incubating on a water bath at 37 C for 30 min.

Add alcohol to stop the reaction. Separate radioactive compounds by paper chromatography. Measure the radioactive intensity by a liquid scintillation counter.
The solvent system used is a mixture of n-propano1:1M sodium acetate, pH
5.0:water (7:1:2). Calculate the activity units of UDP-N-AcetylGlucosamine-2-Epimerase, based on the amount of UDPG1cNAc transformed into ManNAc.
The results show that: The enzyme activity of the mutant strain with maximum activity is 653 IU/mL, and the enzyme activity of the reference control is 21.0 IU/mL. Transfoun WecB by error-prone PCR, to obtain a mutant strain with enzyme activity increased greatly. Pick up the mutant strain with maximum enzyme activity and extract plasmids for sequencing. The results show that:
The mutant gene sequence of UDP-N-AcetylGlucosamine-2-Epimerase is shown as SEQ ID No.58, and the corresponding amino acid sequence is shown as SEQ ID
No.59. Compared with gene sequence of the wild type UDP-N-AcetylGlucosamine-2-Epimerase, 5 base point mutations occur in total:
101G/C, 433C/G, 677G/T, 734T/G, and 1038T/C, There occur 4 missense mutations of amino acids, of which the mutation points are: C34S (cysteine at Site 34 is replaced by serine), H145D (histidine at Site 145 is replaced by aspartate), WSLEGAL\068076\00030\21038773v1 C226F (cysteine at Site 226 is replaced by phenylalanine) ,and V245G (valine at Site 245 is replaced by glycine). The mutant gene is named as wecBM.
4. Integration of pTrc-wecBM Gene Cassette into the nagE Gene Site in the .. Chromosome of Escherichia Coli Using the nagE gene site as integration site of pTrc-wecBM gene cassette into the chromosome. To achieve integration of pTrc-wecBM gene cassette into the chromosome of Escherichia coli, first amplify the wecBM segment (i.e.
pTrc-wecBM) of Trc promoter, as well as the kanamycin resistence gene segment with FLP recognition site (FRT site) at its both ends: FRT-Kanr-FRT (fKanrf), and splice them. Then design homologous primers for deletion of the nagE gene sequence, and using the spliced segment of pTrc-wecBM and fKanrf as template, amplify the linear DNA full-length segment for targeting of Red recombination.
The specific operating process is provided below:
(1)PCR Amplification of pTrc-wecBM Segment Template: wecBM/pTrc99A.
Primer Design: Forward primer (Trcff-F) SEQ ID No.20, and reverse primer (Trcff-R) SEQ ID No.21.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
.. Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out 30 cycles; Step 3: Extend at 72 C for 10 min.
Product Size: 1.3kb.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(2)fKanrf segment amplified by PCR
Primer Design: Forward primer (mfKanf-F) SEQ ID No.1, and reverse primer (mfKanf-R) SEQ ID No.2.
Template: pPic9K.

WSLEGAL\068076\00030\21038773v1 PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
fKanrf size: 1.28kb. Its nucleotide sequence is SEQ ID No.3.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(3)Amplification of fKanrf spliced with pTrc-wecBM
Primer Design: Forward primer (fKanf-F) SEQ ID No.22, and reverse primer (fKanf-R) SEQ ID No.23.
Template: fKanrf.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
fKanrf size from secondary amplificatino: 1.3kb.
The PCR product is separated by 1 % agarose gel electrophoresis, and purified to recover the segment.
(4)Preparation of Linear DNA Full-length PCR Segment for Targeting of Red Recombination Design of Homologous Arm Primers: Design again homologous ami primers for deletion of the nagE gene sequence: Forward primer (nagEKO-F2) SEQ ID
No.24, and reverse primer (nagEKO-R2) SEQ ID No.25.
Template: Mix pTrc-wecBM PCR segment, and fKanrf PCR segment from secondary amplification in the ratio of 1:1.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product: Homologous Arm + pTrc-wecBM-fKanrf +

WSLEGAL\068076\00030\21038773v1 Homologous Arm The PCR product is separated by agarose gel electrophoresis, and purified and recovered to obtain 100 ng/111, linear DNA full-length PCR segment for targeting of Red recombination.
(5)Red Recombination Operation First, plCD46 carrier is introduced into the AT-004-02 strain of Escherichia coli. Then, the prepared linear DNA segment for targeting is electrotransformed, and positive clones are screened. Finally, the resistance gene is removed.
1)Transformation of pKD46 Plasmid ()Preparation of Competence: First, inoculate the bacterial suspension of Escherichia coli AT-004-02 stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C and 225 rpm for 2-3 h. Then add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaC12 on an ice bath for 5 min. Finally, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath. Allow to stand at -4 C
for 12 h for spontaneous sedimentation.
()Plasmid Transformation: Transfer 250 ILIL of spontaneously sedimented thalli, add 5 tit of p1CD46 plasmid, and cultivate at -4 C for 30min. Then heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h. Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate. Cultivate overnight (for 12-16 h) at 30 C. Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification. Store the positive strain for use.
2) Electrotransform linear DNA segment for targeting, and screen positive clone WSLEGAL\068076\00030\21038773v1 ()Preparation of Electrotransfoimed Competence: Inoculate the AT-004-02 strain of Escherichia coli, containing pl(D46, into a test tube of LB medium containing Ampicillin (Amp), and shake-cultivate at 250 rpm, on the next day, inoculate in a ratio of 1% into LB medium containing Amp, and cultivate at 30 C;
when 0D600 reaches approximately 0.2, add 0.2% L-Arabinose, and induce at 30 C
for 35 mm until 0D600 reaches approximately 0.4. Cool on an ice bath. Wash once with ultrapure water, wash twice with 10% glycerin, and finally resuspend with 10% glycerin; the amount of glyerin used is to produce a final concentration of the thalli concentrated by 500-1000 folds.
0 Transfoimation by electric shock: Take out a 2-mm electrotransformation cup from 70% ethanol, wash with sterilized ultrapure water, and irradiate by UV lamp for 30 min. Precool at 4 C for 30 min.
Transfer 90 pt of finally resuspended cells to a precooled centrifuge tube, add 5 pt (more than 100 ng) of the full-length PCR segement (linear DNA) obtained in Step (4), suction gently by a gun, and maintain on an ice bath for 30 min. Electrotransformation Parameters: 2500V, 20052, 25 F.
()Resuscitate and screen positive clones: add 1 mL of LB broth medium, and cultivate at 37 C and 100rpm for 1 h. Then smear one kanamycin (Kan) plate with every 200 L, 5 plates in total. Smear evenly and allow to air-dry.
Cultivate at 30 C for 24 h. Pick up clones grown under kanamycin resistance, and carry out PCR identification to screen positive clones.
No. of the obtained strain: AT-043-01 (AT-004-02, AnagE::pTrc-wecBM-fKanrf).
(6)Removal of the Resistance Gene Introduce pCP20 into the above kanamycin-resistant clones, cultivate at 30 C
for 8 h, then increase to 42 C and cultivate overnight, and thermally induce to express FLP recombinase; the plasmids are lost gradually. Streak the plate of WSLEGAL\068076\00030\21038773v1 antibiotics-free culture medium by an inoculating loop dipped in the bacterial suspension, pick up grown monoclones and dot on the kanamycin-resistant plate;

those that cannot grown are clones of which the kanamycin resistance gene has been removed by FLP recombination. Carry out PCR with identification primer to identify clones losing kanamycin resistance.
No. of the obtained strain: AT-043-02 (AT-004-02, AnagE::pTrc-wecBM).
5. Influence of the integration of pTrc-wecBM gene cassette on the output of N-Acetyl-D-Glucosamine Carry out a shake-flask fermentation trial with the recombinant strain AT-043-02 of which the nagE gene site in the chromosome is integrated with pTrc-wecBM gene cassette, and the reference strain. Transfer the monoclonal strain freshly cultivated in culture medium of the LB plate, inoculate into a test tube (13x150mm) containing 3 mL of the LB broth culture medium, and shake-cultivate at 30 C and 225rpm for 8 h. Then transfer the seed culture solution, inoculate in 3% into a 250-mL shake-flask containing 50 mL of the felinentation culture solution (M9 culture solution). The initial 0D600 is approximately 0.5;
shake-cultivate at 37 C and 225rpm. The fermentation cycle is 72 h. At 24 h and 48 h, adjust to pH 7.0 with 10M NaOH. According to glucose consumption in the .. fermentation broth, add 65% glucose solution to maintain a glucose concentration of 20 g/L. After completion of feinientation, transfer 1 mL of the fermentation broth and centrifugate. Measure the content of N-Acetyl-D-Glucosamine by HPLC
method.
See Table 13 for the output from shake-flask feimentation. The results show that: The output by the reference strain AT-005-02 is very low and is not detected, while the output by the recombinant strain AT-043-02 integrated with pTrc-wecBM gene cassette is increased obviously, and is also increased significantly than that by the unmutant reference strain AT-042-02.

WSLEGAL\068076\00030\21038773v1 Table 13, Output from Shake-flask Fermentation by the Recombinant Strain integrated with pTrc-wecBM Gene Cassette species Output of N-Acetyl-D-Glucosamine (g/L) AT-005-02 (AT-004-02, A nagE) (Reference) Not detected AT-042-02 (AT-004-02, AnagE::pTrc-wecB) 7.1+0.8 AT-043-02 (AT-004-02, A nagE::pTrc-wecBM) 10.9+0.9 The above results show that: The output of N-Acetyl-D-Glucosamine may be increased obviously by overexpression of UDP-N-AcetylGlucosamine-2-Epimerase; moreover, the output of N-Acetyl-D-Glucosamine may also be greatly by the mutant screened by error-prone PCR technology, due to increased activities of the obtained mutant of the epimerase.
Example 4.c This implementation example describes Escherichia coli strains integrated with wecBM gene cassette, and the gene vhb thereof and its mutant for expression of vitreoscilla hemoglobin (Vhb) as well as influence on the output of N-Acetyl-D-Glucosamine.
Amplify the gene vhb for vitreoscilla hemoglobin (Vhb), insert into pTrc99A, so that vhb is controlled by Trc promoter to transform the strains, or screen a mutant of the gene vhb for vitreoscilla hemoglobin (Vhb) and insert into pTrc99A
to transform the strains, to increase the microorganism's utilization ability for dissolved oxygen and increase the fermentation production the output of N-Acetyl-Glucosamine.
1. Escherichia coil strains integrated with pTrc-wecBM gene cassette, and WSLEGAL\068076\00030\21038773v1 the gene vhb for expression of vitreoscilla hemoglobin (Vhb) (1) Amplify the vhb Gene and Insert into pTrc99A
The nucleotide sequence the gene encoding vitreoscilla hemoglobin (Vhb) is SEQ ID No.60, and the amino acid sequence is SEQ ID No.61. Based on the preference cocon bases of Escherichia coli, optimize and synthesize the gene for vitreoscilla hemoglobin (Vhb), and load into pUC57 carrier. Obtain a carrier named as: vhb/pUC57.
Primer Design: Forward primer (vhb-F) SEQ ID No.62, and reverse primer (vhb-R) SEQ ID No.63.
Template: vhb/pUC57.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product Size: 441bp.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
Digest enzymatically the obtained PCR amplification segment and carrier pTrc99A with Nco I and Hind III, separate by agarose gel electrophoresis, purify and recover vhb segment and pTrc99A segment, ligate overnight with T4 DNA
ligase at 16 C, and carry out identification to obtain vhb/pTrc99A plasmid.
(2) Transform Escherichia coli strains integrated with pTrc-wecBM gene cassette by vhb/pTrc99A
1) Preparation of Competence ()Inoculate the bacterial suspension of AT-043-02 stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C
and 225 rpm for 2-3 h.
()Add the culture solution to a 10-inL centrifuge tube, centrifugate at WSLEGAL\068076\00030\21038773v1 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaCl2 on an ice bath for 5 min.
0 Centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath. Allow to stand at -4 C for 12 h for spontaneous sedimentation.
2) Plasmid Transformation ()Transfer 250 ILL of spontaneously sedimentated thalli, add 5 pt of vhb/pTrc99A plasmid, and cultivate at -4 C for 30min.
()Heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h.
0 Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate.
0 Cultivate overnight (for 12-16 h) at 30 C.
()Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification.
0 Positive clones are stored for use.
No. of the obtained strain: AT-056 (AT-043-02, vhb/pTrc99A).
2. Escherichia coli strains integrated with pTrc-wecBM gene cassette, and the gene vhb mutant for expression of vitreoscilla hemoglobin (Vhb) 1) Preparation of Competence ()Inoculate the bacterial suspension of AT-043-02 stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C
and 225 rpm for 2-3 h.
Add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaCl2 on an ice bath for 5 min.

WSLEGAL\068076\00030\21038773v1 0 Centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath. Allow to stand at -4 C for 12 h for spontaneous sedimentation.
2) Plasmid Transformation ()Transfer 250 1_, of spontaneously sedimentated thalli, add 5 tiL of vhbM/pTrc99A plasmid, and cultivate at -4 C for 30min.
()Heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h.
()Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate.
0 Cultivate overnight (for 12-16 h) at 30 C.
()Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification.
Positive clones are stored for use.
No. of the obtained strain: AT-057 (AT-043-02, vhbM/pTrc99A).
2. Escherichia coli strains integrated with pTrc-wecBM gene cassette, and the gene vhb thereof and its mutants for expression of vitreoscilla hemoglobin (Vhb) as well as influence on the output of N-Acetyl-D-Glucosamine Carry out a shake-flask fermentation trial with the strains integrated with pTrc-wecBM gene cassette, and the mutant strains AT-056 and AT-057 with the gene vhb for expression of vitreoscilla hemoglobin. Transfer the monoclonal strain freshly cultivated in culture medium of the LB plate, inoculate into a test tube (13 x150mm) containing 3 mL of the LB broth culture medium, and shake-cultivate at 30 C and 225rpm for 8 h. Then transfer the seed culture solution, inoculate in 3%
into a 250-mL shake-flask containing 50 mL of M9 culture solution. The initial 0D600 is approximately 0.5; shake-cultivate at 37 C and 225rpm. The fermentation cycle is 72 h. At 24 h and 48 h, adjust to pH 7.0 with 10M NaOH. According to WSLEGAL\068076\00030\21038773v1 glucose consumption in the fermentation broth, add 65% glucose solution to maintain a glucose concentration of 20 g/L. After completion of fermentation, transfer 1 mL of the fermentation broth and centrifugate. Measure the content of N-Acetyl-D-Glucosamine by HPLC method.
See Table 14 for the output from shake-flask fermentation by recombinant strains. The results show that: The output may be increased obviously from expression of vhb by the recombinant strains both with transformed vhb/
pTrc99A
and with transformed vhbM/ pTrc99A plasmid; moreover, the output is increased more significant by the recombinant strain with with transformed vhbM/ pTrc99A
plasmid.
Table 14. Output from Shake-flask Fermentation by the Recombinant Strains Integrated with pTrc-wecBM Gene Cassette for Expression of vhb and vhbM
species Output of N-Acetyl-D-Glucosamine (g/L) AT-043-02 (AT-004-02, AnagE::pTrc-wecBM) 10.8 0.9 (reference) AT-056 (AT-043-02, vhb/pTrc99A) 17.3 1.4 AT-057 (AT-043-02, vhbM/pTrc99A) 21.4 1.4 Example 5.a This implementation example describes influences of the strains on the output of N-Acetyl-D-Glucosamine, of which the natural endogenous promoter of the nagB gene is replaced by Trc promoter, or the natural endogenous promoter of the glmS gene is further deleted.
1. The natural endogenous promoter of the nagB gene is replaced by Trc promoter The gene promoter of D-Glucosamine-6-Phosphate Deaminase (NagB) in nag regulon (nagE-nagBACD) is replaced by Trc promoter. The reaction catalyzed by WSLEGAL\068076\00030\21038773v1 D-Glucosamine-6-Phosphate Deaminase (NagB) is reversible; overexpression of nagB may accelerate the forward catalytic reaction by NagB, to achieve the purpose of increasing D-Glucosamine-6-Phosphate (G1cN-6-P).
First, amplify Trc promoter segment and fKanrf segment, and splice together.
Then design homologous primers, and amplify linear DNA full-length segment for targeting of Red recombination.
(1) Amplification of Trc promoter sequence According to public information, look up Trc promoter sequence: SEQ
ID No.32.
Primer Design: Forward primer (KanTrcRed-F) SEQ ID No.33, and reverse primer (KanTrcRed-R) SEQ ID No.34.
Template: pTrc99A
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out 30 cycles; Step 3: Extend at 72 C for 10 min.
Product Size: 166bp.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(2) Amplify the kanamycin resistance gene with recognition sites (FRT sites) for FLP recombinase at its both ends: fKanrf Primer Design: Forward primer (mfKanf-F) SEQ ID No.1, and reverse primer (mfKanf-R) SEQ ID No.2.
Template: pPic9K.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
fKanrf size: 1.28kb. Its nucleotide sequence is SEQ ID No.3.

WSLEGAL\068076\00030\21038773v1 The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(3) Amplification of fKanrf spliced with Trc promoter Primer Design: Forward primer (fKanfRed-F1) SEQ ID No.35, and reverse primer (fKanfRed-R1) SEQ ID No.36.
Template: fKanrf.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out 30 cycles; Step 3: Extend at 72 C for 10 mm.
fKanrf size from secondary amplificatino: 1.3kb.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(4) Preparation of Linear DNA Full-length PCR Segment for Targeting of Red Recombination Design of Homologous Arm Primers: From NCBI, look up NC_000913, nagB
promoter sequence and nagA gene sequence SEQ ID No.13 of Escherichia coli str.

K-12, and design the homologous arm primers for deletion of nagB promoter:
Forward primer (nagBKO-F1) SEQ ID No.40 and reverse primer (nagBKO-R1) SEQ ID No.41.
Template: Mix Trc promoter PCR segment and fKanrf PCR segment from secondary amplification in the ratio of 1:1.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product: Homologous Arm + fKanrf + Trc Promoter +
Homologous Aim.
The PCR product is separated by agarose gel electrophoresis, and purified and WSLEGAL\068076\00030\21038773v1 recovered to obtain 100 ng/IAL linear DNA full-length PCR segment for targeting of Red recombination.
(5) Red Recombination Operation First, pKD46 carrier is introduced into the AT-005-02 strain of Escherichia coli. Then, the prepared linear DNA segment for targeting is electrotransfoitned, and positive clones are screened. Finally, the resistance gene is removed.
No. of the obtained strain: AT-048(AT-005-02, AnagB promotor::Trc promoter).
2. Deletion of the natural endogenous promoter of the glmS gene Deletion of the gene promoter of Glucosamine-6-Phosphate Synthase (glmS).
Glucosamine-6-Phosphate Synthase (GlmS), also called as L-Glutamine-D-fructose-6-phosphate aminotransferase, can catalyze amination of Glucose-6-Phosphate (G1c-6-P) into D-Glucosamine-6-Phosphate (G1cN-6-P), but has a severe problem for product inhibition. When the promoter sequence is deleted so that the enzyme cannot be expressed, it may solve product inhibition of GlcN-6-P.
First, amplify fKanrf segment; then design homologous primers, and amplify linear DNA full-length segment for targeting of Red recombination.
(1) Amplify the kanamycin resistance gene with recognition sites (FRT sites) for FLP recombinase at its both ends: fKanrf Primer Design: Forward primer (mfKanf-F) SEQ ID No.1, and reverse primer (mfKanf-R) SEQ ID No.2.
Template: pPic9K.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
fKanrf size: 1.28kb. Its nucleotide sequence is SEQ ID No.3.
The PCR product is separated by 1% agarose gel electrophoresis, and purified WSLEGAL\068076\00030\21038773v1 to recover the segment.
(2) Preparation of Linear DNA Full-length PCR Segment for Targeting of Red Recombination Design of Homologous Primers: From NCBI, look up NC_000913, the gene promoter sequence SEQ ID No.42 of Glucosamine-6-Phosphate Synthase (GlmS) of Escherichia coil str. K-12, and design the homologous arm primers for deletion of glmS gene promoter: Forward primer (ProglmsKO-F) SEQ ID No.43 and reverse primer (ProglmsKO-R) SEQ ID No.44.
Template: fKand PCR Segment.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product: Homologous Arm + fKanf + Homologous Aim.
The PCR product is separated by agarose gel electrophoresis, and purified and recovered to obtain 100 ng/ L linear DNA full-length PCR segment for targeting of Red recombination.
(3) Red Recombination Operation First, pl(D46 carrier is introduced into the AT-048 strain of Escherichia coli.
Then, the prepared linear DNA segment for targeting is electrotransformed, and positive clones are screened. Finally, the resistance gene is removed.
No. of the obtained strain: AT-049(AT-048, AglmS promotor).
3. Influence of the strains of which nagB promoter replaced by a promoter with higher expression level, or glmS promoter is further deleted, on the output of N-Acetyl-D-Glucosamine Carry out a shake-flask fermentation trial with the strain of which nagB
promoter is replaced by a promoter with higher expression level, and the recombinant strain of which glmS promoter is further deleted. Transfer the monoclonal strain freshly cultivated in culture medium of the LB plate, inoculate WSLEGAL\068076\00030\21038773v1 into a test tube (13 x150mm) containing 3 mL of the LB broth culture medium, and shake-cultivate at 30 C and 225rpm for 8 h. Then transfer the seed culture solution, inoculate in 3% into a 250-mL shake-flask containing 50 mL of the fermentation culture solution (M9 culture solution). The initial 0D600 is approximately 0.5;
shake-cultivate at 37 C and 225rpm. The fermentation cycle is 72 h. At 24 h and 48 h, adjust to pH 7.0 with 10M NaOH. According to glucose consumption in the fermentation broth, add 65% glucose solution to maintain a glucose concentration of 20 g/L. After completion of fermentation, transfer 1 mL of the fermentation broth and centrifugate. Measure the content of N-Acetyl-D-Glucosamine by HPLC
method.
See Table 15 for the output from shake-flask fermentation. The results show that: The output of N-Acetyl-D-Glucosamine is obviously increased by the recombinant strains of which nagB promoter is replaced by Trc promoter, or glmS
promoter is further deleted.
Table 15, Output from Shake-flask Feimentation by Recombinant Strains of which nagB promoter is replaced or glmS promoter is further deleted species Output of N-Acetyl-D-Glucosamine (g/L) AT-001 (Reference) Not detected AT-005-02 (Reference) Not detected AT-048 (AT-005-02, A nagB promotor::Trc 3.3+0.4 promoter) AT-049(AT-048, AglmS promotor) 8.7+0.9 Example 5.b This implementation example describes influences of the strains on the output of N-Acetyl-D-Glucosamine, of which the natural endogenous promoter of the glmS gene is replaced by Trc promoter, and the natural endogenous promoter of WSLEGAL\068076\00030\21038773v1 the nagB gene is further deleted.
1. The natural endogenous promoter of the glmS gene is replaced by Trc promoter The gene promoter sequence of L-Glutamine-D-Fructose-6-Phosphate Aminotransferase is replaced by Trc promoter sequence. L-Glutamine-6-Phosphate Aminotransferase, also called as Glucosamine-6-Phosphate Synthase (GlmS);
replacement of its promoter sequence is replaced by Trc promoter sequence may overexpress glmS, and accelerate GlmS catalytic function, to achieve the purpose of increasing D-Glucosamine-6-Phosphate (G1cN-6-P).
First, amplify Trc promoter sequence segment and fKand segment, and splice together. Then design homologous primers, and amplify linear DNA full-length segment for targeting of Red recombination.
(1) Amplification of Linear DNA Full-length PCR Segment for Targeting of Red Recombination Design of homologous arm primers: According to the glmS gene promoter sequence SEQ ID No.42, design homologous arm primers with the promoter replaced by Trc promoter: Forward primer (ProglmspTrc-F) SEQ ID No.45, and reverse primer (ProglmspTrc-R) SEQ ID No.46.
Template: Mix Trc promoter PCR segment and fKand PCR segment from secondary amplification in the ratio of 1:1.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product: Homologous Arm + fKand + Trc Promoter +
Homologous Arm.
The PCR product is separated by agarose gel electrophoresis, and purified and recovered to obtain 100 ng/ L linear DNA full-length PCR segment for targeting WSLEGAL\068076\00030\21038773v1 of Red recombination.
(2) Red Recombination Operation First, pl(D46 carrier is introduced into the AT-005-02 strain of Escherichia coli. Then, the prepared linear DNA segment for targeting is electrotransfonned, and positive clones are screened. Finally, the resistance gene is removed.
No. of the obtained strain: AT-050 (AT-005-02, A glmS promotor::Trc promoter).
2. Deletion of the natural endogenous promotor of NagB gene Deletion of the gene promoter sequence of D-Glucosamine-6-Phosphate Deaminase (NagB) in the nag regulon (nagE-nagBACD), so that nagB loses its function, may eliminate the reverse catalytic function of NagB and reduce production of G1c-6-P from GlcN-6-P.
First, amplify fKand segment; then design homologous primers, and prepare linear DNA full-length segment for targeting of Red recombination.
(1) Preparation of Linear DNA Full-length PCR Segment for Targeting of Red Recombination Design of Homologous Arm Primers: According to nagB promoter sequence and nagA gene sequence SEQ ID No.13, design the homologous arm primers for deletion of nagB promoter sequence: Forward primer (nagBKO-F2) SEQ ID No.47 and reverse primer (nagBKO-R2) SEQ ID No.48.
Template: fKanrf PCR Segment PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product: Homologous Arm + fKand + Homologous Ann.
The PCR product is separated by agarose gel electrophoresis, and purified and recovered to obtain 100 ng/IAL linear DNA full-length PCR segment for targeting WSLEGAL\068076\00030\21038773v1 of Red recombination.
(2) Red Recombination Operation First, pKD46 carrier is introduced into the AT-050 strain of Escherichia coll. Then, the prepared linear DNA segment for targeting is electrotransformed, and positive clones are screened. Finally, the resistance gene is removed.
No. of the obtained strain: AT-051 (AT-050, AnagB promotor).
3. Influence of the strains of which glmS promoter replaced by a promoter with higher expression level, or is further deleted, on the output of N-Acetyl-D-Glucosamine Carry out a shake-flask fermentation trial with the strain of which glmS
promoter is replaced by a promoter with higher expression level, and the recombinant strain of which nagB promoter is further deleted.
Transfer the monoclonal strain freshly cultivated in culture medium of the LB
plate, inoculate into a test tube (13x150mm) containing 3 mL of the LB broth culture medium, and shake-cultivate at 30 C and 225rpm for 8 h. Then transfer the seed culture solution, inoculate in 3% into a 250-mL shake-flask containing 50 mL
of the fermentation culture solution (M9 culture solution). The initial 0D600 is approximately 0.5; shake-cultivate at 37 C and 225rpm. The fermentation cycle is 72 h. At 24 h and 48 h, adjust to pH 7.0 with 10M NaOH. According to glucose consumption in the fermentation broth, add 65% glucose solution to maintain a glucose concentration of 20 g/L. After completion of fermentation, transfer 1 mL
of the fermentation broth and centrifugate. Measure the content of N-Acetyl-D-Glucosamine by HPLC method.
See Table 16 for the output from shake-flask fermentation. The results show that: The output of N-Acetyl-D-Glucosamine is not obviously increased by the recombinant strains of which glmS promoter is replaced by Trc promoter, and is WSLEGAL068076`00030\21038773v1 not detected. However, the output of N-Acetyl-D-Glucosamine is increased obviously when nagB is meanwhile deleted, than that by the reference strain.
Table 16, Output from Shake-flask Fermentation by Recombinant Strains of which glmS promoter is replaced or nagB promoter is further deleted species Output of N-Acetyl-D-Glucosamine (g/L) AT-001 (Reference) Not detected AT-005-02 (Reference) Not detected AT-050 (AT-005-02, A glmS promotor::Trc Not detected promoter) AT-051 (AT-050, AnagB promotor) 5.6+0.6 Example 5.c This implementation example describes Escherichia coli strains integrated of which the natural endogenous promoter of glmS gene and nagB gene is replaced and/or deleted, and the gene vhb thereof and its mutant for expression of vitreoscilla hemoglobin (Vhb) as well as influence on the output of N-Acetyl-D-Glucosamine.
Amplify the gene vhb for vitreoscilla hemoglobin (Vhb), insert into pTrc99A, so that vhb is controlled by Trc promoter to transform the strains, or screen a mutant of the gene vhb for vitreoscilla hemoglobin (Vhb) and insert into pTrc99A
to transform the strains, to increase the microorganism's utilization ability for dissolved oxygen and increase the fermentation production the output of N-Acetyl-Glucosamine.
1. Escherichia coil strains of which the nagB promoter is replaced by a promoter with higher expression level and the glmS promoter is further deleted, and vhb and its mutants for expression of vitreoscilla hemoglobin WSLEGAL\068076\00030\21038773v1 (Vhb) (1) Amplify the vhb Gene and Insert into pTrc99A
The nucleotide sequence the gene encoding vitreoscilla hemoglobin (Vhb) is SEQ ID No.60, and the amino acid sequence is SEQ ID No.61. Based on the preference cocon bases of Escherichia coli, optimize and synthesize the gene for vitreoscilla hemoglobin (Vhb), and load into pUC57 carrier. Obtain a carrier named as: vhb/pUC57.
Primer Design: Forward primer (vhb-F) SEQ ID No.62, and reverse primer (vhb-R) SEQ ID No.63.
Template: vhb/pUC57.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product Size: 441bp, The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
Digest enzymatically the obtained PCR amplification segment and carrier pTrc99A with Nco I and Hind III, separate by agarose gel electrophoresis, purify and recover vhb segment and pTrc99A segment, ligate overnight with T4 DNA
ligase at 16 C, and carry out identification to obtain vhb/pTrc99A plasmid.
(2) Escherichia coli strains of which the nagB promoter is transformed with vhb/pTrc99A and vhbM/pTrc99A to produce a promoter with higher expression level, and the glmS promoter is further deleted 1) Preparation of Competence ()Inoculate the bacterial suspension of AT-049 stored at -20 C into 10 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C
and 225 rpm for 2-3 h.

WSLEGAL\068076\00030\21038773v1 Add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaCl2 on an ice bath for 5 min.
Centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath. Allow to stand at -4 C for 12 h for spontaneous sedimentation.
2) Plasmid Transformation Transfer 250 'IL of spontaneously sedimentated thalli, add 5 ILL of vhb/pTrc99A and vhbM/pTrc99A plasmids, respectively, and cultivate at -4 C
for 30min.
Heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h.
Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate.
0 Cultivate overnight (for 12-16 h) at 30 C.
()Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification.
Positive clones are stored for use.
No. of the obtained strains: AT-058 (AT-049, vhb/pTrc99A), and AT-059 (AT-049, vhbM/pTrc99A).
2. Escherichia coli strains of which the natural endogenous promoter of the glmS gene is replaced by Trc promoter, and the natural endogenous promoter of the nagB gene is deleted, and the gene vhb mutants for expression of vitreoscilla hemoglobin 1) Preparation of Competence Inoculate the bacterial suspension of AT-051 stored at -20 C into 10 WSLEGAL\068076\00030\21038773v1 mL of LB broth medium in a ratio of 1:50-100, and shake-cultivate at 37 C
and 225 rpm for 2-3 h.
()Add the culture solution to a 10-mL centrifuge tube, centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL 0.1M CaCl2 on an ice bath for 5 min.
0 Centrifugate at 4000g x 5min, discard the supernatant, and suspend with 5 mL of 0.1M CaCl2 on an ice bath. Allow to stand at -4 C for 12 h for spontaneous sedimentation.
2) Plasmid Transformation Transfer 250 IA of spontaneously sedimentated thalli, add 5 tit of vhb/pTrc99A and vhbM/pTrc99A plasmids, respectively, and cultivate at -4 C
for 30min.
Heat on a water bath at 42 C for 1.5 min, add 0.7 mL of SOC medium, and shake at 30 C for 2 h.
()Transfer 0.2 mL of the bacterial suspension, and smear on a penicillin plate.
0 Cultivate overnight (for 12-16 h) at 30 C.
()Pick up monoclone, add 5 mL of LB broth medium and cultivate, and withdraw plasmid for identification.
()Positive clones are stored for use.
No. of the obtained strains: AT-060 (AT-051, vhb/pTrc99A), and AT-061 (AT-051, vhbM/pTrc99A).
2. Escherichia con strains integrated of which the natural endogenous promoter of glmS gene and nagB gene is replaced and/or deleted, and the gene vhb thereof and its mutant for expression of vitreoscilla hemoglobin (Vhb) as well as influence on the output of N-Acetyl-D-Glucosamine WSLEGAL\068076\00030\21038773v1 Carry out a shake-flask fermentation trial with the strains of which the natural endogenous promoter of glmS gene and nagB gene is replaced and/or deleted, and the strains AT-058, AT-059, AT-060, and AT-061 with the gene vhb thereof and its mutant for expression of vitreoscilla hemoglobin (Vhb). Transfer the monoclonal strain freshly cultivated in culture medium of the LB plate, inoculate into a test tube (13 x150mm) containing 3 mL of the LB broth culture medium, and shake-cultivate at 30 C and 225rpm for 8 h. Then transfer the seed culture solution, inoculate in 3% into a 250-mL shake-flask containing 50 mL of M9 culture solution. The initial 0D600 is approximately 0.5; shake-cultivate at 37 C and 225rpm. The fermentation cycle is 72 h. At 24 h and 48 h, adjust to pH 7.0 with 10M NaOH. According to glucose consumption in the fermentation broth, add 65%
glucose solution to maintain a glucose concentration of 20 g/L. After completion of fermentation, transfer 1 mL of the fermentation broth and centrifugate.
Measure the content of N-Acetyl-D-Glucosamine by HPLC method.
See Table 17 for the output from shake-flask fermentation by recombinant strains. The results show that: The output may be increased obviously from expression of vhb by the recombinant strains both with transformed vhb/
pTrc99A
and with transformed vhbM/ pTrc99A plasmid; moreover, the output is increased more significant by the recombinant strain with with transformed vhbM/ pTrc99A
plasmid.
Table 17. Output from Shake-flask Fermentation by the Recombinant Strains for Expression of vhb and vhbM
species Output of N-Acetyl-D-Glucosamine (g/L) AT-049(AT-048, AglmS promotor) 8.6+0.9 WSLEGAL\068076\0003021038773v1 AT-058 (AT-049, vhb/pTrc99A) 10.5+1.0 AT-059 (AT-049, vhbM/pTrc99A) 13.5+1.1 AT-051 (AT-050, AnagB promotor) 5.7+0.5 AT-060 (AT-051, vhb/pTrc99A) 8.4+0.6 AT-061 (AT-051, vhbM/pTrc99A) 11.7+1.0 Example 6 This implementation example describes Escherichia coli strains integrated with pTrc-nanKM gene cassette, of which the natural endogenous promoter of the nanE gene is replaced by Trc promoter, and the gene vhb thereof and its mutant for expression of vitreoscilla hemoglobin (Vhb) as well as influence on the output of N-Acetyl-D-Glucosamine.
1. The natural endogenous promoter with nanE gene of Escherichia coli strains integrated with pTrc-nanKM cassette is replaced with Trc promoter First, amplify Trc promoter sequence segment and fKanrf segment, and splice together. Then design homologous primers, and amplify linear DNA
full-length segment for targeting of Red recombination.
(1)Amplification of Trc promoter sequence According to public information, look up Trc promoter sequence: SEQ
ID No.32.
Primer Design: Forward primer (KanTrcRed-F) SEQ ID No.33, and reverse primer (KanTrcRed-R) SEQ ID No.34.
Template: pTrc99A
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Product Size: 166bp.

WSLEGAL\068076\00030\21038773v1 The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(2)Amplify the kanamycin resistance gene with recognition sites (FRT sites) for FLP recombinase at its both ends: fKanrf Primer Design: Forward primer (mfKanf-F) SEQ ID No.1, and reverse primer (mfKanf-R) SEQ ID No.2.
Template: pPic9K.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out 30 cycles; Step 3: Extend at 72 C for 10 min.
fKanrf size: 1.28kb. Its nucleotide sequence is SEQ ID No.3.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(3)Amplification of fKanrf spliced with Trc promotor Primer Design: Forward primer (fKanfRed-F1) SEQ ID No.35, and reverse primer (fKanfRed-R1) SEQ ID No.36.
Template: fKanrf.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out 30 cycles; Step 3: Extend at 72 C for 10 min.
fKanrf size from secondary amplificatino: 1.3kb.
The PCR product is separated by 1% agarose gel electrophoresis, and purified to recover the segment.
(4)Preparation of Linear DNA Full-length PCR Segment for Targeting of Red Recombination Design homologous primers: Based on promoter sequence SEQ ID No.37 of the nanE gene. Design primers to be replaced with Trc promoter: Forward WS LEGAL \ 068076 \ 00030 \21038773v1 primer (ProNanEpTrc-F) SEQ ID No.38, and reverse primer (ProNanEpTrc-R) SEQ ID No.39.
Template: Mix Trc promoter PCR segment and fKanrf PCR segment from secondary amplification in the ratio of 1:1.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:
Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out 30 cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product: Homologous Arm + fKanrf + Trc Promoter +
Homologous Arm.
The PCR product is separated by agarose gel electrophoresis, and purified and recovered to obtain 100 ng/pt linear DNA full-length PCR
segment for targeting of Red recombination.
(5)Red Recombination Operation First, pKD46 carrier is introduced into the AT-007-02 strain of Escherichia coli. Then, the prepared linear DNA segment for targeting is electrotransformed, and positive clones are screened. Finally, the resistance gene is removed.
No. of the obtained strain: AT-009 (AT-007-02, AnanE promotor::Trc promoter).
2. Escherichia coli strains integrated with pTrc-nanEM gene cassette, of which the natural endogenous promoter of the nanE gene is replaced by Trc promoter, and the gene vhb thereof and its mutant for expression of vitreoscilla hemoglobin (Vhb) First, prepare competence of recombinant Escherichia coli strain AT-009;
then, transform vhb/pTrc99A and vhbM/pTrc99A plasmids into AT-009 by CaC12 transformation method, pick up monoclones and cultivate, and pipet plasmid to identify positive clones.

WSLEGAL\068076\00030\21038773v1 No. of the obtained strains: AT-062 (AT-009, vhb/pTrc99A), and AT-063 (AT-009, vhbM/pTrc99A).
Carry out a shake-flask fermentation trial with the strains AT-062 and AT-063 with the gene vhb and its mutant for expression of vitreoscilla hemoglobin.
See Table 18 for the output from shake-flask fermentation by recombinant strains.
The results show that: The output may be increased obviously from expression of vhb by the recombinant strains both with transformed vhb/ pTrc99A and with transformed vhbM/ pTrc99A plasmid; moreover, the output is increased more significant by the recombinant strain with with transformed vhbM/ pTrc99A
plasmid.
Table 18, Output from Shake-flask Fermentation by the Recombinant Strain species Output of N-Acetyl-D-Glucosamine (g/L) AT-009 (AT-007-02, AnanE promoter::Trc 19.9+1.5 promoter) (reference) AT-062 (AT-009, vhb/pTrc99A) 23.9+1.4 AT-063 (AT-009, vhbM/pTrc99A) 26.8+1.3 Example 7 This implementation example describes Escherichia coli strains integrated with pTrc-nanKM and influences of those on the output of N-Acetyl-D-Glucosamine, of which the natural endogenous promoter of the gene glmS of Glucosamine-6-Phosphate Synthase (GlmS) and/or the nagB gene of D-Glucosamine-6-Phosphate Deaminase (NagB) is replaced and/or deleted, and the gene vhb and its mutants for expression of vitreoscilla hemoglobin (Vhb).
In Escherichia coli strains integrated with pTrc-nanKM cassette, the natural WSLEGAL\068076\00030\21038773v1 endogenous promoter of the nanB gene is replaced by Trc promoter to produce AT-010 (AT-007-02, AnagB promotor::Trc promoter), and the natural endogenous promoter of the glmS gene is further deleted to produce AT-011 (AT-010, AglmS
promotor); In Escherichia coli strains integrated with pTrc-nanKM cassette, the natural endogenous promoter of the glmS gene is replaced by Trc promoter to produce AT-012 (AT-007-02, AnagB promotor::Trc promoter), and the natural endogenous promoter of the nagB gene is further deleted to produce AT-013 (AT-012, AnagB promotor).
Prepare competence of recombinant Escherichia coli strain AT-11 and AT-013; then, transfoim vhb/pTrc99A and vhbM/pTrc99A plasmids into AT-011 and AT-013 by CaC12 transfoimation method, pick up monoclones and cultivate, and pipet plasmid to identify positive clones.
No. of the obtained strains: AT-064 (AT-011, vhb/pTrc99A), AT-065 (AT-011, vhbM/pTrc99A), AT-066 (AT-013, vhb/pTrc99A), and AT-067 (AT-013, vhbM/pTrc99A).
Carry out a shake-flask feunentation trial with the strains AT-064, AT-065, AT-066, and AT-067 with the gene vhb and its mutant for expression of vitreoscilla hemoglobin. See Table 19 for the output from shake-flask fermentation by recombinant strains. The results show that: The output may be increased obviously from expression of vhb by the recombinant strains both with transformed vhb/ pTrc99A and with transformed vhbM/ pTrc99A plasmid;
moreover, the output is increased more significant by the recombinant strain with with transformed vhbM/ pTrc99A plasmid.
Table 19, Output from Shake-flask Femientation by the Recombinant Strain species Output of N-Acetyl-D-Glucosamine (g/L) AT-011 (AT-010, AglmS promotor) (reference) 21.6+1.4 AT-064 (AT-011, vhb/pTrc99A) 24.8 1.4 WSLEGAL\068076\00030\21038773v1 AT-065 (AT-011, vhbM/pTrc99A) 28.6+1.5 _ AT-013 (AT-012, A nagB promotor) (reference) 21.3+1.6 _ AT-066 (AT-013, vhb/pTrc99A)
24.6+1.4 _ AT-067 (AT-013, vhbM/pTrc99A) 27.9+1.3 Example 8 This implementation example describes Escherichia coli strains integrated with pTrc-nanKM gene cassette, of which the natural endogenous promoter of the wecB gene is replaced by Trc promoter, and the gene vhb thereof and its mutant for expression of vitreoscilla hemoglobin (Vhb) as well as influence on the output of N-Acetyl-D-Glucosamine.
1. The natural endogenous promoter of the wecB gene of Escherichia coli strains integrated with pTrc-nanKM cassette is replaced by Trc promoter First, amplify Trc promoter sequence segment and fKanrf segment, and splice together. Then design homologous primers, and amplify linear DNA full-length segment for targeting of Red recombination.
(I) Preparation of Linear DNA Full-length PCR Segment for Targeting of Red Recombination Design of Homologous Arm Primers: According to NCBI, look up NC 000913 to obtain the nucleotide sequence SEQ ID No.53 of the gene promoter of Escherichia coli UDP-N-AcetylGlucosamine-2-Epimerase (WecB), design homologous aim primers with the promoter replaced by Trc promoter: Forward primer (ProwecBpTrc-F) SEQ ID No.54, and reverse primer (Pro wecBpTrc-R) SEQ ID No.55.
Template: Mix Trc promoter PCR segment and fKand PCR segment from secondary amplification in the ratio of 1:1.
PCR reaction conditions: Step 1: Degenerate at 94 C for 1 min; Step 2:

WSLEGAL068076\00030\21038773v1 Incubate at 94 C for 30s, at 55 C for 30s, and at 72 C for 40s, and carry out cycles; Step 3: Extend at 72 C for 10 min.
Amplification Product: Homologous Aim + fKand + Trc Promoter +
Homologous Arm.
The PCR product is separated by agarose gel electrophoresis, and purified and recovered to obtain 100 ng/4 linear DNA full-length PCR segment for targeting of Red recombination.
(2) Red Recombination Operation First, 0(1346 carrier is introduced into the AT-007-02 strain of Escherichia coli. Then, the prepared linear DNA segment for targeting is electrotransformed, and positive clones are screened. Finally, the resistance gene is removed.
No.
of the obtained strain: AT-019(AT-007-02, A wecB promotor::Trc promoter).
2. Escherichia coli strains integrated with pTrc-nanEM gene cassette, of which the natural endogenous promoter of the wecB gene is replaced by Trc promoter, and the gene vhb thereof and its mutant for expression of vitreoscilla hemoglobin (Vhb) First, prepare competence of recombinant Escherichia coli strain AT-019;
then, transform vhb/pTrc99A and vhbM/pTrc99A plasmids into AT-019 by CaC12 transformation method, pick up monoclones and cultivate, and pipet plasmid to identify positive clones.
No. of the obtained strains: AT-068 (AT-019, vhb/pTrc99A), and AT-069 (AT-019, vhbM/pTrc99A).
Carry out a shake-flask fermentation trial with the strains AT-068 and AT-069 with the gene vhb and its mutant for expression of vitreoscilla hemoglobin.
See Table 20 for the output from shake-flask fermentation by recombinant strains.
The results show that: The output may be increased obviously from expression of vhb WSLEGAL\068076\00030\21038773v1 by the recombinant strains both with transformed vhb/ pTrc99A and with transformed vhbM/ pTrc99A plasmid; moreover, the output is increased more significant by the recombinant strain with with transformed vhbM/ pTrc99A
plasmid.
Table 20, Output from Shake-flask Feimentation by the Recombinant Strain species Output of N-Acetyl-D-Glucosamine (g/L) AT-019 (AT-007-02, A wecB promotor: :Trc 23.0 1.8 promoter) (reference) AT-068 (AT-019, vhb/pTrc99A) 27.2 1.9 AT-069 (AT-019, vhbM/pTrc99A) 31.5 2.0 Example 9 This implementation example describes Escherichia coli strains integrated with pTrc-nanEM and influences of those on the output of N-Acetyl-D-Glucosamine, of which the natural endogenous promoter of the gene glmS of Glucosamine-6-Phosphate Synthase (GlmS) and/or the nagB gene of D-Glucosamine-6-Phosphate Deaminase (NagB) is replaced and/or deleted, and the gene vhb and its mutants for expression of vitreoscilla hemoglobin (Vhb).
In Escherichia coli strains integrated with pTrc-nanEM cassette, the natural endogenous promoter of the nanB gene is replaced by Trc promoter to produce AT-032 (AT-031-02, AnagB promotor: :Trc promoter), and the natural endogenous promoter of the glmS gene is further deleted to produce AT-033 (AT-032, A glmS

promotor); In Escherichia coli strains integrated with pTrc-nanEM cassette, the natural endogenous promoter of the glmS gene is replaced by Trc promoter to produce AT-034 (AT-031-02, AnagB promotor::Trc promoter), and the natural endogenous promoter of the nagB gene is further deleted to produce AT-035 (AT-034, AnagB promotor).

WSLEGAL\068076\00030\21038773v1 Prepare competence of recombinant Escherichia coli strain AT-033 and AT-035; then, transfoint vhb/pTrc99A and vhbM/pTrc99A plasmids into AT-033 and AT-035 by CaCl2 transformation method, pick up monoclones and cultivate, and pipet plasmid to identify positive clones.
No. of the obtained strains: AT-070 (AT-033, vhb/pTrc99A), AT-071 (AT-033, vhbM/pTrc99A), AT-072 (AT-035, vhb/pTrc99A), and AT-073 (AT-035, vhbM/pTrc99A).
Carry out a shake-flask fermentation trial with the strains AT-070, AT-071, AT-072, and AT-073 with the gene vhb and its mutant for expression of vitreoscilla hemoglobin. See Table 21 for the output from shake-flask fermentation by recombinant strains. The results show that: The output may be increased obviously from expression of vhb by the recombinant strains both with transformed vhb/ pTrc99A and with transformed vhbM/ pTrc99A plasmid, moreover, the output is increased more significant by the recombinant strain with with transformed vhbM/ pTrc99A plasmid.
Table 21, Output from Shake-flask Fermentation by the Recombinant Strain species Output of N-Acetyl-D-Glucosamine (g/L) AT-033 (AT-032, A glmS promotor) 12.2+1.2 (reference) AT-070 (AT-033, vhb/pTrc99A) 15.0 1.2 AT-071 (AT-033, vhbM/pTrc99A) 18.1+1.3 AT-035 (AT-034, AnagB promotor) 9.8+0.8 (reference) AT-072 (AT-035, vhb/pTrc99A) 13.1 1.2 AT-073 (AT-035, vhbM/pTrc99A) 16.7 1.3 Example 10 WSLEGAL\068076\00030\21038773v1 This implementation example describes Escherichia coli strains integrated with pTrc-nanEM gene cassette, of which the natural endogenous promoter of the wecB gene is replaced by Trc promoter, and the gene vhb thereof and its mutant for expression of vitreoscilla hemoglobin (Vhb) as well as influence on the output of N-Acetyl-D-Glucosamine.
The natural endogenous promoter of the wecB gene of Escherichia coli strains integrated with pTrc-nanKM cassette is replaced by Trc promoter to produce AT-037 (AT-031-02, AwecB promotor::Trc promoter).
Prepare competence of recombinant Escherichia coli strain AT-037; then, transform vhb/pTrc99A and vhbM/pTrc99A plasmids into AT-037 by CaCl2 transformation method, pick up monoclones and cultivate, and pipet plasmid to identify positive clones.
No. of the obtained strains: AT-074 (AT-037, vhb/pTrc99A), and AT-075 (AT-037, vhbM/pTrc99A).
Carry out a shake-flask fermentation trial with the strains AT-074 and AT-075 with the gene vhb and its mutant for expression of vitreoscilla hemoglobin.
See Table 22 for the output from shake-flask fermentation by recombinant strains.
The results show that: The output may be increased obviously from expression of vhb by the recombinant strains both with transformed vhb/ pTrc99A and with transformed vhbM/ pTrc99A plasmid; moreover, the output is increased more significant by the recombinant strain with with transformed vhbM/ pTrc99A
plasmid.
Table 22. Output from Shake-flask Fermentation by the Recombinant Strain species Output of N-Acetyl-D-Glucosamine (g/L) AT-037 (AT-031-02, AwecB promotor::Trc 13.4 1.2 promoter) (reference) AT-074 (AT-037, vhb/pTrc99A) 16.2 1.2 WSLEGAL068076\00030\21038773v1 AT-075 (AT-037, vhbM/pTrc99A) 19.9+1.3 Example 11 This implementation example describes Escherichia coli strains integrated with pTrc-nanBM and influences of those on the output of N-Acetyl-D-Glucosamine, of which the natural endogenous promoter of the gene glmS of Glucosamine-6-Phosphate Synthase (GlmS) and/or the nagB gene of D-Glucosamine-6-Phosphate Deaminase (NagB) is replaced and/or deleted, and the gene vhb and its mutants for expression of vitreoscilla hemoglobin (Vhb).
In Escherichia coli strains integrated with pTrc-nanBM cassette, the natural endogenous promoter of the nanB gene is replaced by Trc promoter to produce AT-044 (AT-043-02, AnagB promotor::Trc promoter), and the natural endogenous promoter of the glmS gene is further deleted to produce AT-045 (AT-044, A glmS

promotor); In Escherichia coli strains integrated with pTrc-nanBM cassette, the natural endogenous promoter of the glmS gene is replaced by Trc promoter to produce AT-046 (AT-043-02, AnagB promotor::Trc promoter), and the natural endogenous promoter of the nagB gene is further deleted to produce AT-047 (AT-046, AnagB promotor).
Prepare competence of recombinant Escherichia coli strain AT-045 and AT-047; then, transform vhb/pTrc99A and vhbM/pTrc99A plasmids into AT-045 and AT-047 by CaC12 transformation method, pick up monoclones and cultivate, and pipet plasmid to identify positive clones.
No. of the obtained strains: AT-076, AT-077, AT-078 (AT-047, vhb/pTrc99A), and AT-079.
Carry out a shake-flask fermentation trial with the strains AT-076, AT-077, AT-078, and AT-079 with the gene vhb and its mutant for expression of vitreoscilla hemoglobin. See Table 23 for the output from shake-flask fermentation by recombinant strains. The results show that: The output may be increased WSLEGAL\068076\00030\21038773v1 obviously from expression of vhb by the recombinant strains both with transfouned vhb/ pTrc99A and with transformed vhbM/ pTrc99A plasmid;
moreover, the output is increased more significant by the recombinant strain with with transfolined vhbM/ pTrc99A plasmid.
Table 23. Output from Shake-flask Fermentation by the Recombinant Strain species Output of N-Acetyl-D-Glucosamine (g/L) AT-045 (AT-044, A glmS promotor) 19.2+1.2 (reference) AT-076 (AT-045, vhb/pTrc99A) 23.0+1.3 AT-077 (AT-045, vhbM/pTrc99A) 28.1+1.5 AT-047 (AT-046, AnagB promotor) 15.5+1.2 (reference) AT-078 (AT-047, vhb/pTrc99A) 20.6+1.3 AT-079 (AT-047, vhbM/pTrc99A) 25.6+1.4 Example 12 This implementation example describes Escherichia coli strains integrated with pTrc-nanKM gene cassette, of which the natural endogenous promoter of the nanE gene is replaced by Trc promoter, the natural endogenous promoter of the weeB gene and NagB gene is replaced and/or deleted, the natural endogenous promoter of the wecB gene is replaced by Trc promoter, and the gene vhb thereof and its mutant for expression of vitreoscilla hemoglobin (Vhb) as well as influence on the output of N-Acetyl-D-Glucosamine.
In Escherichia coli strains integrated with pTrc-nanKM cassette, of which the natural endogenous promoter of the nagB gene is replaced by Trc promoter and meanwhile the natural endogenous promoter of the glmS gene is deleted, the WSLEGAL\068076\00030\21038773v1 natural endogenous promoter of the nanE gene is replaced by Trc promoter to produce AT-015 (AT-011, AnanE promotor::Trc promoter), and the natural endogenous promoter of the wecB gene is further replaced by Trc promoter to produce AT-027 (AT-015, A wecB promotor::Trc promoter); In Escherichia coli strains integrated with pTrc-nanKM cassette, of which the natural endogenous promoter of the glmS gene is replaced by Trc promoter and meanwhile the natural endogenous promoter of the nagB gene is deleted, the natural endogenous promoter of the nanE gene is replaced by Trc promoter to produce AT-017 (AT-013, AnanE promotor::Trc promoter), and the natural endogenous promoter of the wecB gene is further replaced by Trc promoter to produce AT-029 (AT-017, A wecB promotor::Trc promoter);
Prepare competence of recombinant Escherichia coli strain AT-027 and AT-029; then, transform vhb/pTrc99A and vhbM/pTrc99A plasmids into AT-027 and AT-029 by CaC12 transformation method, pick up monoclones and cultivate, and pipet plasmid to identify positive clones.
No. of the obtained strains: AT-080 (AT-027, vhb/pTrc99A), AT-081 (AT-027, vhbM/pTrc99A), AT-082 (AT-029, vhb/pTrc99A), and AT-083 (AT-029, vhbM/pTrc99A).
Carry out a shake-flask fermentation trial with the strains AT-080, AT-081, AT-082, and AT-083 with the gene vhb and its mutant for expression of vitreoscilla hemoglobin. See Table 24 for the output from shake-flask fermentation by recombinant strains. The results show that: The output may be increased obviously from expression of vhb by the recombinant strains both with transformed vhb/ pTrc99A and with transformed vhbM/ pTrc99A plasmid;
moreover, the output is increased more significant by the recombinant strain with with transformed vhbM/ pTrc99A plasmid.
Table 24. Output from Shake-flask Fermentation by the Recombinant Strain species Output of WSLEGAL\068076\00030\21038773v1 N-Acetyl-D-Glucosamine (g/L) AT-027 (AT-015, A wecB promotor::Trc 39.8+2.0 promoter) (reference) AT-080 (AT-027, vhb/pTrc99A) 46.5+2.1 AT-081 (AT-027, vhbM/pTrc99A) 49.5+2.0 AT-029 (AT-017, AwecB promotor::Trc 40.2+2.1 promoter) (reference) AT-082 (AT-035, vhb/pTrc99A) 47.7+2.2 AT-083 (AT-035, vhbM/pTrc99A) 51.6+2.3 Example 13 This implementation example describes a femientation trial for production of N-Acetyl-D-Glucosamine by 10-L fermentation tank Carry a fermentation trial for production of N-Acetyl-D-Glucosamine by 10-L
fermentation tank, using recombinant engineering strain AT-083 as production strain.
1. Seed Cultivation (1)Cultivation of Primary Seed: Pick monoclonal strain freshly cultivated in the LB plate medium, inoculate into 8 mL of LB broth medium, and shake-cultivate at 37 C and 225 rpm for 8 h.
(2)Cultivation of Secondary Seed: Transfer 6 mL of the primary seed culture solution, inoculate into 1000-mL shake flask containing 200 mL of M9 culture solution, and shake-cultivate at 37 C and 225rpm for 16 h, until 0D600 value is 6.0-10, approximately the medium stage of log growth.
(3)Prepare the fermentation medium according to Table 25, where the microelement solution is prepared according to Table 26, and the complex WSLEGAL\068076\00030\21038773v1 vitamins solution is prepared according to Table 27.
Table 25. Fermentation Medium Ingredients Amount (/L) K2HPO4 1.30g KH2PO4 1.00g MgSO4.7H20 0.10g NH4C1 0.02g (NH4)2SO4 0.20g NaH2PO4 0.60g Polyether Defoamer 10 mL
Microelement Solution 4m1 Complex Vitamins Solution 4m1 Glucose 6.00g NOTE:
0 The microelement solution is sterilized separately and then added, and the vitamins solution is filtered and then added;
()Glucose: Concentration 65%(w/v); it is sterilized separately and is added prior to inoculation. Amount to be added: 6.0 g/L;
()The above solutions are combined, and then adjust to pH 7.0 with 10M
NI-140H;
@The fermentation medium is a basal medium prior to addition of glucose; initial loading amount of the basal medium (initial volume accounting for the total capacity of the fermentation tank): 50%.
Table 26. Microelement Solution Ingredients Amount used (g/L) CaCl2 = 2H20 10 FeC13= 6H20 10 MnSO4=5H20 2.5 WSLEGAL\068076\00030\21038773v1 Ingredients Amount used (g/L) A1C13.6H20 2.5 CoC12 = 6H20 1.75 ZnSO4.= 2H20 0.5 NaMoat= 2H20 0.5 CuSO4= 5H20 0.25 H3B 03 0.125 pH 3 - 4 Table 27. Complex Vitamins Solution Ingredients Amount (mg/L) Folic Acid 2 Vitamin B2 Riboflavin 100 Vitamin B1 Thiamine EIC1 1500 Nicotinic Acid 500 Vitamin B6 Pyridoxine HC1 500 Calcium Pantothenate, 500 Ca-panthothenate Biotin 1 Vitamin B12 10 2. Inoculation Inoculate the secondary seed solution to the fermentation tank in the ratio of 40 mL/L; inoculation size: 2.5-5% (v/v); the initial 0D600 is 0.3-0.5.
3. process parameters Carry out a high-density fermentation by 10-L self-control fermentation tank, and collect data by software equipped in the machine to realize online control by computer. The control parameters are: The air flow is 0.5-1 vvm.; dissolved WSLEGAL068076\00030\21038773v1 oxygen is >=20 %, to increase regulation of rotational speed and ventilation;
temperature 37 C; pH 7.0, the automatic flow is maintained stable by addition of saturated ammonia water. Supplement glucose when glucose in the basal medium is consumed up, i.e. dissolved oxygen is risen again. Glucose is supplemented in a speed to control residual glucose concentration is not more than 0.45 g/L. The glucose-supplementing solution contains 65% (w/v) of glucose, is added with 2.5%
Sodium Gluconate or 6% Ribose. The fermentation is stopped after 60-72 h.
Total loading amount: 75%-80%.
4. Example (10-L fermentation tank) (1)Strain No.: AT-083. Batch No.: 1019.
(2)Concentration of Seed Solution: 0D600,9 2.8.
(3)Base Stock: 4L.
(4)Inocu1ation Size 200 mL.
(5)Glucose supplementation speed: The residual glucose concentration is controlled as not more than 0.45 g/L.
(6)Glucose-supplementing solution: The solution contains glucose in a concentration of 65% (w/v) and is added with 2.5% sodium gluconate.
(7)Track Indicators: Measure 0D600 and residual glucose content (residual glucose in the fermentation solution).
(8)Product: N-Acetyl-D-Glucosamine. Potency: 72 h, 156 g/L.
Example 14 This implementation example describes the processing process after separation and purification of N-Acetyl-D-Glucosamine and D-Glucosamine Hydrochloride WSLEGAL\068076\00030\21038773v1 1. Refinement of N-Acetyl-D-Glucosamine (1) Deactivation: The fermentation solution is placed at 80 C for 30 min.
(2) Solid-liquid separation: Centrifugate at 4000-8000 rpm, discard the bacterial residue and proteins, and transfer the feimentation solution. It may also be filtered via ceramic membrane.
(3) Decoloration: Product:Water:Activated Charcoal = 1:(1.5-3):(0.01-0.1);
stir for 0.5-5 h.
(4) Desalt: Desalt by electroosmosis. Initial salt concentration of the fermentation loaded into the concentrated chamber tank: 0.01-0.05 mol/L. Flow rate of the dilute-chamber fermentation solution: 40-80L/h; flow rate of the concentrated-chamber fermentation solution: 40-80L/h; the voltage of single membrane pair is 0.5-1.4 V. It may also be desalted by anion or cation ion exchange resin.
(5) Concentration: The fermentation solution desalted is heated at 50-80 C
under vacuum conditions (0.095MPa) for 8-15 h until oversaturation, by approximately 4-6 folds.
(6) Concentration: The concentrated fermentation solution is cooled to 25-35 C

in water at 25 C, then cooled for 1-3 h to 0-10 C in water at 0 C.. Add anhydrous alcohol (in an amount of approximately 5-20 times the product weight), and stir at .. 700-1500 rpm for 15min- lh.
(7) Washing: Add anhydrous alcohol (same amount as that of the product) and stir for 10-100rpm, 0.5-2h.
(8) Drying: 50-100 C, 3-10h. Purity: 99.96%. The total yield is 91.5%.
2. Refinement of D-Glucosamine Hydrochloride (1) Deactivation: The fermentation solution is placed at 80 C for 30 min.
(2) Solid-liquid separation: Centrifugate at 4000-8000 rpm, discard the bacterial residue and proteins, and transfer the feimentation solution. It may also be filtered via ceramic membrane.

WSLEGAL068076\00030\21038773v1 (3) Decoloration: Product:Water:Activated Charcoal = 1:(1.5-3):(0.01-0.1);
stir for 0.5-5 h.
(4) Desalt: Desalt by electroosmosis. Initial salt concentration of the fermentation loaded into the concentrated chamber tank: 0.01-0.05 mol/L. Flow rate of the dilute-chamber fermentation solution: 40-80L/h; flow rate of the concentrated-chamber feunentation solution: 40-80L/h; the voltage of single membrane pair is 0.5-1.4 V. It may also be desalted by anion or cation ion exchange resin.
(5) Concentration: The feimentation solution desalted is heated at 50-80 C
under vacuum conditions (0.095MPa) for 8-15 h until oversaturation, by approximately 4-6 folds.
(6) Hydrolysis: Introduce the concentrated fermentation solution to an enamel or glass container, add concentrated hydrochloric acid (37%) to a final concentration of 12%-16%, stir thoroughly, and maintain at 70 C for 90 min.
Hydrochloric Acid may be used in a recycling way.
(7) Crystalliation: First cool to 25-35 C in water at 25 C, and then cool to 4 C
in water at 0 C for 1-3 h.
(8) Washing: Add anhydrous alcohol (same amount as that of the product) and stir for 10-100rpm, 0.5-2h. Centrifugate at 700-1500 rpm for 15-60 min to obtain Glucosamine Hydrochloride; the conversion rate is 89.5%.
(9) Dissolution: Dissolve the washed product in water in an similar volume to that of the original fermentation solution.
(10) Decoloration: Add activated charcoal (in an amount of 1%). Mix for 30 min. Then centrifugate at 700-1500 rpm for 15-60min. Or filter to obtain a colorless filtrate.
(11) Recrystalliation: Evaporate at 50 C and 55 cmHg vacuum until oversaturation. Add anhydrous alcohol (in an amount of approximately 5-20 times the product weight), and stir at 700-1500 rpm for 15min- lh.

WSLEGAL\068076\00030\21038773v1 (12) Washing: Add anhydrous alcohol (same amount as that of the product) and stir for 10-100rpm, 0.5-2h. Then centrifugate at 700-1500 rpm for 15-60min.
(13) Drying: 50-100 C, 3-10h. Purity: 99.92%. The total yield is 84.6%.
Although this Invention is described detailedly by common explanations and specific implementation schemes, it may be revised or improved on top of this Invention; this point is as plain as the nose on your face for a technician in this field. Therefore, such revisions or improvements that are not deviated from the spirits of this Invention still fall in the range under protection required by this Invention.

WSLEGAL\068076\0003021038773v1

Claims (19)

Claims
1. A method for production of N-Acetyl-D-Glucosamine and/or D-Glucosamine by microbial fermentation, including:
A) cultivation of a microorganism in a fermentation medium, where the said microorganism contains at least one genetic modification that expresses vitreoscilla hemoglobin (Vhb); and B) collection of N-Acetyl-D-Glucosamine produced in the cultivation step A);
the microorganism is transfoimed by a nucleic acid molecule with a polynucleotide encoding vitreoscilla hemoglobin (Vhb) defmed by SEQ ID NO: 61, wherein said vitreoscilla hemoglobin contains a genetic modification that increases activity of vitreoscilla hemoglobin, wherein the said genetic modification contains the substitutions at the following corresponding sites, methionine at site 45 is substituted by leucine, cysteine at site 86 is substituted by glycine, and tyrosine at site 95 is substituted by serine.
2. The method of Claim 1, where the nucleic acid sequence encoding the said vitreoscilla hemoglobin (Vhb) is SEQ ID NO: 64.
3. The method of Claim 1, wherein gene copies in the polynucleotide encoding vitreoscilla hemoglobin (Vhb), are more than or equal to 1; the polynucleotide contains an endogenous promoter, or a promoter with a higher expression level than that of the natural endogenous promoter; wherein the promoter with the higher expression level is selected from HCE promoter, gap promoter, trc promoter, and T7 promoter.
4. The method of Claim 3, where the promoter with higher expression level than the natural endogenous promoter is trc promoter.
5. The method of any one of Claims 1-4, further comprising the step of:
C) deacetylation ofN-Acetyl-D-Glucosamine to produce D-Glucosamine Salt.
6. The method of any of any one of Claims 1-4, where the said microorganism contains one or more of the following genetic modifications:
(1) at least one genetic modification that increases the effects of N-Acetyl-D-Mannosamine Kinase (NanK) in microorganism;
(2) at least one genetic modification that increases the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase in microorganism;
(3) at least one genetic modification that increases the effects of D-Glucosamine-6-Phosphate Deaminase in microorganism;
(4) at least one genetic modification that increases the effects of D-Glucosamine-6-Phosphate Synthase in microorganism; or (5) at least one genetic modification that increases the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) in microorganism.
7. The method of Claim 6, where the genetic modification of (3) further contains at least one genetic modification that decreases the effects of Glucosamine-6-Phosphate Synthase.
8. The method of Claim 6, where the genetic modification of (4) further contains at least one genetic modification that decreases the effects of D-Glucosamine-6-Phosphate Deaminase.
9. The method of Claim 6, where the genetic modification to increase the effects of N-Acetyl-D-Mannosamine Kinase in microorganism are selected from: a) increased effects of N-Acetyl-D-Mannosamine Kinase; and/or b) overexpression of N-Acetyl-D-Mannosamine Kinase.
10. The method of Claim 9, where the microorganism is transformed by molecules of at least one recombinant nucleic acid, containing a nucleotide sequence enco ding N-Acetyl-D-Manno s amine Kinase; the sequence enco ding N-Acetyl-D-Mannosamine Kinase is SEQ ID NO: 26.
11. The method of Claim 6, where the genetic modification to increase the effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase in microorganism are selected from: a) increased effects of N-Acetyl-D-Mannosamine-6-Phosphate Epimerase; and/or b) overexpression of N-Acetyl-D- Mannosamine- 6-Phosphate Epimerase.
12. The method of Claim 11, where the microorganism is transformed by molecules of at least one recombinant nucleic acid, containing a nucleotide sequence encoding N-Acetyl-D-Mannosamine-6-Phosphate Epimerase; the sequence encoding the said N-Acetyl-D- Mannosamine-6-Phosphate Epimemse (NanE) is SEQ ID NO:
56.
13. The method of Claim 6, where the genetic modification increasing the effects of UDP-N-Acetyl-D-Glucosamine-2-Epimerase in microorganism is selected from a) increasing the effects of U1i)P-N-Acetyl-D-Glucosamine-2-Epimerase in microorganism; and/or b) overexpression of UDP-N-Acetyl-D- Glucosamine-2-Epimerase in microorganism.
14. The method of Claim 13, where the microorganism is transformed by molecules of at least one recombinant nucleic acid, containing a nucleotide sequence encoding UDP-N-Acetyl-D-Glucosamine-2-Epimerase; the sequence encoding UDP-N-Acetyl-D-Glucosamine-2-Epimerase (WecB) is SEQ ID NO: 58.
15. The method of any one of Claims 1-4, where the said microorganism contains one or more of the following genetic modifications:
(1) at least genetic modification that decreases the effects of Mannose transporter EIIM, P/IIIman(ManXYZ) in said microorganism;
(2) at least one genetic modification that decreases the effects of N-Acetylneuraminate Lyase (NanA) in said microorganism;
(3) at least one genetic modification that decreases the effects of N-Acetyl-D-Glucosamine-6-Phosphate Deactylase (NagA) in said microorganism;
(4) at least one genetic modification that decreases the effects of N-Acetyl-D-Glucosamine Specific Enzyme Irag (NagE) in said microorganism;
(5) at least one genetic modification that increases the effects of PhosphoGlucosamine Mutase (G1mM) in said microorganism; or (6) at least one genetic modification that increases the effects of bifunctional N-acetyl Glucosamine-l-Phosphate Uridyltransferase (GlmU) in said microorganism.
16. A vitreoscilla hemoglobin (Vhb) comprising: the amino acid sequence as shown in SEQ ID NO:65.
17. A polynucleotide encoding vitreoscilla hemoglobin (Vhb) of Claim 16, wherein the said polynucleotide shares 100% identity with SEQ ID NO: 64.
18. A plasmid containing the polynucleotide of Claim 17.
19. A transgenic microorganism that has been transfoimed with the polynucleotide of Claim 17.
CA3020193A 2016-04-05 2017-04-14 Method for producing n-acetyl-d-glucosamine and/or d-glucosamine hydrochloride by microbial fermentation Active CA3020193C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610208203.9 2016-04-05
CN201610208203 2016-04-05
CN201710217601.1A CN107267578B (en) 2016-04-05 2017-04-05 Method for producing N-acetyl-D-glucosamine and/or D-glucosamine salt by microbial fermentation
CN201710217601.1 2017-04-05
PCT/CN2017/080649 WO2017174036A1 (en) 2016-04-05 2017-04-14 Method for producing n-acetyl-d-glucosamine and/or d-glucosamine hydrochloride by microbial fermentation

Publications (2)

Publication Number Publication Date
CA3020193A1 CA3020193A1 (en) 2017-10-12
CA3020193C true CA3020193C (en) 2023-02-21

Family

ID=60073746

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3020193A Active CA3020193C (en) 2016-04-05 2017-04-14 Method for producing n-acetyl-d-glucosamine and/or d-glucosamine hydrochloride by microbial fermentation

Country Status (7)

Country Link
US (3) US11466300B2 (en)
JP (1) JP6771644B2 (en)
CN (5) CN107267576B (en)
AU (1) AU2017247309B2 (en)
CA (1) CA3020193C (en)
SG (1) SG11201808796TA (en)
ZA (1) ZA201807355B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108330095B (en) * 2018-03-01 2020-12-29 江南大学 Recombinant corynebacterium glutamicum for accumulating N-acetylneuraminic acid and application thereof
CN110343624B (en) * 2018-04-03 2021-06-15 中国科学院微生物研究所 Recombinant strain and application thereof in improving yield of cellulase
CN114732822B (en) * 2019-03-13 2023-06-30 中国人民解放军军事科学院军事医学研究院 Application of glucosamine and derivatives thereof as antiviral drugs
CN110028533A (en) * 2019-04-10 2019-07-19 浙江中医药大学 A kind of method and application of the refining amino glucosamine salt hydrochlorate from microbial fermentation solution
CN110029068B (en) * 2019-04-10 2022-03-25 天津科技大学 Aspergillus niger genetic engineering strain for high yield of organic acid under low dissolved oxygen condition and application thereof
KR102472558B1 (en) * 2019-06-28 2022-12-01 씨제이제일제당 주식회사 A method of producing sulfur-containing amino acids and derivatives thereof
CN110590867B (en) * 2019-09-12 2021-07-20 河南巨龙生物工程股份有限公司 Synthesis method of D-glucosamine hydrochloride
CN110938666B (en) * 2019-11-20 2022-03-18 上海应用技术大学 Preparation method of microbial chitosan
CN111018957A (en) * 2019-12-03 2020-04-17 天津科技大学 Signal peptide for mediating PGase secretion expression and application thereof
CN111018926B (en) * 2019-12-17 2023-10-10 大自然生物集团有限公司 Method for extracting high-purity glucosamine hydrochloride from glucosamine fermentation broth
CN110760622B (en) * 2019-12-17 2023-06-27 大自然生物集团有限公司 Feeding method for producing glucosamine by fermenting bacillus subtilis
CN111548979B (en) * 2020-05-25 2022-08-30 江南大学 Recombinant escherichia coli for synthesizing lactoyl N-neotetraose and construction method and application thereof
CN111518857A (en) * 2020-06-11 2020-08-11 江苏海飞生物科技有限公司 Enzyme method for producing glucosamine salt and purification method thereof
CN112011584A (en) * 2020-07-23 2020-12-01 南京先之达医药科技有限公司 Method for preparing acetyl chitosamine by enzymatic conversion method
CN114592020B (en) * 2020-12-07 2023-07-14 上海医药工业研究院 Method for producing N-acetylglucosamine by fermentation
CN112760348B (en) * 2020-12-31 2022-03-08 安徽丰原发酵技术工程研究有限公司 Fermentation production method of N-acetylglucosamine
KR102254635B1 (en) * 2021-01-27 2021-05-21 씨제이제일제당 주식회사 Novel glucosamine-6-phosphate deaminase variant and a method for producing L-glutamic acid using the same
CN113817788B (en) * 2021-03-10 2024-02-02 江苏澳新生物工程有限公司 Enzymatic preparation method of glucosamine
CN113845553A (en) * 2021-10-09 2021-12-28 山东润德生物科技有限公司 Preparation method of N-acetylglucosamine with low water activity and N-acetylglucosamine
CN114645070B (en) * 2022-02-28 2022-12-20 北京焉支山科技有限公司 Preparation method of hexose-6-phosphoric acid composition and application thereof in cosmetics
CN115444102A (en) * 2022-09-19 2022-12-09 四川饭扫光食品集团股份有限公司 Low-salt fermented bean sauce and preparation method thereof
CN116731934B (en) * 2023-08-08 2023-10-13 欧铭庄生物科技(天津)有限公司滨海新区分公司 Escherichia coli and application thereof in production of glucosamine
CN117757683B (en) * 2023-12-26 2024-06-18 善恩康生物科技（苏州）有限公司 Bacillus coagulans high-density fermentation metabolism regulation and control process

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030713A1 (en) 1997-01-14 1998-07-16 Bio-Technical Resources Process for production of n-glucosamine
US6372457B1 (en) 1997-01-14 2002-04-16 Arkion Life Sciences Llc Process and materials for production of glucosamine
JP2003334081A (en) * 2002-05-16 2003-11-25 Japan Science & Technology Corp Gene, enzyme, method for producing enzyme, and method for producing chitin oligosaccharide
MXPA04012978A (en) * 2002-07-01 2005-09-12 Arkion Life Sciences Llc D B A Process and materials for production of glucosamine and n-acetylglucosamine.
CA2665332A1 (en) * 2006-10-03 2008-04-10 Centre National De La Recherche Scientifique (Cnrs) High yield production of sialic acid (neu5ac) by fermentation
CN103060302A (en) * 2011-10-20 2013-04-24 中国科学院微生物研究所 N-acetyl-D-neuraminic acid (Neu5Ac) aldolase from shigella dysenteriae, coding gene and application
CN103060252B (en) * 2012-12-25 2015-04-15 江南大学 Bacillus subtilis engineering bacteria with high yield of acetylglucosamine and application thereof
ES2700274T3 (en) 2013-03-14 2019-02-14 Glycosyn LLC Microorganisms and methods for producing sialylated oligosaccharides and containing N-acetylglucosamine
CN103602627B (en) 2013-11-25 2015-03-18 武汉中科光谷绿色生物技术有限公司 Novel N-acetylneuraminic acid-producing escherichia coli engineering bacteria as well as construction method and application thereof
CN104059872B (en) * 2014-07-16 2017-01-11 华东理工大学 High-yield N-acetylglucosamine metabolic engineering bacterium, as well construction method and applications thereof
CN104293724A (en) * 2014-09-22 2015-01-21 上海工业生物技术研发中心 Genetically engineered bacteria for efficiently producing N-acetylglucosamine
CN104498517B (en) * 2014-11-29 2017-04-12 滨州市金朗生物科技有限公司 Construction and application methods of escherichia coli with high yield of producing N-acetylglucosamine
CN104988108A (en) * 2015-05-27 2015-10-21 武汉中科光谷绿色生物技术有限公司 High-yield N-acetylneuraminic acid metabolic engineering bacterium and construction method and application
WO2017174036A1 (en) * 2016-04-05 2017-10-12 孙镧 Method for producing n-acetyl-d-glucosamine and/or d-glucosamine hydrochloride by microbial fermentation
CN106148262B (en) * 2016-07-01 2019-09-03 江南大学 Improve the recombined bacillus subtilis and its construction method of acetylglucosamine yield

Also Published As

Publication number Publication date
US20190376102A1 (en) 2019-12-12
US11118205B2 (en) 2021-09-14
CA3020193A1 (en) 2017-10-12
CN107267579A (en) 2017-10-20
CN107267578A (en) 2017-10-20
JP6771644B2 (en) 2020-10-21
CN107267575B (en) 2020-11-06
CN107267575A (en) 2017-10-20
ZA201807355B (en) 2019-08-28
AU2017247309A1 (en) 2018-10-25
CN107267579B (en) 2020-08-21
CN107267577A (en) 2017-10-20
JP2019517275A (en) 2019-06-24
CN107267576A (en) 2017-10-20
US11466300B2 (en) 2022-10-11
SG11201808796TA (en) 2018-11-29
US20200308615A1 (en) 2020-10-01
US20190390238A1 (en) 2019-12-26
US11136608B2 (en) 2021-10-05
CN107267576B (en) 2020-08-21
AU2017247309B2 (en) 2020-07-16
CN107267578B (en) 2020-06-30

Similar Documents

Publication Publication Date Title
CA3020193C (en) Method for producing n-acetyl-d-glucosamine and/or d-glucosamine hydrochloride by microbial fermentation
JP5769683B2 (en) Processes and materials for the production of glucosamine and N-acetylglucosamine
CN104059872B (en) High-yield N-acetylglucosamine metabolic engineering bacterium, as well construction method and applications thereof
JP2006508643A5 (en)
EP3441473A1 (en) Method for producing n-acetyl-d-glucosamine and/or d-glucosamine hydrochloride by microbial fermentation
AU2019101117A4 (en) Method for the enzymatic production of uridine monophosphate and cytidine monophosphate
EP2348101B1 (en) Corynebacterium genus microorganism having ability to produce n-acetyl glucosamine and method for producing n-acetyl glucosamine or glucosamine using same
WO2017174040A1 (en) Method for producing n-acetyl-d-glucosamine and/or d-glucosamine salt by microbial fermentation
CN113755411B (en) Recombinant microorganism for high-yield of beta-nicotinamide mononucleotide and method for producing beta-nicotinamide mononucleotide by recombinant microorganism
WO2017174039A1 (en) Method for producing n-acetyl-d-glucosamine and/or d-glucosamine salt by means of microbial fermentation
WO2017174037A1 (en) Method for producing n-acetyl-d-glucosamine and/or d-glucosamine salt by microbial fermentation
WO2017174038A1 (en) Method for producing n-acetyl-d-glucosamine and/or d-glucosamine salt by microbial fermentation
CN102199644B (en) Genetic engineering preparation method of cytidine triphosphate
CN116555378A (en) Method for producing ribonucleosides or derivatives thereof, biological enzyme preparations and use thereof
CN116555147A (en) Construction method and application of recombinant escherichia coli for high yield of N-acetylneuraminic acid
CN116004599A (en) Microbial cell transformation method for irreversibly synthesizing nidus Collocaliae acid
CN116426550A (en) Method for efficiently synthesizing beta-nicotinamide mononucleotide by utilizing nicotinamide riboside kinase mutant and recombinant bacteria thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181005

EEER Examination request

Effective date: 20181005

EEER Examination request

Effective date: 20181005

EEER Examination request

Effective date: 20181005